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ABSTRACT 
Cancer is one of the leading causes of morbidity and mortality in developed and developing 
nations. It is estimated that 86% of new cases and 64% of death due to cancer are from Africa 
and 13.1 million deaths are estimated to occur worldwide by the year 2030. Cancer death 
rates have not subsided despite recent advances in cancer drug development and treatment. 
Present cancer drug regimens are limited due to unpredictable efficiency, severe side effects, 
resistance and high cost. Plants provide a vast array of natural compounds such as terpenoids, 
phenolics and alkaloids with antiproliferative pro-apoptotic and antioxidant effects. Plants are 
principal sources of compounds for drug discovery and development of several clinically 
proven useful anticancer drugs. The present study focused on the isolation of compounds 
from the Holarrhena floribunda (H. floribunda) leaves for their potential anticancer 
activities. 
Standard methods were employed to assess the antiproliferative potential, apoptosis, cell 
cycle analysis and reactive oxygen species of the methanolic leaf extract (MLE) of H. 
floribunda. The standard methods of isolation such as column chromatography, thin layer 
chromatography, high performance liquid chromatography (HPLC) and nuclear magnetic 
resonance (NMR) were used to isolate and purify bioactive compounds from the leaves. To 
elucidate the mechanism of cytotoxicity of the isolated compounds, apoptosis effect was 
studied by flow cytometry analysis using the ApopercentageTM dye, Annexin-V/PI stain, 
induction of caspase-3 using the Caspase-3/7 Glo assay kit and PARP-1 deactivation using 
Western blot analysis. The mode of action was further assessed by evaluating reactive oxygen 
species (ROS), mitochondrial toxicity, light and fluorescent microscopic morphological 
evaluations of F-actin and topoisomerase-I relaxation assay. In addition, potential cancer 
prevention of the plant was also evaluated by assessing the antioxidant activity of the 
flavonoids compounds isolated from the MLE. 
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The results of the present study show that the MLE of H. floribunda inhibited the 
proliferation of the cancer cell lines (HeLa, HT-29 and MCF-7) in a dose- and time-
dependent manner. The anti-proliferative activity of the methanolic extract is selective 
towards cancer cells more than normal KMST-6 fibroblast cells used in the study. The extract 
showed cytotoxicity, cell cycle arrest, induced generation of ROS and apoptosis. The 
methanolic extract of the leaves led to the isolation of two pure steroidal alkaloid and four 
flavonoid compounds. The two steroidal alkaloids - holamine and funtumine were found to 
be selectively cytotoxic to human cancer cells more than the normal fibroblasts. The 
cytotoxicity of the two steroidal alkaloids was mediated through the induction of apoptosis. 
The apoptosis induction was found to be triggered by the activation of caspase-3, deactivation 
of PARP-1, increased ROS, cell cycle arrest at G0/G1 and G2/GM phases, mitochondria 
toxicity, F-actin disorganization and topoisomerase-I inhibition. 
However, four flavonoids (kaempferol-3-O-rutinoside, quercetin-3-galactoside/glucoside, 
quercetin-3-O-glucoside and kaempferol-3-O-glucoside) isolated were subjected to 
antioxidant activity assay using oxygen radical absorbance capacity (ORAC), ferric 
reducing/antioxidant power (FRAP), trolox equivalent antioxidant capacity (TEAC) and lipid 
peroxidation inhibition. Two flavonoids with a quercetin nucleus were found to be active in 
the entire antioxidant spectrum, except pro-oxidant activity while the remaining two 
compounds with a kaempferol nucleus were selective in their activity. Structure-activity 
relationship analysis shows that the activity of the flavonoids depends on the ortho di-
hydroxyl group on the B-ring of the flavonoids. The present study on H. floribunda has 
shown that the leaves contain bioactive compounds with potential as anticancer agents and 
cancer protective and preventive activity. More work is still needed to elucidate other 
possible anticancer mechanisms that might be relevant to the cytotoxic effects of the two 
isolated alkaloids. 
Key words: alkaloids, antiproliferative acivity, apoptosis, cancer, caspase, cell cycle, 
chromatography, cytotoxicity, drugs, F-actin, flavonoids, flow cytometry, Holarrhena 
floribunda, lipid peroxidation, mitochondria, mortality, plants and ROS 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction and Background to the Study  
Cancer is a disease at the cellular level involving heritable disorders in cellular control 
mechanisms. The disease is a manifestation of aetiological and pathogenic disturbances of 
mechanisms that control cell division, differentiation and homeostasis. It presents more than 100 
distinct clinical pathologies (Ji-Hwan et al., 2007). It is the largest single cause of death in both 
men and women, claiming over 7 million lives each year worldwide. More than 11 million 
people are diagnosed with cancer every year. It is estimated that globally, there will be 16 
million new cases every year by 2020 (Anand et al., 2008). Despite intensive research and 
advances in scientific knowledge relating to cancer and associated disease conditions, the death 
rate from some common forms of cancer such as lung, breast and colon continues to rise (Sporn, 
1996). In addition, improvements in the detection and treatment of cancer have not translated 
into decline in the overall rate of mortality for most cancers of epithelial origin in the last 30 
years (Sporn, 1997). This is mainly because they are limited by tumour drug resistance and side 
effects of anticancer drugs on normal tissues and cells (Lee, 2001).  
Colorectal cancer accounts for over 90% of malignant tumours of the large bowel (Greenstein et 
al., 1989). Death due to colon cancer alone is about 639,000 worldwide per year and it is the 
third leading cause of cancer-related deaths worldwide (WHO, 2009). This malignancy is caused 
by environmental factors and chemicals in diets capable of promoting tumour growth (Pisani et 
al., 2002) as well as some drugs and cosmetics (Rojanapo et al., 1996). Skin cancer is also one of 
the most common of all human cancers, and its incidence is increasing rapidly worldwide. It 
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contributes approximately 30% of all newly diagnosed cancers in the world, and solar ultraviolet 
radiation is an established cause of approximately 90% of skin cancer (Armstrong and Kricker, 
2001).  
Animal investigations supported by epidemiological studies have suggested an inverse 
relationship between the consumption of fruits and vegetables and the incidence of cancers in 
multiple organs, including lungs, larynx, oral pharynx, gastrointestinal tract and pancreas (Block 
et al., 1992). These studies support the view that more than 70% of all types of cancer do not 
depend on the individual’s genetic background and can be prevented by changes in lifestyle, 
such as a “correct” diet (Wong et al., 2005). Many naturally occurring substances present in the 
human diet, including micronutrients, phytochemicals, vitamins, vitamin precursors and 
minerals, have been found to possess both complementary and overlapping mechanisms of 
chemopreventive activity in multistage carcinogenesis (Wang et al., 2002). Chemoprevention is 
recognized as an important therapeutic strategy for the management of cancer. The enormous 
levels of clinical attrition for current chemical-based synthetic anticancer drugs underscore the 
dire need to develop novel anticancer drugs. 
The key to effective chemoprevention is the identification of a chemopreventive agent that can 
effectively inhibit cancer development without toxic side effects. Herbs and natural products lack 
much of the toxicity that is present in synthetic chemicals, thus enhancing their appeal for long-
term prevention strategies (Zou et al., 2005). Medicinal plants rich in antioxidant phytochemicals 
are increasingly being explored for chemopreventive potential (Manikandan et al., 2007). 
Approximately 5-15% of the more than 250,000 species of higher plants have chemically and 
pharmacologically been investigated for various ailments that afflict humans (Baladrin et al., 
1993). Sixty percent of approved drugs for cancer treatment between the 1981-2002 originated 
from natural plant sources (Newman et al., 2003). Data obtained from scientific research 
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emphasize the superior role of natural products as both valuable lead compounds and potentially 
new drugs (Müller, 1998). Moreover, a significant number of the world’s flora still need to be 
explored for the potential bioactive compounds for clinical evaluations. 
The plant used in this study is Holarrhena floribunda, commonly found in undergrowth close to 
forests and woodland savannah, where it normally grows on sandy, humid or lateritic soils. Each 
part of the plant is reputed to have different medicinal uses in folk medicine. The leaves are used 
for sterility, vaginitis, abortion and hypertension, and the root decoctions are indicated in 
blennorrhoea, gonorrhoea and sterility, while decoctions of roots and stems are used for abortion, 
diabetes, dysentery, infectious diseases and local anaesthesia (Kerharo and Adam, 1974; 
Tamboura et al., 1998; Adjanohoun et al., 1989; Neuwinger, 1996). Conessine, a compound 
derived from the stem of the plant, is used for destruction of amoeba without emetic effect 
(Berhaut, 1971). Bioactive compounds isolated from the stem have been shown to possess 
inhibitory activity against resistant strains of Plasmodium falciparum, the malaria pathogen. 
Also, conessine isolated from the stem is reported to have significant effects against various 
bacteria (Bogne et al., 2007). Recently, the leaf extract of this plant has been found to have in 
vitro antioxidant activities against reactive oxygen species OH-, NO- , DPPH and lipid 
peroxidation (Badmus et al., 2010). 
1.2 Objectives of the Study 
The objectives of this study were: 
1. To evaluate the anti-tumour activity of crude methanolic extract of the leaves of H. 
floribunda in different cancer cell lines and a normal cell line. 
2. To evaluate the mechanism(s) of action of the plant extracts. 
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3. To perform bioassay-guided isolation, purification and identification of bioactive 
compounds from the leaves of H. floribunda. 
4. To test the anti-tumour activity of the isolated compounds in different cancer cell lines 
and a normal fibroblast cell line. 
5. To evaluate the antioxidant activity of the isolated compounds. 
6. To evaluate the mechanism(s) of action of isolated compounds. 
To achieve these goals, the following steps were taken: 
 Collection of the plant material (leaves). 
 Evaluation of anticancer activity of the methanolic extract using different bioassay 
systems. 
 Bioassay-guided fractionation of the methanolic extract using chromatographic methods 
like column chromatography, thin layer chromatography and nuclear magnetic resonance 
spectroscopy (NMR). 
 Cytotoxicity profiling using the 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction assay. 
 Determination of the best performing fraction(s) in the cancer cell lines by calculating 
IC50 using non-linear regression analysis of dose-response curves. 
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 Further exploration of fraction(s) that show(s) better inhibition of proliferation of the 
cancer cell lines to elucidate mechanisms of action via cell cycle analysis, apoptosis 
induction using Annexin-V FITC-PI staining and Apopercentage™ assays, and reactive 
oxygen species (ROS) determination. 
  Determination of the mechanisms of cell death type I in treated cells by evaluating 
involvement of PARP using Western blot techniques. 
 Evaluation of the effects of the compounds on the activity of topoisomerase-I, an enzyme 
that cleaves one strand of double-stranded DNA, relaxes the strand, and reanneals the 
strands. 
 Determination of the effects of the compounds on actin filaments, using fluorescence 
microscopy. 
 Estimation of ROS induction using fluorescence microscopy in the presence of 5-(and-
6)-chloromethyl-2’, 7’ dichlorodihydrofluorescein diacetate (CM-H2DCFDA). 
 Assessment the effects of the compounds on the mitochondria using mitotracker red dye 
 Microscopic observation of cellular morphology and nuclear morphology. 
 Determination of antioxidant activity of the isolated flavonoids compounds. 
 Characterization and elucidation of the isolated compounds. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Cancer Initiation 
Cancer is a Greek word indicating growth of epithelial lining surfaces - either external (skin or 
mucous membranes) or internal (glandular acini or tubules). The growth remains unspecialized 
or poorly differentiated in appearance (Oertel, 1930). Cancer growth or tumour expansion is the 
consequence of cells free of physiological controls and maintenance. Cancer was described by 
Horst Oertel, Professor of Pathology at McGill University, Montreal, as far back as 1930 to be an 
expression of atypical cell regeneration, a result of disturbances in the normal relations between 
tissue cells, their vascular supply and innervations which lead to modifications in cell 
differentiation, metabolic and formative functions. He further stated that cancer cells are 
independent of physiological environments where they are derived from. They grow as a new 
entity with their own blood and nerve supply which are adapted only to their growth (Oertel, 
1930). Carcinogenesis is defined as a stepwise accumulation of genetic changes that unshackles 
neoplastic cells from the homeostatic mechanisms that govern normal cell proliferation (Hahn 
and Weinberg, 2002). The slight and noticeable departure from the description by former and 
latter definitions of cancer is that the recent description shows that the advancement in cancer 
biology has delineated the involvement of genetic events in the progression of a normal cell to 
neoplastic development. 
Cancer may also be formed from clonal multiplication of cells, which escaped apoptosis and 
accumulate genetic/epigenetic alterations (Trosko, 2001). Accumulation of aberrant cells with 
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genetic lesions is a fulcrum of carcinogenesis (Nguyen-Ba and Vasseur, 1999). Neoplasia can be 
classified as benign or malignant, depending on their cellular characteristics. Malignant 
neoplasia proliferate uncontrollably, differentiate themselves, invade other tissues and frequently 
metastasize to a region of the body that are not related to their origin (Hanahan and Weinberg, 
2000). Benign neoplasia, on the other hand, grow more slowly with no adverse effects on 
immediate and surrounding tissue functions, except if they compress vital structures (Player et 
al., 2004). 
The causes of cancer development are due to complex multivariate factors (Clapp et al., 2008). 
Diet, lifestyle, viral agents, genetics, environment and occupational exposures all can contribute 
to various stages in the initiation or progression of a tumour (Clapp et al., 2008). Epidemiology 
studies established the causes of the majority of cancers, including environmental factors such as 
chemicals, radiation and viruses (Wogan et al., 2004; Weinstein, 1988). Also, an individual 
genetic disposition to this factor is an important contributor to the emergence of cancer 
incidence. These environmental agents are termed carcinogens that are categorized as either 
endogenous or external factors. A carcinogen is a substance that is genotoxic and which initiate 
carcinogenesis by causing mutations in DNA (mutagen) (Clapp et al., 2008). Carcinogens 
include ionizing radiation, ultraviolet light, chemicals and viruses (Weinberg, 1989; Doll and 
Peto, 1981; Borek, 1993). Cells interact with ionizing radiation within a few seconds, reaction 
with chemicals take a prolonged time while, in contrast, viruses induce new genetic information 
into the genome of target cells. These reactions modify the normal function of cellular genes 
(Borek, 1993). The agents that initiate carcinogenesis have the capacity to interact with the DNA 
base sequence and introduce faulty genetic information. A single exposure to these agents is 
capable of activating a carcinogenic process (Straub and Burlingame, 1981). Examples of these 
agents are PAH (polycyclic aromatic hydrocarbons), nitrosamines, halogenated hydrocarbons, 
benzene, cadmium, formaldehyde. 
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A co-carcinogen refers to a substance that enhances the potency of genotoxic substances, but 
lack ability to cause a tumour on its own. A tumour promoter does not cause a tumour, but 
enhances tumour formation upon repeated exposure to it. Multiple exposures of promoters affect 
gene expression by enhancing the rate of replication of faulty DNA base sequences, which lead 
to expression of faulty genetic information (Trosko and Upham, 2005; Warren et al., 1982; 
Carpenter, 2006). 
However, in addition to chemicals, viruses also cause cancer and these are known as tumour 
viruses. They are either DNA viruses which include EBV, KSHV, HBV and MCPyV or RNA 
viruses such as HCV and HTLV-1 (Saha et al., 2010). Tumour viruses may directly transform 
the cell by integrating oncogenes into a cell or activating cellular oncogenes. These mechanisms 
can lead to tumorigenesis if a dysfunctional immune surveillance system is unable to prevent or 
modulate tumour development (Carrillo-Infante et al., 2007). 
2.2 Cancer Development  
Carcinogenesis is a process that involves abnormal accelerated cellular changes in the genes 
controlling proliferation, differentiation and apoptosis (Sun et al., 2004; Hong and Sporn, 1997). 
Malignant development of normal cells requires acquisition of six fundamental events: self-
sufficient proliferation, insensitivity to anti-proliferative signals, evasion of apoptosis, unlimited 
replicative potential, the maintenance of vascularization and for malignancy, tissue invasion and 
metastasis (Hanahan and Weinberg, 2000).  
There is no difference in the carcinogenesis process in human and experimental animals. The 
rates and periods of exposure to different environmental carcinogens determine the speed and 
frequency of mutation, rates of cell proliferation and phenotypic expression of mutated genes. In 
addition, individual genetic compositions to the susceptibility of the environmental agent and 
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their defense mechanism play roles in neoplasic stages (Oliveira et al., 2007). Cancer 
development is functionally grouped into three phases: initiation, promotion and progression 
(Kinzler and Vogelstein, 1996; Bertram, 2000; Berenblum and Armuth, 1981; Heidelberger et 
al., 1983). 
Initiation is a series of heritable genomic changes within cancer cells, such as point mutations, 
gene deletions and amplification, and chromosomal rearrangements leading to irreversible 
cellular changes. Initiation can also occur through spontaneous mutations of DNA by 
depurination, deamination and errors in DNA replication (Gomes-Carneiro et al., 1997; Trosko, 
2001). Occurrence of cell division after the cells had been initiated before the DNA repair system 
clears the insult makes the damage to be permanent and irreversible (Farber, 1984; Trosko, 
2001). The initiation phase is an additive process because neoplastic development depends on the 
dose of carcinogen, an increase in the dose expands the multiplicity of neoplasia and reduces the 
latent period of its manifestation. Mutated cells can be initiated only if the genes that regulate the 
terminal differentiation are mutated (Trosko, 2001; Farber, 1984).  
Initiated cells can remain latent for years and grow into an autonomous tumour mass in a clonal 
fashion. In this phase, initiated cells ensure symmetrical cell division. The expansion of initiated 
cells occurs by mitogenic processes caused by an increase in the number of new cells and 
apoptosis inhibition. Apoptosis promotes the natural death of damaged cells (Trosko, 2001; 
Trosko, 2003). Survival and clonal expansion of initiated cells by tumour promoters lead to 
cancer cell development. Irreversible genetic changes prepare normal cells to enter immortality 
(Trosko, 2001; Shacter and Weitzman, 2002). Initiated cells are similar phenotypically when 
compared with normal cells, although mutations have occurred, but not differentiation (Trosko, 
2003).  
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The promotion phase is a reversible stage of carcinogenesis that requires several years or decades 
for its manifestation. It is an expansion of mutated cells to form actively dividing multicellular 
premalignant lesions (Sun et al., 2004). Progression is substantial growth in tumour size and 
either growth related or mutually exclusive metastasis. Accumulation of genetic lesions is 
important to cancer development. The lesion is essential for initiation which also involves 
promotion or progression of tumour development (Kinzler and Vogelstein, 1996). The sustained 
genetic lesions induce the activation of cellular proto-oncogenes or inactivation of tumour 
suppressor genes. 
The acquired intrinsic autonomous properties of cancer cells are not mutually exclusive to the 
ultimate development of cancer. The process of tumorigenesis also involves non-cancer cell 
participation, many of which consist of heterocellular tumour cell populations. For example, the 
contribution of vascular endothelial cells to the development of neo-angiogenesis (new blood 
vessel formation) for the survival of immortal cells (Rakoff-Nahoum, 2006; Kinzler and 
Vogelstein, 1996). 
2.3 Cancer Epidemiology 
According to the World Health Organization (WHO) and its cancer research agency, the 
International Agency for Research on Cancer (IARC), about 12.7 million new cancer cases were 
diagnosed in 2008 worldwide and cancer caused more than 7.6 million deaths in the same year 
(http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900; accessed 14 October 
2013). Cancers which exceeded 40% of all cases most frequently diagnosed include lung, female 
breast, colorectal and stomach cancers. Table 2.1 summarizes estimated age-standardized cancer 
incidence and mortality rate per 100,000 by world area in 2008 (Ferlay et al., 2010). Figure 2.1 
provides estimates of the 10 most commonly diagnosed cancers in 2012 (Ferlay et al., 2010). 
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2.4 The Cell Cycle  
2.4.1 The Normal Cell Cycle 
The cell cycle (Figure 2.2) is a series of cell divisions which are basic requirements for the 
development of a fertile zygote to an adult individual (van den Heuvel, 2005). Each set of 
divisions requires complete orderly events that are known as the cell cycle. The cell cycle 
involves a network of interacting proteins that receive signals from outside and inside the cells. 
The signals are processed and integrated which then evokes the fate of the cell whether to 
proliferate or to enter the quiescent state (Weinberg, 2007).  
Table 2.1: Estimated age-standardized cancer incidence and mortality rate per 100,000 by world area, 
2008.  
 
 Incidence Mortality 
 Male Female Overall Male Female Overall 
Eastern Africa 121.2 125.3 122.8 105.4 95.9 99.9 
Middle Africa 88.1 96.7 91.8 78.5 75.6 76.4 
Northern Africa 109.2 98.9 103.2 89.5 68.2 78.0 
Southern Africa 235.9 161.0 189.6 172.1 108.1 133.2 
Western Africa 92.0 123.5 107.6 80.1 91.2 85.4 
Eastern Asia 222.1 158.1 188.4 155.5 87.3 120.1 
South-Central Asia 99.7 110.8 104.6 78.0 71.7 74.5 
South-Eastern Asia 143.9 141.7 141.5 112.3 89.4 99.5 
Western Asia 152.8 119.5 133.8 113.9 74.3 92.2 
Caribbean 196.3 153.5 172.6 116.6 86.2 99.9 
Central America 136.2 134.4 134.4 84.7 80.6 82.0 
Northern America 334.0 274.4 299.9 122.4 91.5 105.1 
South America 186.7 162.9 171.9 116.6 88.2 100.3 
Central and Eastern Europe 259.2 184.2 210.6 181.5 94.0 128.1 
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Northern Europe 292.3 249.5 266.1 134.6 99.7 114.5 
Southern Europe 289.9 212.2 245.0 149.9 81.2 111.7 
Western Europe 337.4 250.9 287.7 138.4 84.3 108.0 
Australia/ New Zealand 356.8 276.4 313.3 126.6 86.0 104.1 
Melanesia 146.0 133.4 138.5 119.8 95.9 106.8 
Micronesia 153.8 164.4 157.5 104.7 70.3 86.1 
Polynesia  225.0 201.5 209.8 133.6 87.9 109.1 
Table excludes non-melanoma skin cancer (Ferlay et al., 2010). 
 
It is an organized and monitored high energy demanding set of events required for proper cell 
division into two daughter cells (Norbury and Nurse, 1992). The cell cycle is a process 
alternating between phases: S phase (doubling process during which DNA is synthesized) and M 
phase (when the cell contents are divided into two equal daughter cells). The periods between 
these phases are known as gap periods (G phase) (Sandal, 2002). Cells are stimulated by 
extracellular mitogens and growth factors during the G1 phase. In responding to stimulation, the 
cell passes through G1 and proceeds with DNA synthesis in the S phase. G2 is the interval 
between the completion of DNA synthesis and mitosis. M phase is marked by the generation of 
bipolar mitotic spindles, segregation of sister chromatids and cell division (Israels and Israels, 
2000). 
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 Source: (Ferlay et al., 2012). 
Figure 2.1: Estimates of the 10 most commonly diagnosed cancers in 2012  
Stages of the M phase include prophase, metaphase, anaphase and telophase. DNA replication 
occurs in the S phase, which is preceded by a gap called G1 during which the cell prepares for 
DNA synthesis followed by another gap known as G2 when the cell gets ready for mitosis. Cells 
in G1 can enter G0 (a resting state) before it commits to DNA replication. The G0 phase 
accounts for the non-proliferatiing cells (Norbury and Nurse, 1992). Proliferating cells enter G1 
phase from G0, after completing cytokinesis. G1 phase is mitogenic dependent up to the 
restriction point after which cells can proliferate independently of mitogenic stimuli and are 
committed to S phase, when DNA replication occurs. Progression through the mammalian cell 
cycle requires the accurate orchestration of this sequence of events (Diaz-Moralli et al., 2013). 
The cell is imparted with quality control points known as checkpoints. Checkpoints sense 
damaged DNA before the cell enters the S phase (G1 checkpoint) or M phase (G2 checkpoint) 
(Weinberg, 2007). The culmination of any of these checkpoints (Figure 2.2) is the ability to turn 
off the previous state and promote the future state of the cell cycle (irreversible progression). 
 
 
 
 
CHAPTER 2 | 2.4.1 THE NORMAL CELL CYCLE 
14 
Cell cycle checkpoints inhibit DNA replication when DNA is damaged, inhibition of mitosis 
when DNA has not been replicated or is damaged and inhibition of cytokinesis when mitosis has 
not been properly executed (Weinberg, 2007). Loss of checkpoint control results in genomic 
instability, accumulation of damaged DNA and uncontrolled cell proliferation which are 
implicated in many human cancers (Sherr, 2000; Weinberg, 2007). 
Intrinsic and extrinsic pathways are two main classes of regulatory mechanisms driving the cell 
cycle. The intrinsic mechanism appears in every cycle while the extrinsic mechanism acts only 
when a defect is detected. The mechanism of regulation is divided into phosphorylation; 
dephosphorylation and proteolytic degradation (Ekholm and Reed, 2000). The transmission of 
phases in the cell cycle is propelled by a complex of protein kinases with their respective cyclins 
with subsequent phosphorylation by an activating kinase (Figure 2.2). Cyclin is the regulatory 
unit and CDK is its catalytic partner (Israels and Israels, 2000). Cyclin/CDK complexes 
phosphorylate specific protein substrates to move the cell through the cycle with activation of 
DNA synthesis (in late G1 and S) and formation of the structural components associated with 
mitosis (in late G2 and M) (Israels and Israels, 2000). 
During the G1 phase, there is increased expression of D cyclins (D1, D2, D3) - these cyclins 
associate with CDK4 and CDK6 to form complexes which result in phosphorylation and 
activation of the CDKs. The activated CDKs phosphorylate the retinoblastoma (Rb) tumour 
suppressor. The Rb plays a critical role in regulating G1 progression through the restriction point 
(Israels and Israels, 2000). Rb acts as a gatekeeper of the cycle and thus guards the restriction 
point, preventing cell cycle progression in the hypophosphorylated state while 
hyperphosphorylated Rb is associated with the release of elongation factor E2F and passage 
through the cell cycle. Rb is maintained in its hyperphosphorylated state throughout the 
remainder of the cycle (Israels and Israels, 2000). 
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 G1, S, G2 and M are promoted by cyclin-dependent kinases regulated positively by cyclins and 
negatively by CDK inhibitors (CDKIs) (Schwartz and Shah, 2005). 
Figure 2.2: The four phases of the cell cycle (G1, S, G2 and M) 
The integrity of the cell's genome is monitored by the transcription factor p53 which halts 
progression of the cell cycle to allow time for DNA repair. This is accomplished by p53 
inhibition of Rb phosphorylation. The level of p53 is maintained low in normal proliferating 
cells. In the presence of DNA damage, p53 binds to its sequence-specific DNA site - gene 
induction results in increased p53 protein synthesis (Israels and Israels, 2000). Thus, p53 controls 
cell cycle through upregulation of p21 (CKI) an active inhibitor of CDKs 2, 4 and 6. The 
inhibition of kinase activity prevents phosphorylation of Rb and the cell is arrested at G1 to 
allow time for DNA repair. The p53 induced un-redeemable damaged cell enters into apoptosis 
by inducing the expression of the pro-apoptotic protein Bax (Israels and Israels, 2000). 
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2.4.2 The Cancer Cell Cycle 
The delicate balance between the rate of cell cycle progression (cell division) and cell growth 
(increased cell mass) on the one hand and programmed cell death (apoptosis) on the other is 
important to cancer development (Reed, 1999). Tumour heterogeneity and diversity do not stand 
as barriers to share some prominent properties such as unrestricted proliferation. Aberrations in 
proteins that are key to cell proliferation control and survival are important to all types of tumour 
formation (Evan and Vousden, 2001). The connection between altered cell cycle regulatory 
proteins and malignant transformation had been described by several scientific reports which has 
led to the notion of cancer as a disease of the cell cycle (Diaz-Moralli et al., 2013).  
Overexpression of CDKs and cyclins and loss of CKI and pRb expression are altered 
modifications linked to tumorigenesis that result from chromosome alterations such as 
amplifications and translocations of oncogenes and deletions of tumour suppressors or epigenetic 
inactivation such methylation of tumour suppressor promoters (Shapiro, 2006; Malumbres and 
Barbacid, 2001). Misregulated CDKs is known to induce constitutive mitogenic signalling and 
defective responses to anti-mitogenic signals cause aberrant proliferation, genomic and 
chromosomal instability (Malumbres and Barbacid, 2009; Massague, 2004). CDKs (CDK4, 6 
and 2) involved in G1 to S transition control and regulations have been shown to be altered in 
80-90% of tumours (Tetsu and McCormick, 2003; Malumbres, 2011).  
ATM (ataxia-telangiectasia-mutated)-CHK2-p53, a DNA damage checkpoint pathway, 
reportedly leads to CDK hyperactivity, unregulated cell cycle progression, genomic instability, 
and cancer when they are dysregulated (Malumbres and Barbacid, 2009). Such genes involved in 
cancer transformation are termed oncogenes (growth promoting) and tumour suppressor genes 
(growth inhibiting) (Butel, 2000). More than 100 oncogenes and 30 tumour suppressor genes 
(TSG) are known and are the major classes of cancer-related genes that are in focus in addition 
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to tumour viruses some of which are of no cognates (Surekha, 2001). Oncogenes in their normal 
proto-oncogene state drive the cell cycle forward, allowing cells to proceed from one cell cycle 
stage to the next (Chow, 2010). This highly regulated process becomes dysregulated due to 
activating genetic alterations that lead to cellular transformation. Tumour suppressor genes, on 
the other hand, restrict cell cycle progression. Their control over cell division is lost with genetic 
alterations leading to their inactivation (Chow, 2010). 
Epigenetic changes in these genes are also contributing factors to the unrestricted proliferative 
potential of cancer cells. These changes show the negative impact of mutagens (exogenous and 
endogenous), germline mutations and various types of genomic instabilities acquired during 
tumour development (Surekha, 2001). Both the oncogenes and TSG are known to code for 
diverse functions such as growth factors (cytokines), growth factor receptors, adapter molecules, 
protein kinases, G-proteins, nuclear transcription factors, molecules that repair DNA, apoptosis, 
metastasis and invasion (Surekha, 2001). Six essential manifestations of the alterations in these 
genes have been aptly described by Hanahan and Weinberg to lead to self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless 
replicative potential, sustained angiogenesis, tissue invasion and metastasis (Hanahan and 
Weinberg, 2000).  
2.5 Apoptosis 
2.5.1 Overview of the Process 
The term apoptosis was originally described by John Kerr, an Australian pathologist in 1965. 
The word was coined in 1972 by John Kerr, Alasrtair Currie and Andrew Wyllie for what is now 
known as programmed cell death (Kerr et al., 1972). Apoptosis describes a morphological 
distinct form of biologically programmed cell demise (Elmore, 2007). Programmed cell death 
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(PCD) is endowed like the cell cycle with a complex network of cell death pro- and anti proteins 
working in tandem in a delicate balance to achieve tissue homeostasis (Reed, 1999).  
PCD occurs naturally as a homeostatic mechanism during development and aging to maintain 
appropriate cell populations in tissues and as a defence mechanism when cells are damaged by 
disease or noxious agents (Norbury and Hickson, 2001). It is a genetically regulated active 
process of removing cells in both physiological and pathological processes. It is a normal 
physiological response to specific suicide signals or lack of survival signals (Kerr et al., 1994). It 
is an energy dependent coordinated cascade of events and its response to death signals leads to 
the activation of a group of cysteine proteases called caspases (Elmore, 2007).  
Apoptosis plays a significant role in shaping tissues during morphogenetic development, 
endocrine dependent atrophy and as an important component of processes of normal cell 
turnover in many tissues. It also plays a pivotal role in organism survival by limiting the 
accumulation of harmful cells, such as self-reactive lymphocytes, virus-infected cells and tumour 
cells, proper development of immune system function, normal embryonic development and 
maintenance of cell homeostasis (Reed, 1995; Wyllie, 1997; Reed and Tomaselli, 2000).  
Morphological changes during apoptosis could be assessed using light and electron microscope 
(Hacker, 2000). Cell morphological changes are a hallmark that can be used to describe 
apoptosis, including chromatin condensation, nuclear fragmentation accompanied by cell 
rounding up, cellular volume reduction (pyknosis) and retraction of pseudopodes (Kroemer et al., 
2005). A cell undergoing apoptosis loses microvilli and junctional complexes making it to shrink 
and to be released (detach) from neighboring cells with enlarged nucleolus and abnormal 
granular appearance (Wyllie, 1997). Cell shrinkage and pyknosis are the earlier processes of 
apoptosis, which is characterized by smaller size, dense cytoplasm and tightly packed organelles, 
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while pkynosis is a result of chromatin condensation (Elmore, 2007) which form a cap like 
densely heterochromatic regions in the nucleus (Wyllie, 1998). Cell surface molecules changes 
occur to facilitate recognition of neighbouring cells or phagocytes (Wyllie, 1998). Plasma 
membrane blebbing, karyorrhexis and separation of cell fragments into apoptotic bodies 
(apoptosomes) occur during a process called budding.  
Apoptotic bodies consist of cytoplasm with tightly packed organelles with or without nuclear 
fragments. This does not affect the integrity of the organelle as they are enclosed within an intact 
plasma membrane (Elmore, 2007). Apoptotic bodies are phagocytosed by macrophages, 
parenchymal cells or neoplastic cells and degraded within phagolysosomes (Elmore, 2007). The 
phagocytosis process prevents apoptotic cells to release their constituents into the surrounding 
interstitial tissue, thereby preventing secondary necrosis and also the engulfing cells do not 
produce inflammatory cytokines (Savill and Fadok, 2000; Kurosaka et al., 2003). 
Apoptosis is triggered by a series of stimuli such as DNA lesions as a result of ultraviolet (UV) 
radiation, ionizing radiation, oxidative stress, errors in replication or recombination and as well 
as environmental and therapeutic toxins (Kumari et al., 2008). A number of physiological and 
pathological stimuli that initiate apoptosis have been described and are grouped into four main 
categories (Pritchard and Watson, 1996; Savitz and Rosenbaum, 1998; Arends and Wyllie, 
1991). The first category includes alkylating anticancer drugs and ionizing radiation that cause 
DNA damage. The second category induces apoptosis by receptor activation through 
glucocorticoids acting on the thymus, tumour necrosis factor-α or by withdrawal of growth 
factors such as nerve growth factor and interleukin (IL)-3. The third category encompasses 
agents that induce apoptotic downstream components which include kinase inhibitors and 
phosphatases. The agents that cause direct cell membrane damage includes heat, UV light and 
oxidizing agents (superoxide anion, hydrogen peroxide) fall into the fourth category (Wyllie, 
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1997; Savitz and Rosenbaum, 1998; Rudin and Thompson, 1997; MacLellan and Schneider, 
1997). 
The DECISION PHASE of apoptosis is a genetically controlled first stage after induction by an 
appropriate stimulus. This is followed by an execution phase, which is the stage for the 
manifestation of morphological changes in apoptosis. The third stage is the engulfment of the 
dying cell and eventually is followed by degradation of the engulfed cell DNA (Goran, 2005). 
The two main genes that control apoptosis in the decision stage are known as Bcl-2 and p53 
genes. Bcl-2 family of mammalian proteins either inhibits or promotes apoptosis. Bcl-2 and Bcl-
xL inhibit apoptosis while Bax, Bad, Bak and Bcl-xs which are Bcl-2 associated proteins 
promote apoptosis (Hockenbery et al., 1993; Yang et al., 1997; Savitz and Rosenbaum, 1998; 
Haunstetter and Izumo, 1998). The p53 nuclear phosphoprotein functions by binding to DNA as 
a transcription factor and controls cell proliferation and repair. C-myc gene also induces 
apoptosis in the presence of p53 gene (Miyashita and Reed, 1995). 
The EXECUTION PHASE involves proteolytic cleavage of enzymes belonging to the cysteine 
protease family referred to as caspases leading to their activation. Activation of caspases, which 
occurs when the enzymes cleave after aspartic acid residues is a fundamental event in the 
apoptotic process (Wyllie, 1997). Caspases are biosynthesized in the zymogen forms that are 
activated by upstream signals into mature proteases. Initiator caspases (caspase-1.-2,-4, -5, -8, -9, 
-10 and -14) are activated by oligomerization-induced autoprocesssing while effector caspases 
(caspase-3, -6 and -7) are activated by other proteases, including initiator caspases and granzyme 
B (Butt et al., 1998; Li et al., 1997; Martin et al., 1998; Yang et al., 1998). 
There are two mains molecular pathways of apoptosis. An additional pathway involves T-cell 
mediated cytotoxicity and perforin-granzyme-dependent killing of the cell. The evidence that the 
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two main pathways interact and one pathway influences the other had been provided by Igney 
and Krammer (2002). The main two pathways of apoptosis are known as extrinsic and intrinsic 
while the additional pathway is called the perforin/granzyme pathway and all these mechanisms 
are all linked to the same terminal or execution pathway (Igney and Krammer, 2002).  
The extrinsic mechanism involves transmembrane receptor mediated interactions of death 
receptors that are members of the tumour necrosis factor (TNF) receptor superfamily. They 
transmit the death signals from the cell surface to the intracellular signalling pathways. 
FasL/FasR, TNF-/TNFR1, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5 are death ligands and 
their corresponding receptors had been well characterized (Suliman et al., 2001; Rubio-
Moscardo et al., 2005). The aggregation of these receptore and their respective ligand complexes 
initiate activation of procaspase-8 into its active form which subsequently activates caspase-3 
(Goran, 2005). 
The intrinsic pathway is a result of damage to the mitochondria inner membrane by various 
stimuli such as oxidative stress. Damage to the inner mitochondrial membrane leads to 
mitochondrial membrane transition pore opening which subsequently releases cytochrome c, 
apoptosis-inducing factor (AIF) and endo G. The complexes of cytochrome c with Apaf-1 
activate procaspase-9 in cytosol (Figure 2.3). The activated procaspase-9 (caspase-9) activates 
downstream effector caspases such as caspase-3, -6 and -7. The endo G released in turn cleaves 
chromosomal DNA independent of caspase activation (Nakagawa et al., 2000). 
T-cell mediated cytotoxicity is a perforin/granzyme pathway of inducing cells to undergo 
apoptotic cell death. Cytotoxic T lymphocytes (CTLs) kill cells through the extrinsic pathway 
with the application of FasL/FasR interaction (Brunner et al., 2003). The killing of tumour cells 
and virus-infected ones occurs through secretion of the transmembrane pore-forming molecule, 
perforin, with the release of serine proteases granzyme A and granzyme B as cytoplasmic 
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granules through the pore into target cells (Trapani and Smyth, 2002). Granzyme B cleaves 
proteins at aspartate residues and therefore activates caspase-10 and cleaves factors like ICAD 
(inhibitor of caspase activated DNAse). 
 
The major apoptotic pathways involve either membrane death receptor stimulation (extrinsic pathway) and/or mitochondrial 
disruption (intrinsic pathway)(Remillard and Yuan, 2004). 
Figure 2.3: The two major apoptotic pathways 
Activation of procaspase-8 leads to cytochrome c release from mitochondria, thereby linking the 
extrinsic and intrinsic pathways (Goran, 2005). Granzyme A on the other hand induces apoptosis 
through caspase activation independent pathway (Pardo et al., 2004). Once in the cell, granzyme 
A activates DNA nicking via DNAse NM23-H1. This DNAse is important in immune 
surveillance to prevent cancer progression through induction of tumour cell apoptosis (Sakahira 
et al., 1998).  
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2.5.2 Apoptosis and Cancer  
The human body produces about 10 billion cells per day to balance homeostasis of cells and 
counteract cells dying through apoptosis. The rate of apoptosis determines the number of cells 
generated, especially in the disease state, during normal development and aging (Renehan et al., 
2001). Deregulated apoptosis is implicated in pathological conditions. Decreased apoptosis is 
linked to cancer, autoimmune disorders and viral infections while excessive apoptosis is related 
to ischaemic injury (myocardial infarction, stroke, AIDS, neurodegenerative disease, sepsis and 
multiple organ dysfunction syndromes) (Zornig et al., 2001; Saikumar et al., 1998). 
Cancer is an example of either an overproliferation of cells or suppressed apoptosis. Evasion of 
apoptosis is one of the hallmarks of cancer development and progression. Escape of cell death 
due to host inability to eliminate potential malignant cells caused by elevated and ablated 
expression of tumour suppressor genes and oncogenes as well as interaction with other growth 
promoting lesions play a vital role in carcinogenesis (Lyons and Clarke, 1997). Mechanisms that 
lead to evasion of apoptosis has generally been divided into three categories: (1) Imbalance 
between pro-apoptotic and anti-apoptotic proteins (2) reduced caspase function and (3) 
disruption of death receptor signalling  (Hanahan and Weinberg, 2000).  
2.5.2.1 Imbalance Between Pro- and Anti-Apoptotic Bcl-2 Proteins 
The Bcl-2 family of proteins is known to have more than 30 members with either pro- or anti-
apoptotic functions, indicating that they might be involved in different roles in carcinogenesis 
(Cory et al., 2003). Alteration in the expression of anti-apoptosis and pro-apoptosis members of 
the Bcl-2 family in human cancer was the first to be described (Reed, 1997b; Reed, 1997a). The 
mechanism involved in abnormal levels of Bcl-2 family proteins in most instances imply 
changes in the transcriptional and posttranscriptional regulatory networks that control the 
eventual products of their genes (Reed, 1999). It involves structural alterations to the genes such 
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as t(14;18) chromosomal translocations that activate Bcl-2 in most non-Hodgkin's lymphomas 
(Tsujimoto et al., 1985). B cell lymphoma overexpresses Bcl-2 which serves as evidence for 
suppressed apoptosis for cancer incidence. Single nucleotide substitution and frame shift 
mutations that inactivate Bax in malignancies of the colon, stomach and haematopoietic system 
and retrovirus gene insertions that activate the bcl-XL gene in murine leukaemias (Thomas et al., 
1998). 
The expression of either Bcl-2 an anti-apoptotic protein and downregulation of Bax pro-poptotic 
protein is what tumour cells need to acquire resistance to apoptosis (Elmore, 2007). The 
expression of both proteins is controlled by the p53 tumour suppressor gene (Miyashita et al., 
1994). The condition that favours anti-apoptotic over pro-apoptotic signatures in Bcl-2 family 
members renders tumour cells resistant to a wide range of cell death stimuli, including 
essentially all chemotherapeutic drugs, radiation, hypoxia, cell detachment from extracellular 
matrix, growth factor withdrawal, glucose deprivation, elevated cytosolic Ca2+, oxidants, tumour 
suppressors such as p53 that induce apoptosis, and oncogenes such as myc and cyclin D1/Bcl-l 
that drive cell division, but also promote death (Reed, 1994). The resistance to cell death that 
occurs due to overexpressed Bcl-2 in cancer has relevance to cancer cell behaviour and newer 
cancer therapies which include angiogenesis inhibitors (hypoxia, hypoglycaemia), tumour 
invasion and metastasis (cell adhesion), multistep carcinogenesis (myc, cyclin D1), and 
antibodies designed to block growth factor receptors (anti-HER2) (Reed, 1999). 
Bcl-2 transgenic mice have been shown to develop malignancy at old age, which implies that 
overexpression of bcl-2 is not sufficient for malignant transformation. In addition, bcl-2 
transgene expression has been reported to significantly extend the lifespan of B lymphoid 
tumours, indicating that bcl-2 overexpression provides a predisposition for the development of 
B-cell lymphomas (Strasser et al., 1990). The assumption that Bcl-2 prolong lifespan of normally 
 
 
 
 
CHAPTER 2 | 2.5.2.2 REDUCED CASPASE FUNCTION 
25 
short lived cells to accumulate additional oncogenic mutation was corroborated by observations 
that leukaemias develop very rapidly in mice with the combination of a bcl-2 and c-myc 
transgene than in mice bearing either of the two alone (Zhivotovsky and Orrenius, 2006). 
2.5.2.2 Reduced Caspase Function  
Human caspases are classified according to their function, size of their pro-domain or cleavage 
specificity. Group I caspases are proteases that are basically associated with innate immunity 
against pathogens (inflammatory) which includes caspase-1, -4 and -5. Group II caspases are 
involved in the regulation of apoptosis (Olsson and Zhivotovsky, 2011). Group II caspases are 
divided into two classes: initiator caspases, which include caspase-2, -8, -9 and -10 and effector 
caspases also known as executioner caspases which include caspase-3, -6 and -7. Initiator 
caspases are monomeric zymogens while the effector is constitutively produced in cells as 
dimers. Dimerization triggered by the formation of multi-component complexes activates 
initiator caspases while the proteolytic activity of initiator caspases is required to trigger the 
activity of effector caspases (Boatright et al., 2003). The vital role played by the caspases in both 
the upstream and downstream process of apoptosis conceivably implies that dysregulation of 
their functions might influence cell proliferation (Zhivotovsky and Orrenius, 2006). It is not, 
however, out of a place to hold that low levels of caspases or impairment in caspase function 
may result in a decrease in apoptosis or carcinogenesis. 
Caspase-9 is not mutated or silenced in the majority of cancers (Kim et al., 2010). Decreased 
levels were reported in 46% of colon cancers while its expression was found to be increased in 
gastric cancer (Yoo et al., 2002; Yoo et al., 2004; Palmerini et al., 2001). Somatic mutation 
without altering amino acid sequence occurs at very low frequency in colorectal, gastric and lung 
carcinomas (Soung et al., 2006). It has been observed that 55% of caspase-9 was phosphorylated 
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at Thr125 in gastric carcinomas, presumably preventing the activation of the enzyme (Allan and 
Clarke, 2009; Yoo et al., 2007).  
Initiator caspases are known to allow one specific caspase to respond to one death stimulus. This 
sole obligatory role makes them an important candidates for putative tumour suppressors (Olsson 
and Zhivotovsky, 2011). Caspase-8 and -10 are found in a genomic locus 2q33-34 frequently 
known to be affected in cancer (Grenet et al., 1999). Caspase-10 was not mutated in breast 
cancer, lung cancer and hepatocellular carcinoma, but in 4.3% of colon cancer samples analyzed 
(Oh et al., 2010). Increased levels of expression of caspase-10 are observed in gastric cancers 
compared to normal mucosa. It is therefore implied that caspase-10 function is of no relevance to 
gastric cancer (Park et al., 2002).  
Paediatric tumours and their cell lines contain silenced caspase-8 owing either to gene deletion or 
promoter methylation (Teitz et al., 2000a). Loss of caspase-8 expression is known to often 
correlate with mycn oncogene amplification and increased levels of the corresponding protein 
(Harada et al., 2002). Cells with low apoptosis capacity is linked to all the described alterations 
in caspase-8 compared to cells harbouring normal caspase-8 which strongly suggests tumour 
suppressor functions (Olsson and Zhivotovsky, 2011). Caspase-8 is involved in the suppression 
of oncogenic transformation independent of its role in cell death induced by death receptors 
(Krelin et al., 2008). Neuroblastoma, medulloblastoma and small-cell lung carcinoma (SCLC) 
are reported to lack caspase-8 due to gene silencing (Shivapurkar et al., 2002; Takita et al., 2000; 
Zuzak et al., 2002). It has therefore been suggested that caspase-8 acts as a tumour suppressor in 
the neuroectodermal or neuroendocrine cell lineage (Mazumder and Almasan, 2002; Teitz et al., 
2000b). It is likely that DNA methylation of caspase-8 occurs via DNA methylation in 52% 
cases (Hopkins-Donaldson et al., 2003). 
 
 
 
 
CHAPTER 2 | 2.5.2.3 DISRUPTION OF DEATH RECEPTOR SIGNALLING 
27 
Detailed investigations of caspases in execution phase produced conflicting results. The 
expression of caspase-3 in some cancer cells is induced, but suppression occurs in non-cancerous 
cells (Nakagawara et al., 1997; Fujikawa et al., 2000). The expression of this protein and 
malignant grade has been reported to be either positively or negatively correlated (Nakagawara 
et al., 1997; Satoh et al., 2000). Localization of caspase-3 in both nuclear fractions of pancreatic 
and neuroblastoma tumours was found to be correlated with low malignancy. Low frequencies of 
mutated caspase-3 are detected in some human cancers such as colon and stomach, non-Hodgkin 
lymphoma (NHL) and hepatocellular carcinoma (Soung et al., 2004). Breast and prostate cancers 
were observed to express non-mutated caspase-3 and the expression increases with tumour 
progression (Kim et al., 2010). Caspase-6 and -7 are rarely found in mutated form in human 
cancers (Anwar et al., 2004; Jager and Zwacka, 2010).  
High levels of caspase-3 expression while low levels of caspase-6 and -7 are reported in gastric 
carcinoma more than in normal mucosa (Yoo et al., 2002; Yoo et al., 2004). In the majority of 
cases of invasive carcinoma of the breast caspase-6 was found to be expressed (Vakkala et al., 
1999). However, only small fractions of human cancer are related to inactivating mutations or 
silencing of caspase genes (Jager and Zwacka, 2010). It is not yet certain whether mutation in 
these caspases play role in tumorigenesis. Some of prevalent cancer type lack mutant caspase 
genes and show normal expression of caspases (Jager and Zwacka, 2010). 
2.5.2.3 Disruption of Death Receptor Signalling  
Death receptors are part of the TNF receptor gene family with over 20 proteins of different 
biological activities which include the regulation of cell death, cell survival, differentiation or 
immune regulation (Ashkenazi and Dixit, 1998). They have similar cysteine-rich extracellular 
domains and are identified by their cytoplasmic domain of about 80 amino acids known as the 
death domain (Walczak and Krammer, 2000). Death domain functions essentially as an apoptotic 
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inducer by transmitting death signals from the cell's surface to intracellular targets and play 
major roles in the extrinsic pathway of apoptosis (Debatin and Krammer, 2004).  
Examples of death receptors are TNFR1 (DR1), Fas (DR2, CD95 or APO-1), DR3 (APO-3), 
DR4 [or TNF-related apoptosis inducing ligand receptor 1 (TRAIL-1)], DR5 (TRAIL-2), DR6, 
ectodysplasin A receptor (EDAR) and nerve growth factor receptor (NGFR) (Wong, 2011). The 
best characterized death receptors are CD95 (APO-1/Fas), TNF receptor 1 (TNFR1), TRAIL-R1 
and TRAIL-R2 (Debatin and Krammer, 2004). Death receptors are activated in response to 
binding of ligands upon oligomerization. The corresponding ligands of the TNF superfamily of 
death receptors include CD95 ligand, TNF alpha, lymphotoxin-alpha, TRAIL and TWEAK 
(Walczak and Krammer, 2000).  
Several abnormalities in death signalling pathways such as downregulation or defects in receptor 
functions, mutations within the genes encoding receptors and apoptotic signalling pathway 
defects are the reported mechanisms by which cells evade apoptosis (Wong, 2011; Landowski et 
al., 1997; Hitoshi et al., 1998). Heterozygous mutations of CD95 gene on chromosome 10q23 are 
found in a number of human tumours (Takayama et al., 2002; Muschen et al., 2002). Also, loss 
of expression of TRAIL receptors I and II localized on chromosome 8p due to loss of 
heterozygosity or hypermethylation are reported in several tumours (Pai et al., 1998; van Noesel 
et al., 2002). Downregulation of FAS surface expression levels are found to be associated with 
melanoma, oesophageal cancer and pulmonary adenocarcinomas. FAS mutations are also 
reported in nasal NK/T cell mutation and testicular germ cell tumours (Takakuwa et al., 2002; 
Takayama et al., 2002). Substitution of guanine with adenine at position 422 which changes an 
arginine to histidine and also cytosine to guanine at position 626 replacing threonine with 
arginine in the extra domain of DR4 are associated with risk of lung and head and neck cancer 
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(Fisher et al., 2001). Missense mutations in DR5 are reported in 7% of gastric cancer samples. A 
mutated protein inhibits TRAIL-induced apoptosis when transfected into cells (Park et al., 2001).  
Some mutations induced loss of apoptotic activity when overexpressed while some are neutral. 
Mutant DR5 corresponding to the Ipr locus was found to be 50% less in inducing apoptosis while 
guanine to adenosine substitution at nucleotide base 1063 led to a change of glutamic acid to 
lysine, resulted in total loss of apoptotic function (McDonald et al., 2001; Lee et al., 1999). 
Reduced expression of CD95 is reported to be involved in treatment-resistance in leukemia or 
neuroblastoma cells (Friesen et al., 1997; Fulda et al., 1998). Reduced membrane expression of 
death receptor and abnormal expression of decoy receptors play roles in the evasion of the death 
signalling pathways in cancers (Fulda, 2010a). 
Accumulating scientific evidence suggests that down-regulation of pro-apoptotic proteins, in 
combination with the expression of other structural and regulatory proteins are essential for 
metastatic progression. The overall status of the cell death machinery, however, might explain 
how it affects tumorigenesis rather than an expression of the individual proteins (Zhivotovsky 
and Orrenius, 2006). 
2.5.3 Orchestration of Apoptosis by p53 
The p53 protein is also called tumour protein 53. It is one of the best characterized tumour 
suppressor proteins encoded by the tumour suppressor gene located on the short arm of 
chromosome 17 (17p13.1) (Wong, 2011). The p53 protein regulates the transcription of genes 
responsible for the cyclin-dependent kinase inhibitor p21 waf1/cip1, the protein GADD45, and 
apoptosis proteins Bax and Bcl-2, and thereby controls cell cycle arrest and apoptosis and its 
own function by regulating Mdm2 transcription (van Oijen and Slootweg, 2000). In addition to 
its role in induction of apoptosis and cell cycle regulation, some other key functions such as cell 
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development and differentiation, gene amplification, DNA recombination, chromosomal 
segregation and cellular senescence have been adduced for it (Lane, 1992).  
A mouse model carrying mutant p53 lacking proline-rich domain that confers inability to induce 
cell cycle arrest, but retain ability to induce apoptosis was found to be protected from tumour 
development, suggesting the importance of the tumour suppressing ability of p53 (Toledo et al., 
2006). In addition, the second mouse model with functional cell cycle arrest, but inactive 
apoptosis induction ability in mutant p53 (p53-R172P) suggests that cell cycle arrest and 
chromosome stability are also critical to tumour development (Liu et al., 2004). These models 
show that p53 activities contribute to its tumour suppressor potential in different cellular contexts 
(Freed-Pastor and Prives, 2012). 
The main mutations found in p53 are point mutations, although small gene deletion or insertions 
have also been detected (van Oijen and Slootweg, 2000). The p53 tumour suppressor gene 
defects had been shown to be associated with more than 50% of human cancers (Elmore, 2007). 
Oncogenic property due to p53 mutation is referred to as a gain of oncogenic function.  
It has been reported that some target genes of p53 involved in apoptosis and cell regulation are 
aberrantly expressed in melanoma cells, leading to abnormal activity of p53 and contributing to 
the disproportionate proliferation of these cells. It has been demonstrated that mice with N-
terminal mutant deletion of p53 (122p53) that corresponds to 133p53 had decreased survival, a 
different and more aggressive tumour spectrum, conferred a marked proliferative advantage on 
cells, reduced apoptosis and profound proinflammatory phenotype (Lane, 1992).  
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2.5.4 Inhibitors of Apoptosis Proteins (IAPs) 
IAPs are highly conserved structurally and functionally related family of proteins that regulate 
apoptosis, cytokinesis and signal transduction (LaCasse et al., 2008). Examples of IAPs in 
humans are XIAP, cIAP1, CIAP2, survivin and livin. Their functions are not limited to 
regulation of apoptosis, but also mitosis as found in survivin (Altieri, 2001; Holcik and 
Korneluk, 2001; Debatin and Krammer, 2004).  
They directly inhibit caspase-3 and caspase-7 and block caspase-9 activation, but caspases -1, -6, 
-8 and -10 are not under its regulation. IAPs regulate caspases in the distal portions of the 
apoptotic proteolytic cascades when ectopically expressed in cells with some functioning as the 
ultimate effectors as found in caspase-3 and -7 (Reed, 1999). Its inhibitory effect is through the 
presence of one or more baculoviral repeat (BIR) motifs in their molecules. They inhibit caspase 
activity by binding their conserved BIR domains to the active sites of caspases or by keeping the 
caspases away from their substrates (Wei et al., 2008).  
It has been suggested that the expression of IAPs as downstream inhibitors of apoptosis might be 
essential to both tumour formation and chemoresistance and also that IAPs can function as 
oncogenes (Zhivotovsky and Orrenius, 2006). The increased levels of IAPs have been reportedly 
found in a wide variety of cancer cells and primary tumour biopsies. (Zhivotovsky and Orrenius, 
2006). The chromosomal amplification of the 11q21-q23 region, which contains both c-IAP1 and 
c-IAP2 was observed in a variety of malignancies and oesophageal squamous cell carcinomas 
frequently display amplification of IAPs (Uren et al., 2000).  
Abnormal IAP expression has been reported in pancreatic cancer cells and is found to be also 
responsible for resistance to chemotherapy (Wong, 2011). In addition, Livin was observed to be 
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expressed in melanoma and lymphoma and Apollon was upregulated in gliomas and was 
responsible for cisplatin and camptothecin resistance (Vucic et al., 2000; Ashhab et al., 2001).  
Survivin was noted to be overexpressed in haematological malignancies and also in small-cell 
lung carcinomas (Chen et al., 1999). It is suggested that overexpression of survivin in the 
majority of NSCLCs together with abundant or upregulated expression of XIAP indicate that 
these tumours are endowed with resistance against a variety of apoptosis-inducing conditions 
(Small et al., 2010; Krepela et al., 2009).  
Accumulating evidences suggest that survivin expression can identify the lesions at highest risk 
for malignant transformation and invasion. Its presence in the body fluids, however, might be an 
important biological marker and predictive sign of treatment outcome (Wang et al., 2004). 
Abnormal expression of the survivin gene in different tumours and its role in tumourigenesis are 
related to function during mitosis, rather than inhibition of apoptosis (Earnshaw, 2005). IAPs are 
the most important regulators of apoptosis because they synchronize both the intrinsic and 
extrinsic pathways of apoptosis. Eight human IAP proteins are known to date with survivin and 
XIAP as the most characterized. 
2.6 Free Radicals and Reactive Oxygen Species (ROS) 
2.6.1 ROS Signalling in Normal and Cancer Cells 
Free radicals are commonly known as reactive oxygen species (ROS) while some are referred to 
as reactive nitrogen species (RNS) (Valko et al., 2006). ROS is defined as intermediate oxygen 
carrying metabolites with or without an unpaired electron with oxidizing capacity. They are 
persistently generated molecules that are transformed and consumed in all aerobic organisms 
(Dickinson and Chang, 2011).  
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ROS describes oxygen derived radicals such as superoxide anions (O2-·), hydroxyl radicals 
(OH·), peroxyl (ROO·), alkoxyl (RO·) as well as oxygen derived non-radical species such as 
hydrogen peroxide (H2O2) while RNS include nitric oxide (NO·), peroxynitrite (ONOO-), 
nitrogen dioxide and nitrite (NO2-) (Halliwell and Cross, 1994; Mahelkova et al., 2008). They are 
chemically active prooxidant products of incomplete oxygen reduction (Sreevalsan and Safe, 
2013; Valko et al., 2006). They convert other components in a chain reaction into free radicals 
through oxidation (Rammal et al., 2010; Valko et al., 2007).  
ROS are produced either to serve essential biological functions or represent byproducts of 
metabolic processes (Shen et al., 1996). Oxygen free radicals either as reactive oxygen or 
reactive nitrogen species are products of normal biological systems which play paradoxical roles 
in living systems (Nyska and Kohen, 2002; Uttara et al., 2009). ROS are generated either from 
both endogenous and exogenous sources (Valko et al., 2006). Endogenous source of ROS 
includes mitochondria, cytochrome P450 metabolism, peroxisome and inflammatory cell 
activation (Inoue et al., 2003).  
Electron transport chains of mitochondria and endoplasmic reticulum are the major sources of 
superoxide anion in aerobic cells. A significant increase is observed in the presence of 
uncouplers of oxidative phosphorylation, hyperbaric oxygen treatment, pathologic conditions 
and alterations of mitochondrial lipids (Mates and Sanchez-Jimenez, 2000). Superoxide can also 
be generated from leaking of electrons onto oxygen in nuclear membranes in the presence of 
NAD(P)H, decomposition of oxyhaemoglobin, photo-irradiation of tryptophan, eumelanin, 
pheomelanin by UV-light, endothelium autoxidation of catecholamines, thiols, a reduced form of 
riboflavin and its derivatives, enzymes such as xanthine oxidase, dehydrogenases and oxidases 
(Mates and Sanchez-Jimenez, 2000). Other endogenous sources of ROS are neutrophils, 
eosinophils and macrophages. Activated macrophages induce an increase in oxygen uptake and 
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give rise to ROS, which include superoxide anion, nitric oxide and hydrogen peroxide (Conner 
and Grisham, 1996). Microsomes and peroxisomes are also responsible for ROS production. 
Microsomes is associated with 80% of hydrogen peroxide produced in vivo at hyperoxia site 
while peroxisomes produce hydrogen peroxide under physiological conditions (Gupta et al., 
1997).  
An exogenous source of ROS includes xenobiotics, chlorinated compounds, metal ions, 
radiation, barbiturates and a host of other environmental agents. These are known to directly or 
indirectly generate reactive species in cells (Klaunig and Kamendulis, 2004). ROS/RNS are 
produced during irradiation by UV light; X-ray and gamma-rays; products of metal-catalyzed 
reactions; are present as pollutants in the atmosphere; produced by neutrophils and macrophages 
during inflammation; by-products of mitochondria-catalyzed electron transport reactions 
(Cadenas, 1989). They play paradoxical roles in biological systems such as defence against 
infectious agents which involve cellular signalling systems and also at low concentrations they 
induce a mitogenic response. In contrast to their beneficial roles they are mediators of damage to 
cell structures, including lipids and membranes, proteins and nucleic acid (Valko et al., 2004). 
Figure 2.4 shows the integrated ROS signalling network in cell mitochondria and its downstream 
physiologic and pathologic effects. 
It is estimated that 10,000 to 20,000 free radicals attack each body cell per day (Valko et al., 
2006). The overwhelming generation of ROS/RNS either through an endogenous or exogenous 
source in excess of the capability threshold of the cell antioxidant defense system is termed 
oxidative stress (Valko et al., 2006). Oxidative stress leads to oxidative degeneration of 
biomolecules such as proteins, lipids and DNA. The accumulation of oxidative damage is known 
to alter physiological functions of the cell as found in alterations in signal transduction and gene 
expression to mitogenesis, transformation, mutagenesis and cell death (Hunt et al., 1998; Mills et 
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al., 1998). Pathological conditions attributed to oxidative lesion include myocardial infection, 
atherosclerosis, neurodegenerative disorders, rheumatoid arthritis and cancer (Devasagayam et 
al., 2004). 
 Mitochondrial respiratory chain is recognize as a major site of ROS production in the form of superoxide, hydrogen 
peroxide and hydroxyl free radical (Bellance et al., 2009) 
Figure 2.4: ROS signalling and its downstream physiologic and pathologic effects 
2.6.2 Reactive Oxygen Species (ROS) and Carcinogenesis  
Mammalian cells are naturally endowed with an antioxidant defense system that buffers the 
effects of oxidants produced in the cells (Lokanatha et al., 2014). The overwhelming production 
of radicals over the body’s antioxidant capability or due to the inability of the body system to 
mop the excess radicals can lead to the pathway of carcinogenesis. Oxidative stress is 
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established, however, when the there is a disruption in the antioxidant/oxidant delicate balance 
(Lokanatha et al., 2014). Building up of the oxidants in excess of normal body antioxidant 
threshold limit leads to deleterious effects on macromolecules. Oxidative DNA mutation can be 
single or double stranded DNA breaks, purine, pyrimidine or deoxyribose modifications and 
DNA cross-links (Funda and Hakan, 2008). The damage can lead to either arrest or induction of 
transcription, induction of signal transduction pathways, replication errors, genomic instability 
(Valko et al., 2006), gene amplification and rearrangements that result in the activation of proto-
oncogenes or inactivation of tumour suppressor genes, all of which are associated with 
carcinogenesis (Tanaka et al., 1998).  
Free radicals such as hydroxy radicals modify DNA by different mechanisms which include 
sugar and base modifications, strand breaks and DNA protein cross-links (Wallace, 1998). 
Guanine (G)-cytosine (C) to thymine (T)-adenine (A) DNA base transversion modification is 
reported to have mutagenesis potential (Grollman and Moriya, 1993). G-C to T-A transversion is 
reported in either inactivation of tumour suppressor genes or activation of oncogenes, suggesting 
that ROS-related mutations play pivotal roles in the initiation step in the development of cancer 
(Lokanatha et al., 2014). Free radical generation with high rates of oxidative DNA damage give 
some tumour potential to mutate, inhibit anti-proteases and damage surrounding tissues.  
Oxidative modification of DNA is also a factor that contributes to the genetic instability and 
metastatic potential of tumour cells in fully developed cancers (Malins et al., 1996). The exact 
mechanism of action of ROS in carcinogenesis has not been fully deciphered. However, two 
mechanisms have been proposed to play a role in oxidative damage and in the development of 
carcinogenesis (Valko et al., 2004). The first mechanism involves modulation of gene expression 
while the second is radicals induce genetic alterations (Valko et al., 2004). The first mechanism 
is through epigenetic effects on gene expression which lead to the stimulation of growth signals 
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and proliferation (Crawford et al., 1995). Strand breakage misrepair, alterations in gene 
expression and loss of heterozygosity contribute to gene expression modulation (Bohr et al., 
1995). Stimulation of protein kinase and poly (ADP-ribosylation) shows that signal transduction 
pathways are also involved in ROS modulation of essential genes (Cerutti and Trump, 1991). 
The second mechanism by which ROS induce carcinogenesis implicates gene mutations and 
chromosomal rearrangements which play roles in the initiation of carcinogenesis (Guyton and 
Kensler, 1993). Oxidative DNA damage leads to chromosomal abnormalities, blockage of DNA 
replication and cytotoxicity (Bohr et al., 1995). A mutation can occur through misrepair and 
incorrect replication while chromosomal rearrangement can be the result of strand breakage 
misrepair (Halliwell and Aruoma, 1991). 
Therefore, it has been shown that oxidants contribute to carcinogenesis by their abilities to 
induce DNA base changes in certain oncogenes and tumour suppressor genes (Jackson, 1994). 
For example, K-ras and C-Raf-1 have been shown to be activated by hydroxyl radicals due to 
induction of DNA point mutations in G-C base pairs and N-terminal deletions in these genes 
(Jackson, 1994). CpG base point mutations induced by ROS are also found to be present in some 
tumour suppressor genes such as p53 and retinoblastoma (Rb) leading to their inactivation 
(Nigro et al., 1989). 
In addition, the tumorigenesis inducing role of ROS is not only limited to DNA oxidation, but 
also by activating signalling  pathways that regulate cellular proliferation, angiogenesis and 
metastasis (Storz, 2005). The effect of ROS as stated above is dependent largely on the level of 
expression of ROS. The low levels are known to activate proliferative signals while high levels 
reduce cell proliferation by activating damage or cell death signals (Rosa et al., 2012). It has 
been observed that ROS activate kinases, protein serine/threonine kinases, small G-proteins or 
transcription factor signaling (including nuclear factor kB, activator protein 1 and hypoxia 
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inducible factor 1 alpha) and inactivate phosphatase, all of which lead to loss of proliferation 
control (Rosa et al., 2012). 
2.7 Antioxidants  
An antioxidant is any substance that delays, prevents or removes oxidative damage to a target 
molecule (Halliwell and Gutteridge, 2007). Evidences have shown that oxidative stress is 
important for cancer development (Halliwell, 2007) and paradoxically apart from the oxidative 
damage of DNA, proteins and lipid attributed to ROS, they still play significant beneficial roles 
in all aerobes at certain conditions (Halliwell, 2006a). The balance between antioxidants and free 
radicals permits useful biological functions unhindered (Halliwell and Gutteridge, 2007). An 
antioxidant is, however, expected to allow the beneficial roles performed by the ROS with 
minimal oxidative damage (Halliwell and Gutteridge, 2007). Increased oxidative damage occurs 
not only through induced oxidative stress, but also via failure to repair or replace damaged 
biomolecules and/or decrease antioxidant levels (Halliwell, 2006b). Coping with oxidative 
damage, therefore, requires repair of oxidized DNA, reassembling of [Fe-S] clusters in enzymes, 
repair of oxidized Met sulfoxide reductases and destroy oxidized lipids and proteins (Moskovitz 
and Stadtman, 2003).  
Antioxidants act by scavenging radicals, donating hydrogen and electrons, decomposing 
peroxide, quenching singlet oxygen, inhibiting enzyme and chelating metals (Lobo et al., 2010). 
They are categorized into two groups of enzymatic antioxidants - superoxide dismutase (SOD), 
catalase, glutathione peroxidase (GPx) and non-enzymatic (ascorbic acid, apha-tocopherol) 
found in the intracellular and extracellular environment (Kohen and Nyska, 2002). They function 
at three different stages of ROS reactions which are prevention (keeping the formation of ROS at 
bearable levels), interception (scavenging reactive species either by catalytic and/or non-catalytic 
molecules) and repair (repairing damage tissue) (Kohen and Nyska, 2002). Prevention is known 
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as the first line of defense, radical scavenging is the second line of defense while repair and de 
novo is the third line of defense (Lobo et al., 2010). The first line defense antioxidants act by 
quenching superoxide anion, decomposing hydrogen peroxide and sequestration of metal ions. 
The antioxidants in this category are SOD, catalase, GPx, glutathione reductase, glutathione-S-
transferase (GST). Also, antioxidant minerals that act as metalloenzymes such as Se, Mn, Cu and 
Zn are also part of the first line of defence (Irshad and Chaudhuri, 2002). Glutathione (GSH), 
vitamin C, uric acid, albumin, bilirubin, vitamin E, carotenoids, flavonoid and ubiquinol are 
radical scavenging antioxidants that form the second line antioxidant defense(Irshad and 
Chaudhuri, 2002). Some of these important antioxidants such as β-carotene, vitamin C and E are 
required in the diets as they cannot be synthesized by most mammals, including human (Irshad 
and Chaudhuri, 2002). Third line of defense are enzymes that involve in repair damaged 
biomolecules and reconstitute damaged cell membrane such as DNA repair enzymes 
(glycosylases and nucleases), transferases, proteases, methionine sulphoxide reductase (Henle 
and Linn, 1997). They still perform another important function known as adaptation where 
signals for the production and reactions of free radicals trigger the formation and transportation 
of the appropriate antioxidant to the right site (Niki, 1993).  
It is well established that inability of inherent antioxidant capacity of the body to clear the 
overwhelming productions of ROS from the body systems lead to degenerative diseases (Saeed 
et al., 2012). Epidemiological studies and metal analyses have shown that diets rich in plant 
polyphenols protect against development of cancers, cardiovascular diseases, diabetes, 
osteoporosis, etc. (Pandey and Rizvi, 2009). This is because ingestion of plant antioxidants have 
been inversely correlated with morbidity and mortality from degenerative diseases (Gulcin, 
2012). Antioxidant compounds from plants prevent or delay oxidative modification of 
macromolecules by inhibiting the initiation or propagation of oxidative chain reactions (Velioglu 
et al., 1998). This has led to growing interest in medicinal plants with antioxidant constituents 
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such as phenolic compounds, terpenoids and vitamins as potential food additives in the 
prevention of oxidative related diseases (Craig, 1999). 
2.8 Medicinal Plants  
2.8.1 Plants as Natural Health Remedies 
Plants are the basic sources of folklore medicine based on the empirical findings of our forebears 
for the treatment of illness common in their contemporary period (Gurib-Fakim, 2006). At that 
time, they did not understand the scientific basis for its use, but they knew from the experience 
that it is effective when used at the right doses (Gurib-Fakim, 2006). A medicinal plant is any 
plant with parts (leaves, stem bark, roots, etc.) that can be put to use for the relief of pain, 
prevention or cure a disease or ability to alter physiological and pathological processes, or any 
plant used as a source of drugs or their precursor (Rates, 2001).  
Medicinal plants contain compounds that either act singly, additively or in synergy to alleviate 
health challenges. A single plant may contain substances that stimulate digestion, or anti-
inflammatory compounds that reduce swelling and pain, phenolic compounds with antioxidant 
activity, tannins with natural antibiotics, antidiuretic substances that enhance the elimination of 
waste products and toxins and alkaloids that enhance mood and give a sense of well-being. The 
presence of secondary metabolites in plants serves as the basis for its medicinal value. Although, 
the presence of these compounds does not enjoy any biochemical justification, but they provide 
an invaluable resource for the discovery of novel and potent drugs for diseases that plague 
humanity (Gurib-Fakim, 2006). 
Plants have been sources of medicine in the form of crude drugs such as tinctures, teas, poultices, 
powders and other herbal combinations/condiments for various illnesses for thousands of years 
(Samuelsson, 2004). The type of plant or part of a plant to be used for a particular ailment is 
passed down through an oral rendition which, are known to have played significant roles in 
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traditional medicine (Douglas Kinghorn, 2001; Samuelsson, 2004). The WHO estimated that 
80% of the population in developing countries rely on the use of plants for curing different 
ailments while plants also play a significant secondary role in the health care sector of the 
developed countries (Jabeena et al., 2014). The development and deployment of technology 
since the 19th century, however, have led to the isolation of particular bioactive agents 
responsible for the observed effects in complex mixtures of compounds present in crude 
formulations or condiments (Newman et al., 2000; Samuelsson, 2004). The isolated bioactive 
compounds are presently being used as drugs or in the various stages of preclinical and clinical 
trials. The isolated compounds in use as drugs represent a very good platform for the exploitation 
of medicinal plants (Balunas and Kinghorn, 2005). 
Drugs of plant origin contribute about 25% of the world’s total drug prescriptions with 121 
active compounds that are currently being used. The WHO considered 252 drugs as the basic 
essential need out of which 11% are of plant origin and a number are precursors of synthetic 
drugs, e.g., digoxin from Digitalis spp., quinine and quinidine from Chinchona spp., vincristine 
and vinblastine from Catharanthus roseus. Reliance on the structural base diversity of natural 
products which give it an edge to be a lead compound and essential template for the design and 
rational planning of new drugs, biomimetic synthesis development and discovery of new 
therapeutic properties not yet attributed to known compounds (Hamburger and Hostettmann, 
1991). The importance of natural product, notwithstanding, exploration of potential of plants for 
the discovery of novel drugs is still very poor because out of about 250,000-500,000 plant 
species only about 5000 species have been studied for medicinal use (Payne et al., 1991). 
2.8.2 Plants as Sources of Anticancer Drugs 
The importance of natural plant products for the treatment of disease has been recognized since 
ancient times. Natural products are small-molecule secondary metabolites from terrestrial and 
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marine plants, microorganisms and animals with diverse structural quality for novel drug 
discovery (Pan et al., 2010). The advancement in technology and progress in combinatorial 
chemistry, notwithstanding, plant agents still make a tremendous contribution to the drug 
discovery process most of which are currently in clinical trials (Cragg et al., 1997; Farnsworth et 
al., 1985). More than 60% of drugs currently used as anticancer have their origin from the 
natural sources (Newman et al., 2003) (Figure 2.5). A review of anticancer drugs in North 
America, Europe and Japan between the period of 1981-2006 show that 47.1% of 155 clinically 
approved anticancer drugs are of natural origin (Newman and Cragg, 2007). 
The discovery of anticancer agents from plant sources started in the 1950s with the development 
of the vinca alkaloids, vinblastine and podophyllotoxins. It is remarkable to note that most of the 
new cancer drugs from natural sources in the last 50 years have been from soil microorganisms, 
terrestrial fungi and higher plants (Kinghorn, 2008). The search has also led to the discovery of 
more anticancer agents with different cytotoxic mechanisms of action, including the taxanes and 
camptothecins (Cragg and Newman, 2005). The upsurge in the number of naturally based 
anticancer drugs might not be unconnected to the adaptation of new technologies, such as 
combinatorial synthesis and automated high throughput screening, which enhances bioactive 
screening, purification and structural analysis from natural products (Nobili et al., 2009).  
The development of drugs that are selective to cancer cells with no effects on normal cells are 
desperately needed to solve the challenges of the burgeoning increase in deaths due to various 
forms of cancer, which stands as another reason for the increased exploration for anticancer 
drugs from the natural sources (Sporn and Liby, 2005). There are four major structural classes of 
plant derived compounds presently in use in Western medicine as a single chemical entity: vinca 
alkaloids (vinblastine, vincristine, vinorelbine), epipodophyllotoxin lignans (etoposide, 
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teniposide, etoposide phosphate), taxane diterpenoids (paclitaxel, docetaxel) and camptothecin 
quinoline alkaloid derivatives (topotecan, irinotecan) (Brunton et al., 2005; DeVita et al., 2008). 
2.8.1.1 Vinca Alkaloids 
Vinblastine and vincristine are alkaloids isolated from the Madagascar periwinkle, Catharantus 
roseus G. Don (Apocynaceae) (Figure 2.5). The mechanisms of action of the two alkaloids 
involves blocking the polymerization of tubulin molecules into microtubules, preventing the 
formation of the mitotic spindle which results in metaphase arrest and apoptosis (Verma and 
Singh, 2010). Vindesine is semisynthetic analogue of the vinca alkaloid vinblastine which acetyl 
group was changed to amido. It is used mainly to treat acute lymphocytic leukaemia, but less 
prescribed for used in breast cancer, colorectal cancer, non-small-cell lung carcinoma (NSCLC) 
and renal cancer. Some countries such as Britain, South Africa and certain European countries 
have approved its use, but the USA Food and Drug Administration (FDA or USFDA) is yet to 
give approval (Jordan and Wilson, 2004). Vinorelbine, trading under the name Navelbine, is a 
semisynthetic analogue of vinblastine. It is differs from vinblastine because of loss of water from 
the piperidine ring and also the bridge linking the indole ring to the piperidine nitrogen is one 
carbon shorter. It was approved for treatment of NSCLC in France in 1989 and metastatic breast 
cancer (MBC) in 1991. It was, however, approved for use by FDA in December 1994 (Smith, 
1995; Jabeena et al., 2014).  
Dihydro-fluoro derivatives of vinorelbine known as vinflunine was approved by the European 
Medical Agency (EMEA) in 2009 as a second line chemotherapy in metastatic urothelial cancer. 
The mechanism of this derivative is similar to the other members of vinca alkaloids by 
interacting with tubulin molecules, inhibiting microtubule polymerization and the formation of 
tubulin paracrystals. This leads to G2/M phase arrest and induction of apoptosis. It is in Phase 
II/III clinical trial for the treatment of MBC and NSCLC. Phase I/II trials to evaluate its potential 
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in other advanced solid tumours have been alluded to (Bachner and De Santis, 2008; Mamtani 
and Vaughn, 2011). Vincristine sulphate, a nanoparticle-encapsulated molecule designed 
specifically to reduce potential toxicity associated with cancer therapeutic agents was approved 
for use as treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute 
lymphoblastic leukaemia (ALL) in second or greater relapse whose disease has progressed after 
two or more anti-leukaemia therapies (Jabeena et al., 2014).  
2.8.1.2 Taxane Diterpenoids  
Paclitaxel was discovered from the bark of the Pacific Yew, Taxus brevifolia Nutt (Taxaceae) 
provides further evidence for the success of natural product drug discovery (Figure 2.5). It 
promotes microtubule formation and it has been used in the treatment of ovarian cancer, breast 
cancer and also NSCLC (Kinghorn and Seo, 1996). Docetaxel is the first derivative of paclitaxel 
to reach clinical trials. It shows a wide range of clinical activity against tumours from different 
origin with the attendant toxicity pattern than the parent compound. Different structural 
modifications have been made to improve the efficacy of this compound with enhanced 
cytotoxicity in resistant tumours, decreased toxicity in normal tissue and improved solubility. 
The inability of paclitaxel and docetaxel to cross the blood brain barrier (BBB) is the major 
obstacle for these compounds (Bissery et al., 1995; Gelmon, 1994). Cabazitaxel is a semi-
synthetic taxane that binds with tubulin leading to microtubule depolymerization and cell 
division inhibitions, G2/M cell cycle arrest and the inhibition of tumour cell proliferation (Paller 
and Antonarakis, 2011).  
Cabazitaxel is a poor substrate for the membrane bound multidrug resistance efflux pump P-
glycoprotein (Pgp), it has ability to penetrate the BBB unlike other taxanes and may be useful for 
treating MDR tumours. Its combination with prednisone significantly extends overall survival in 
men with hormone-refractory prostate cancer previously treated with a docetaxel-containing 
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regimen and also improves disease control (Jabeena et al., 2014). Abraxane is an albumin bound 
nanoparticle formulation of paclitaxel approved in the US in 2005 for use as a breast cancer 
treatment and in 2012 approved as first line of treatment of metastatic NSCLC among patients 
who could not receive radiation therapy or curative therapy (Jabeena et al., 2014). Paclitaxel 
poliglumex is a semi synthetic innovative macromolecular taxane designed to improve the 
therapeutic index of paclitaxel. It is undergoing Phase III clinical evaluation of NSCLC and also 
Phase III trial in combination with carboplatin for the treatment of performance status (PS 2) 
patients with chemotherapy naive advanced NSCLC. Although it does not prove to be better in 
respect to the superior survival in the first line treatment of PS 2 patients with NSCLC when 
compared with paclitaxel/carboplatin regimen, it was more convenient with respect to 
progression-free survival and overall survival (Bao and Pokman, 2011). Taxaprexin (7-DHA-
Taxol) is made by linking paclitaxel to docosahexaaenoic acid (DHA). It is a fatty acid that is 
easily taken up by tumour cells. Its limitation is the low activity in patients with advanced 
NSCLC as a single therapy. Despite this limitation of low objective response rate, treatment with 
this agent is associated with survival comparable to platinum based combination therapy. 
Presently, however, the agent is undergoing different phases of clinical trials in advanced lung 
cancers, eye melanoma and advanced skin melanoma (Payne et al., 2006).  
2.8.1.3 Epipodophyllotoxin Lignans  
Podophyllotoxin is a compound obtained from Podophyllum peltatum. Its mechanism of action 
as an anticancer agent is the ability to bind reversibly to tubulin (Wilson, 1975). Etoposide and 
teniposide are analogues of podophyllotoxin which have different mechanisms of action 
compared to the parent compound (Srivastava et al., 2005). They act as inhibitors of the enzyme 
topoisomerase-II and can be used as treatment of various cancers. Many semi-synthetic 
analogues of podophyllotoxin have been synthesized to overcome shortcomings of the lead 
compound such as poor water solubility, acquired drug resistance and metabolic inactivation, 
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e.g., NK-611, GL-331, azatoxin, Top-53, etoposide phosphate and tafluposide are produced as 
either clinical drugs or novel clinical trial candidates for various cancers (Sargent et al., 2003; 
Liu et al., 2002; Huang et al., 2000). 
2.8.1.4 Camptothecin Quinoline Alkaloid Derivatives  
Camptothecin (CPT) is a quinoline alkaloid isolated from Camptotheca acuminate (Figure 2.5). 
It is a known topoisomerase-I inhibitor that induces cell death by DNA damage (Hsiang et al., 
1985). A number of analogues have been synthesized and approved for clinical use such as 
topotecan, irinotecan and belatecan which effectively inhibit DNA topoisomerase-I and 
overcome low aqueous solubility and severe toxicity associated with the lead compound 
(Oberlies and Kroll, 2004). 9-Aminocamptothecin (9-AC) is another analogue of CPT with 
potent preclinical studies, but a phase II trial was not as successful as the phase I as it was found 
not to have activity against lung and colon cancer despite modest activity against ovarian and 
malignant lymphoma (Pazdur et al., 1997; Vey et al., 1999). However, in combination with other 
drugs, Phase I/II trials are determined to evaluate its safety, efficacy and tolerability (Farray et 
al., 2006). Diflomotecan is the first homo E-ring modified CPT analogue to be developed 
(Jabeena et al., 2014). In addition to its topoisomerase inhibitory capacity, it possesses better 
lactone stability than the others. Ipsen pharmaceutical has completed a Phase II open label study 
on the drug at a fixed dose of 7 mg as a 20 min intravenous infusion once every 3 weeks in 
patients with sensitive small cell lung cancer who have had failed platinum based regimens 
(Scott et al., 2007).  
Gimatecan is an oral topoisomerase-I inhibitor, which is undergoing a Phase I trial for the 
treatment of advanced solid tumour and treatment of recurrent epithelial ovarian and fallopian 
cancer in a Phase II trial in a patient that has previously undergone platinum and taxane regimens 
(Zhu et al., 2009; Pecorelli et al., 2010). In addition, different conjugated CPT has been produced 
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by conjugating small molecules at the C-20 hydroxyl for stabilization of the lactone ring. This 
stabilization is to delay opening and reducing affinity to serum albumin - ultimately to slow 
release of the active drug and alter therapeutic index (Jabeena et al., 2014). Examples of this 
category of CPT are TP-300 and EZN-2208 which are currently undergoing a Phase I trial 
against solid tumour and advanced malignancies, respectively (Anthoney et al., 2012; Kurzrock 
et al., 2012). 
Combretastatin is a drug isolated from the bark of Combretum caffrum Kuntze (Combretaceae) 
from South Africa known to act by inhibiting tubulin assembly. Combrestastatin A4 has been 
found to be active against cancers of colon, lung and leukaemia (Jabeena et al., 2014). It is 
known to act by binding to the colchicine site of tubulin leading to the disruption of microtubule 
formation (Sackett, 1993). CA-4P and CA-1P prodrugs developed from combretastatins bind 
with the colchicine site of beta-tubulin and are known to be most active prodrugs from plant 
origin (Cirla and Mann, 2003). Clinical trials in Phase I/II of CA-4P focus on the safety, 
tolerability of its combination with other treatment regimens like chemotherapy, radiotherapy 
and antiangiogenic therapies (Nathan et al., 2012). Combination of conventional therapies and 
CA-4P has led to Phase II studies in the treatment of NSCLC and anaplastic thyroid cancer 
(Jabeena et al., 2014). 
Other anticancer agents from natural plants are omacetaxine mepesuccinate, an alkaloid from 
Cephalotaxus harringtonia, is a known protein translation inhibitor (Wetzler and Segal, 2011). 
Ingenol mebutate is a substance found from the sap of Euphorbia peplus (Fallen and 
Gooderham, 2012). Pentacyclic triterpenoid known as Betulinic acid was isolated from Betula 
species (Betulaceae) and also from Mauritiana rugosa and Mauritiana oenoplia (Zizyphus 
species) (Pisha et al., 1995; Shoeb et al., 2006). Betulinic acid expresses different biological 
 
 
 
 
CHAPTER 2 | 2.8.3 THE APOCYNACEAE FAMILY 
48 
activities such as anti-HIV, anti-inflammatory, antioxidant, antiretroviral and antibacterial 
(Tzakos et al., 2012; Nguemfo et al., 2009).  
2.8.3 The Apocynaceae Family  
The Apocynaceae family referred commonly to as oleander or dogbane, has about 250 genera 
and over 2,000 species of tropical trees, shrubs and vines found mostly in tropical and 
subtropical regions (Wiart, 2006). The inclusion of Asclepiadaceae species has enlarged the 
family from two to five subfamilies (Endress and Bruyns, 2000). The subdivision of 
Apocynaceae into the Plumerioideae, Cerberoideae and Apocynoideae significantly corresponds 
with the bearing of different types of alkaloids in the plants. Therefore, alkaloids can stand as 
another taxonomical tool for the Apocynaceae family. Indole alkaloids are synonymous only to 
representatives of Plumerioideae and it has never been found in the other two sub divisions 
while skytanthus alkaloids are only found in Cerberoideae. Steroidal alkaloids are the exclusive 
preserve of Apocynoideae, a subdivision that Holarrhena belongs to (Endress et al., 1989).  
The family is characterized with almost all species producing milky sap, simple opposite or 
whorled leaves, large colorful and slightly fragrant flowers with five contorted lobes with paired 
fruits (Wiart, 2006). The family is known for its poisonous plants and sources of bioactive 
substances like alkaloids, terpenoids and iridoids used extensively for medicinal purposes 
(Connor, 1977). 
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Numerous medicinal functions have been attributed to this family in folklore medicine. 
Treatment ranges from malaria, cancer, headache, leprosy, diarrhoea, diabetes, ulcers, 
toothache and also the reputed hypoglycemic, purgative, emetic and antiseptic effects (Lin, 
2005; Rajakaruna et al., 2002; Nalwaya et al., 2009; De Padua et al., 1999). In addition to 
traditional importance attributed to this family, several bioactive compounds with broad 
biological activities had been isolated from the family and published in scientific journals 
which lend credence to folklore claims. 
2.8.4 Bioactive Compounds Isolated from Apocynaceae  
Nerium oleander is a plant commonly found in Mediterranean regions and sub-tropical Asia 
and is reputed to have various medicinal properties (Chopra et al., 1956). (Siddiqui et al., 
1995) reported the isolation of two novel pentacyclic triterpenoids (cis-karenin and trans-
karenin) with cytotoxic activities against a KB carcinoma cell line from Nerium oleander. 
Another study on Nerium oleander also led to the isolation of odoroside A, odoroside B and 
oleandrin which were active against human breast cancer cell line (Siddiqui et al., 2012). 
Carissa lanceolata is used traditionally by Aboriginals of western Australia for the treatment 
of medical conditions like toothache and respiratory infections (Lassak and McCarthy, 1983). 
Carissone, dehydrocarissone and carindone were isolated from the dichloromethane extract 
of the wood of C. lanceolata (Lindsay et al., 2000). 
The isolated compounds from C. lanceolata were found to be active against Staphylococcus 
aureus, Escherichia coli and Pseudomonas aeruginosa (Lindsay et al., 2000). The work of 
Girardot and co-workers led to the isolation of four vobasinyl-iboga bisindole and one 2-acyl 
monomeric indole alkaloids from the stem of Muntafara sessilifolia (Girardot et al., 2012). 
Some of the indole alkaloids isolated from Muntafara sessilifolia were found to be active 
against chloroquine resistance strain FcB1 of Plasmodium falciparum and cytotoxic against 
the human lung cell line MRC-5 and skeletal muscle cell line L-6 (Girardot et al., 2012). 
Eight novel pregnane-type steroidal glycosides were isolated from methanolic extract of 
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Gymnema griffithii fruits pericarp (Srisurichan et al., 2014). Some of these compounds are 
reported to either have cytotoxicity ability or α-glucosidase inhibitory activity (Srisurichan et 
al., 2014). Several studies have also reported bioactivity of the pregnane glycosides as 
antiproliferative, cytotoxic, antidepressant and antifugal (Cioffi et al., 2006; Plaza et al., 
2005; De Leo et al., 2005; Waheed et al., 2011; Yoon et al., 2011).  
Vincristine and vinblastine are well known antineoplastic drugs derived from Catharanthus 
roseus plant. Vincristine is used for the treatment of Hodgkin’s lymphoma and vinblastine 
for childhood leukemia (Johnson et al., 1963). It has been  suggested that the plant still holds 
potential for the isolation of more chemotherapeutic compounds (El-Sayed et al., 1983). 
Wang and his co-workers reported the isolation of pregnanone named calotropone and 
cardiac glycoside gofruside from the ethanol extract of Calotropis gigantea L. The two 
compounds showed remarkable cytotoxicity against K562 and SGC-7901 cell lines (Wang et 
al., 2008).  
Perakine N4-oxide, raucaffrinoline N4-oxide and vinorine N4-oxide isolated from Alstonia 
yunnanensis showed significant cytotoxicity and selective inhibition of Cox-2 (Cao et al., 
2012). Triterpenoids isolated from the leaves of Pleicocarpa pycnantha are also found to 
possess antineoplastic activities against panel of cancer cell lines (Omoyeni et al., 2014). The 
activities of isolated compounds from the Apocynaceae tend more toward the 
antiproliferative which might not be unconnected to the diverse presence of alkaloids. It is 
however, not surprising that some of the drugs presently in used and those under clinical 
evaluations take their roots from the Apocynaceae family. It is on this premises that the 
bioactive constituents of Holarrhena floribunda leaves are being investigated for possible 
activity against cancer. 
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2.8.5 Holarrhena floribunda (G. Don) Dur. et Schinz 
2.8.5.1 Taxonomy 
Holarrhena floribunda (G. Don) is a tree that belongs to the Apocynaceae family commonly 
referred to as the false rubber tree (Schmelzer, 2008). Holarrhena is a small paleotropical 
genus of 4 species restricted to tropical west Africa and southern Asia (Endress et al., 1989). 
It is at variance both morphologically and chemically with other Apocynaceae family 
members (Endress et al., 1989). Considering the aestivation of the corolla lobes, fruits, seed, 
pollen structure and the alkaloids chemistry Holarrhena belongs to the Apocynoideae sub 
division of Apocynaceae (Endress et al., 1989). It is a big tree with an approximate height of 
17 m by 1 m girth of deciduous forest, savannah wood land in secondary regeneration 
commonly found from Senegal east to Sudan and South to DR Congo and Cabinda (Angola) 
(Schmelzer, 2008). It has smooth gray bark with a pale brown slash yielding copious latex 
(Iwu, 2014). Its leaves are simple, opposite, and entire; stipules are obscure; petiole is up to 1 
cm long, shortly hairy and glandular at base; blade is ovate to elliptical, 2-14 (-20) cm x 2.5-
8-(-11) cm, base cuneate to rounded, apex acuminate to acute, shortly hairy to glabrous, 
pinnately veined with 5-14 pairs of lateral veins (Schmelzer, 2008).  
Inflorescence is a seemingly axillary cyme, dense and many-flowered; peduncle is between 
0.5-1.5 cm long; bract is linear, 1-2 mm long, shortly hairy. Flowers is bisexual, regular, 5 
merous, fragrant; pedicel is 0.5-1 mm long; sepals elliptical, 1-4.5 mm long, free or fused at 
base, shortly hairy; corolla tube cylindrical, 6.5-9 mm x 0.5-1.5 mm, shortly hairy outside 
and inside form the throat to the insertion of the stamens, lobes elliptical, 7-11.5 mm x 2-3.5 
mm, spreading to recurved, shortly hairy to glabrous, white; stamen inserted 2-3 mm from 
the corolla base, included; ovary superior, ovoid, constisting of 2 carpels connate at extreme 
base, style cylindrical 2 mm long, pistil head ovoid, stigma 2-lobed. Fruits composed of 2 
long and slender follicles 30-60 cm x 5-7 mm, pendulous, dehiscent, pale grey to dark brown, 
many- seeded. Narrowly oblong 11-16 mm long grooved seeds, glabrous and with dense tuft 
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of 4-6 cm long hairs at apex. Seedling with epigeal germination; cotyledons are 2.5-3 mm 
long.  
2.8.5.2 Traditional Medicinal Uses  
The leaves of Holarrhena floribunda are used in folklore medicine as an anti-malarial in 
Ghana (Bouquet and Debray, 1974). The bark is put to use in Ivory Coast as treatment for the 
diarrhoea and leaves for amenorrhoea are used either in decoction or macerated in palm wine 
(Kerharo and Adam, 1974). The bark is also used in Ivory Coast as an enema or in baths to 
treat skin infection (Schmelzer, 2008). Diuretic activity is obtained with a mixture of the 
leaves with kolanut while in Sierra Leone it is used as a cure for gonorrhoea and also for the 
management of diabetes (Kerharo and Adam, 1974). The decoction and concotions with 
palm kernel oil extraction are given to children with febrile convulsions probably due to 
cerebral malaria in Nigeria and to both children and adults by Baka pygmies in Cameroon 
(Fotie et al., 2006). The bark is used as a febrifuge and tonic in the eastern and southern 
Africa. The root is boiled in milk and used to bathe boys attaining puberty and it is also used 
as a cure for snakebite and venereal disease (Iwu, 2014). Its fruits are used in Guinea Bissau 
to prepare a remedy for dropsy. The leaves sap is sprinkled on wounds as a heamostatic. The 
leaves are marched with those of Myrianthus arboreus P. Beauv and fruits of Capsicum 
pepper in water and applied as enema against kidney pain (Schmelzer, 2008).  
The tree is known to yield a large number of alkaloids (Kerharo and Adam, 1974). Total 
alkaloids are greatest in the roots (2%), stem bark (1-1.5%) and least in the leaves (<1.0%). 
In addition, seasonal variation is known to play a role on the percentage of alkaloids present 
in the different parts of the plant (Kerharo and Adam, 1974). The plant also contains non-
steroidal alkaloids, triacanthine, phenolic acids, flavonoids kaempferol and quercetin (Iwu, 
2014). Acid phenols (p-hydroxybenzoic, protocathechuic and p-coumaric acids) are present 
in the leaves and seeds (Oliver-Bever, 1986). 
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Major Phytochemicals present in Holarrhena floribunda are steroid alkaloids from two main 
chemical families: counanin and pregnen-5. Conessine, holarrhenine, holadienine, holamine, 
holaphylline, holaphyllamine, kurchicine, progesterone and some flavones (robinoside) had 
also been reported (Tamboura et al., 1998). Connesine make up 50% of the total alkaloids 
and it is responsible for antibiotic activity of the plant (Janot et al., 1950). Most of the main 
alkaloids are derivatives of pregnane with 0.6% of non-steroidal alkaloids tricanthine (an 
adenine derivative) (Janot et al., 1950). Many of the steroids alkaloids derived from 
conamine, holarrhenine are reported to possess hypotensive activity and are also used as a 
local anaesthetic and spasmolytic (Foussard-Blanpin et al., 1969). Conessine and holarrheine 
are limited by their cardiotoxic activities despite their hypotensive activities while tricanthine 
possesses both hypotensive and cardiotonic activity on the heart of rabbit in doses of 1/30th of 
the LD50 (Foussard-Blanpin et al., 1969). It causes beneficial long-lasting vasodilation of the 
coronary arteries in addition to its antispasmodic and respiratory analeptic properties. Its 
clinical use has been considered against cardiovascular misnormal and it is also found to 
stimulate erythropoiesis in an experimental anaemia rabbit model (Foussard-Blanpin et al., 
1969). Holamine, holaphylline and holaphyllamine have anti-inflammatory properties, cause 
sodium retention and act as antidiuretic in rats (Schmelzer, 2008). Pregnane derivatives can 
be an important starting material for the partial synthesis of pharmaceutical steroids such as 
adrenocortical hormones (corticosteroids) and sex hormones (oestrogens, progestrogens and 
androgens) (Schmelzer, 2008). 
However, the plant is reported to have activity against chloroquine-resistant and chloroquine-
sensitive strains of plasmodia. The activity that was found to be more of synergestic effects 
of the complex mixture contained in the plant rather than the single component (Fotie et al., 
2006). Holarrhena floribunda exhibited significant cytotoxicity activity out of some plant 
extracts screened (Abreu et al., 1999). Recently, the phytochemical constituents such 
alkaloids, saponins cardiac glycoside and tannins have also reported. In addition, some MLEs 
of Holarrhena floribunda fractions are reported to have antioxidant, antimutagenic and lipid 
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peroxidation inhibitory activities in the liver, brain and egg yolk homogenates (Badmus et al., 
2010; Badmus et al., 2013).  
Figure 2.6 shows a photomicrograph of Holarrhena floribunda and its taxonomic 
classification. The geographical distribution of the plant on the African continent is depicted 
in Figure 2.7. 
 
Kingdom Plantae 
Phylum Tracheophyta 
Class Magnoliopsida 
Order Gentianales 
Family Apocynaceae 
Genus Holarrhena 
Species Holarrhena floribunda 
Figure 2.6: Photomicrograph of Holarrhena floribunda (G. Don) and its taxonomy 
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(Source: Schmelzer, 2008). 
Figure 2.7: Map of Africa showing geographical distribution (part shaded) of Holarrhena floribunda 
2.8.5.3 Applicability of Holarrhena floribunda to this Study 
The relevance of Holarrhena floribunda used in this study has been covered in detail in 
Chapter 1, especially with regard to the set objectives of the study and the steps taken to 
achieve these objectives.  Chapter 3 describes the materials and methodology applied in this 
study. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Introduction 
This chapter describes the setting, design and methodology used for this study. These 
encompassed the plant material, maintenance of cancer cells, the chemicals and assay kits, 
and the types of experiment carried out at each stage of the study. 
3.2 Plant Material  
Holarrhena floribunda leaves were collected in Igbajo, Osun state, Nigeria, during the rainy 
season in July, 2011. It was identified and authenticated by the duo of Chukwuma, E.C. and 
Ugbogu, O.A. at the Federal Research Institute of Nigeria (FRIN). It was deposited at the 
Institute’s herbarium and voucher number FHI 109764 was issued. The plant material was 
made to undergo different processes of chromatographic separation discussed below to 
obtain pure compounds used in the study. 
3.3 Methods 
3.3.1 Maintenance of Cancer Cells  
All tissue culture operations were carried out in a model NU-5510E NuAire DHD autoflow 
automatic CO2 air-jacketed incubator and an AireGard NU-201-430E horizontal laminar 
airflow tabletop workstation that provides a HEPA filtered clean work area (NuAire). Cancer 
cells such as HT-29 (human colon adenocarcinoma), Hela (human cervical cancer) and 
KMST-6 (normal human fibroblasts) were a kind gift from Dr Mervin Meyer of the 
Department of Biotechnology, University of The Western Cape, while MCF-7 (Human 
breast adenocarcinoma) was kindly provided by Professor Maryna De Kock, Department of 
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Medical Biosciences, University of the Western Cape, South Africa. The cell lines were 
maintained in complete growth medium containing Dulbecco’s Modified Eagle Medium 
(DMEM) and supplemented with 10% foetal bovine serum (FBS), 1% 
penicillin/streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin) and grown as 
monolayer cultures at 37C in a humidified incubator (Relative Humidity/RH 80%) in an 
atmosphere of 5% CO2:95% air. 
3.3.2 Cell Growth and Propagation 
Cells in cryovials were removed from a -120°C storage freezer and thawed immediately in a 
37°C waterbath. The content of the vial was transferred to a T-25 culture flask (surface area 
(SA) 2500 mm2) containing 5 ml complete growth medium. The T-25 culture flask was 
placed on a PrimoVert phase-contrast microscope to visualize the presence of cells, and then 
placed it in a 5% CO2incubator at 37°C. The cells were allowed to attach for 24h in the 
incubator after which the flask was removed and attachment confirmed by microscopy. The 
flask was incubated until 80-90% confluency was reached. 
3.3.3 Subculturing of Cells  
Cells were trypsinized at 80-90% confluency. The complete medium was aspirated from the 
culture flask containing confluent cells. The cells were washed with 2 ml PBS for 1 min. The 
PBS was replaced with 0.5 ml 0.25% trypsin-EDTA and placed in the incubator for 3-5 min 
in order to allow for the cells to detach. The flask was then removed from the incubator and 
placed in a laminar flow cabinet. The trypsin action was deactivated by the addition of 2 ml 
complete medium. The detached cells were aspirated and transferred to a 15-ml conical 
centrifuge tube, placed in a centrifuge and spun for 5 min at 2500 rpm to separate the cells 
from the medium-trypsin solution. After centrifugation, the supernatant was discarded and 
the cell pellet resuspended in 5 ml complete medium. The cells were mixed to ensure a 
homogeneous cell suspension, 1 ml of which was transferred to T-75 culture flask (SA 7500 
mm2) containing 12 ml complete growth medium to maintain stock cultures.  
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3.3.4 Cell Counting and Viability Testing 
Cell counts were carried out using TC20TM automated cell counter (Bio-Rad). The automated 
cell counter uses an optical method to count the cells in fluid samples enclosed in a cell 
counting slide or chamber. Cell viability was assessed by mixing cell suspension with 0.4% 
trypan blue stain in a 1:1 ratio (v/v) and 10 µl trypan blue stained cell suspensions was placed 
in a counting slide chamber and inserted into the TC20TM automated cell counter, with the 
total number of cells counted together with the number of viable cells displayed on the screen 
of the cell counter in 30 sec. Thereafter, the required number of cells needed for a particular 
experiment was calculated in relation to the number of viable cells displayed on the cell 
counter. 
3.3.5 Stock Solutions and Buffers  
Details of stock solutions and buffers are summarized in Table 3.1. 
Table 3.1: Preparation of stock solutions and buffers 
Stock Solution Preparation 
Ammonium Persulfate 
(APS) (10%) 
APS (10%) solution was prepared fresh by dissolving 40 mg of APS in 400 
µl distilled water in a microcentrifuge tube and maintained on ice for until 
used (<5h). 
Fluorescein Stock Solution Fluorescein (C20H10Na2O5) (22.5 mg) was dissolved in 50 ml of phosphate 
buffer (pH 7.4), mixed and protected from light. Fluorescein stock solution is 
stable for a year at 4⁰C in the dark. 
Glycerol Bromophenol Blue 
(GBB) 
This contains 30% glycerol (v/v), 15 mM ethylenediaminetetracetic acid 
(EDTA; pH 8.0) and 0.5% bromophenol blue (w/v) 
MTT (5 mg/ml) 
 
A 5 mg/ml stock solution of MTT 3-(4, 5-dimethyl-thiazol-2-yl-2, 5-
diphenyltetrazolium bromide) was prepared in PBS. 
Paraformaldehyde Fixative 
(4%) 
Paraformaldehyde (16 g) was dissolved in distilled water by stirring at 70°C 
in a fume cupboard. A stepwise drop of 2 M NAOH was added until the 
mixture remained cleared and the mixture was made up to 80 ml with 
distilled water. The solution was filtered through a 0.45-µm filter and stored 
at 4°C. 
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TBSTween Tris (2.4 g), NaCl (8.8 g) and 0.1% Tween 20 were made up in 1 L distilled 
water (pH 7.8). 
Peroxyl Radical (25 mg/ml ) AAPH (2, 2’-Azobis (2-methylpropionamidine) dihydrochloride (150 mg) in 
6 ml of phosphate buffer (pH 7.4). 
Phenylmethanesulfonyl-
fluoride (PMSF) 
A 10 mM stock solution was prepared in isopropanol. 
75 mM Phosphate buffer 
(pH 7.4) 
Sodium dihydrogen monophosphate (NaH2PO4.H20) 10.36 g of was 
dissolved in 800 ml distilled water. The pH was adjusted to 7.4 with 75 mM 
di-sodium hydrogen monophosphate (Na2HPO4.H2O). The buffer volume 
was made up to 1000 ml with sodium dihydrogen monophosphate. The 
buffer is stable for a month at 4°C. 
Propidium Iodide (PI) A stock solution of 1 mg/ml was prepared by dissolving 1 mg of PI in 1 ml 
3.8 mM sodium citrate (pH 7.0) solution. A working solution consists of 950 
µl PBS, 400 µl PI and 100 µl RNase. 
RNase (DNase-free) A 20 mg/ml stock solution was prepared in a 0.1 M sodium citrate and 0.3 
mM EDTA (pH 4.8). This solution was boiled for 15 min and cooled quickly 
by placing it in ice and stored at -20°C. 
Trolox Stock Solution Trolox (6-hydroxy-2, 5, 7, 8-tetra methylchroman-2-carboxylic acid) 
(0.00625 g) was dissolved in 50 ml phosphate buffer (pH 7.4) and mixed 
until dissolved. The stock solution was kept in a 2-ml Eppendorf tube and 
stored at -20°C. Trolox sock solution is stable for 6 months at -20°C. 
 
3.3.6 Preparation of the Methanolic Leaf Extract of Holarrhena floribunda  
The leaves of Holarrhena floribunda were allowed to dry at room temperature. The dried 
leaves weighing 1.748 kg were soaked in 5.25 L of absolute methanol. The mixture was 
thoroughly mixed and filtered after 48 hr using a Buchner vacuum filter. The residue was 
reconstituted in fresh absolute methanol for 24 hr and filtered again using a Buchner vacuum 
filter. The filtered supernatant was evaporated to dryness with a Rotary evaporator. The 
weight of dried methaolic extract of the leaves was 380.70 g representing 21.78% yield in 
relation to the weight of the leaves used. 
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3.3.7 Fractionation of the Methanolic Leaf Extract of Holarrhena 
floribunda 
The fractionation of the methanolic leaf extract (MLE) was carried out by using a silica gel 
packed column with gradient mixture of ethylacetate and methanol. The ratio of 
ethylacetate:methanol used were 9:1 (2 l), 8:2 (2 l), 6:4 (2 l) and 4:6 (2 litre), respectively. A 
total of 51 eluents (500 ml each) was collected. The eluents were monitored by thin layer 
chromatography (TLC) using the chloroform:methanol mixture (8:2) as mobile phase. The 
eluents with similar patterns and relative retention factor (RRf) values after being sprayed 
with vanillin-sulphuric acid and Dragendorff reagent were combined to yield 18 fractions. 
3.3.8 Bioassay-Guided Fractionation 
The 18 fractions obtained from the MLE were subjected to bioassay-guided fractionation 
using the tetrazolium salt 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) cytotoxicity assay to check for the fractions that can be further purified for anticancer 
activity. 
3.3.9 Isolation and Characterization of Cytotoxic Compounds  
The bioassay-guided fractionation of 18 sub-fractions led to the identification of 3 sub-
fractions with significant cytotoxic activities. The 3 sub-fractions were found to contain the 
same active compounds according to their TLC profiles. One of the sub-fractions (0.6 g of 
sub-fraction 17) was, however, subjected to alumina oxide (Fluka AG, Buch SA) Fluka type 
507C neutral packed column chromatography. The gradient mixture of mobile phase started 
from 0.1% (300 ml), 0.3% (300 ml), 0.5% (300 ml), 0.7% (200 ml), 1% (2.5 L), 3% (200 
ml), 5% (1 l) to 10% (100 ml) of dichloromethane (DCM):methanol (MeOH). Eighty four 
(84) eluents were collected and stratified according to the pattern observed on the alumina 
coated TLC plate to generate 21 sub-sub-fractions which were subjected to nuclear magnetic 
resonance (NMR) for possible characterization and identification of pure compounds. 
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3.3.9.1 Nuclear Magnetic Resonance (NMR) 
Identification and characterization of isolated compounds was performed on NMR. The 
NMR spectra were recorded on 200 MHz Varian Unity Inova spectrometer (Gemini 2000) 
equipped with an Oxford magnet (14.09 T) and a 5 mm indirect detection PFG probe housed 
at the Department of Chemistry, University of The Western Cape. The VNMR 6.1C, 1D and 
2D software was used for the operation and generation of spectra. The isolated compounds 
(10 mg) were dissolved in D-chloroform (1 ml). 1H chemicals shifts were referenced to the 
residual signals of the protons of solvent and were quoted in ppm downfield from 
tetramethylsilane (TMS). 
3.3.9.2 Isolation and Characterization of Flavonoids  
Sub-fractions 13 and 14 from the main total extract were selected for further purification 
based on the TLC profile displayed by the sub-fractions. The sub-fractions had some spots on 
the TLC profiles that were positive to vanillin-sulphuric acid and also UV visible. The sub-
fractions were subjected to silica gel packed column chromatography with 1% DCM:MeOH 
(1 L), 3% (1 L), 5% (1 L), 7% (1 L) and 10% solvent systems. This was followed by 
DCM:MeOH:H2O in ratio 88:12:1 (1 L), 86:14:3 (1 L) and 85:15:3 (2 L), respectively. 
However, these latter solvent systems were not employed for sub-fraction 14. The sub-
fractions obtained were subjected to Sephadex column chromatography using 100% ethanol 
as mobile phase. The compounds obtained were purified using high performance liquid 
chromatography (HPLC). 
3.3.9.3 High Performance Liquid Chromatography (HPLC) 
HPLC separates compounds on the basis of their polarity. It can be used for analyzing, 
purifying and quantifying compounds (Levin, 2010). HPLC was carried out using an Agilent 
1100 HPLC system (Agilent Technologies, Santa Clara, CA, USA) consisting of a 
quaternary solvent delivery system, an on-line degasser, an auto-sampler, a column 
temperature controller and ultraviolet (UV) detector coupled with an analytical workstation 
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and Discovery® C18 column, 5 µm, 250 mm x 10 mm i.d. (Sigma-Aldrich, St. Louis, MO, 
USA). The experiment was carried out using a reversed phase Phenomenex C-18 silica (250 
x 10 mm, 5 micron) column as a stationary phase at a temperature of 30 ⁰C. The optimum 
resolution was obtained using a linear gradient elution of 30-60% mobile phase A 0.01% 
acetic acid in methanol and mobile phase B 0.01% acetic acid in water for 30 min, 60-100% 
at 30-40 min at a constant flow rate of 1.5 ml with a wavelength of 240 nm. 
3.3.9.4 Thin Layer Chromatography (TLC) 
TLC is a solid-liquid form of chromatography where the stationary phase is normally a polar 
absorbent and the mobile phase can be a single solvent or combination of solvents. TLC uses 
thin glass/aluminum plates coated with either aluminum oxide or silica gel as solid phase. 
TLC distributes compounds between a solid phase applied and a liquid phase (eluting 
solvent) that is moving over the solid phase (Bele and Khale, 2011). TLC was performed on 
normal phase Merck Silica gel 60 F254 on pre-coated aluminum plates (0.2 mm; Merck, 
Dermstadt, Germany). 
3.3.10 Morphological Evaluation of Cells  
Different cell lines were cultured in 6-well plates and treated after 24-hour incubation in 
37°C in a humidified CO2 incubator. The cell morphology was studied using a Zeiss light 
microscope. 
3.3.11 MTT Cytotoxicity Assay 
The MTT assay is a measure of viability, which based on the ability of mitochondrial 
succinate dehydrogenase enzymes in living cells to metabolize yellow 3-(4, 5-dimethyl 
thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) into an insoluble coloured purple 
formazan product which can be measured at wavelengths between 500 and 600 nm by 
spectrophotometry (van de Loosdrecht et al., 1994; Slater et al., 1963). Viable cells were 
seeded at a density of 5 x104 (100 µl/well) in 96-well plate and incubated in a humidified 
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atmosphere of 5% CO2 and 95% air at 37°C for 24 hours to form a cell monolayer. After 24 
h, the supernatant on the monolayer was gently discarded and 100 µl of medium and varying 
concentrations of test compounds in log dose were added and incubated for various times 
under standard incubation settings. 
After each specific time point (24, 48 and 72 h), 20 µl of 5 mg/ml MTT in PBS was added to 
each well and incubated for 3 hours at 37 ˚C in 5 % CO2 atmosphere. Supernatant was 
removed and 150 µl of isopropanol was added and the plates were gently shaken for 15 min 
to solubilize the formazan and absorbance was measured at 560 nm using a Glomax Multi 
Detection System (Promega, USA). The percentage inhibition of proliferation was calculated 
using the formula below and IC50 values calculated from log dose-response curves using 
GraphPad Prism version 6.05 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com).  
Test OD% Inhibition of Proliferation = 100 -  X 100%Untreated OD  
3.3.12 Trypan Blue Dye Exclusion Assay  
Trypan blue is a ~960 Dalton molecule with two azo chromophore groups. Trypan blue dye 
exclusion is one of the methods used to measure cell viability, based on the principle that 
intact membranes are not permeable while compromised cell membranes permit entry of the 
dye and binds with intracellular proteins.  
This allows for the counting of unstained live cells and blue dead cells in a cell population 
(Denizot and Lang, 1986; Altman et al., 1993). Viable cells were seeded at the cell density of 
5 x 104 (1 ml/well) in 12-well plates and incubated in a humidified atmosphere of 5% CO2 
and 95% air at 37°C for 24 hours to form adherent cell monolayers. After 24 h, supernatant 
on the monolayer was gently discarded and cells treated with 1 ml medium containing 
varying concentrations of extract (100, 200, 300, 400 and 500 µg/ml) for 24 h. The adherent 
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cells were detached by trypsinization using 0.25% EDTA trypsin. The cells were centrifuged 
using Bio-Rad tabletop centrifuge at 730 x g for 5 min and the supernatant discarded. Cell 
pellets were re-suspended in fresh medium from where 10 µl of cell suspension was added to 
an equal volume of 0.4% trypan blue dye and loaded into BioRad TC20 cell counter. 
Readings were automatically generated from the machine and recorded based on the formula 
below; 
Total Cells - Dead Cells% Inhibition = 100 -  X 100%Total Cells  
3.3.13 Clonogenic Assay  
The clonogenic assay evaluates the ability of a cell to form colony of 50 or more cells after 
treatment with either cytotoxic agent or ionizing radiation. The cells (5 x 104/ml) were plated 
in 6-well plates and allowed to attach for 24 h. After 24 h, the cells were treated with MLE of 
Holarrhena floribunda (100, 200, 300, 400 and 500 µg/ml) and incubated for 24 hours in a 
humidified CO2 incubator. The medium containing extract was removed and replenished 
with fresh neat medium for 5 days in an incubator. After incubation, the medium was 
removed and the cells washed with PBS. The cells were fixed in 500 µl fixative (75% 
methanol and 25% acetic acid) for 5 min at room temperature. The fixative was removed and 
the cell stained with 0.5% crystal violet for 30 min at room temperature. The cells were 
washed with running tap water to remove the dye. Colonies were counted and the survival 
rate was calculated as the percentage of cells treated over untreated controls.  
3.3.14 Cytotox-Glo™ Cytotoxicity Assay  
The MultiTox-Glo multiplex cytotoxicity assay gives ratiometric, inversely correlated 
measures of cell viability and cytotoxicity. The assay measures live and dead cell protease 
activities using fluorogenic, cell permeant, peptide substrate (glycyl-phenylalanyl-
aminofluorocoumerin, GF-AFC) for live cells while luminogenic cell-impermeant peptide 
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substrate (alanyl-alanyl-phenylalanyl-aminoluciferin, AAF- Glo™) for dead cells (Promega, 
2012). Cells were seeded in 96-well white-walled tissue culture plates and treated using 
different concentrations of MLE of Holarrhena floribunda as reported above. The 
experiment was carried out according to the instructions of the manufacturer as contained in 
Promega Technical Bulletin (Promega, 2012). 
3.3.15 ApopercentageTM Apoptosis Assay 
Viable cells contain an asymmetrical distribution of phospholipids between the inner and 
outer leaflet of their plasma membranes. Phosphatidylcholine and sphingomyelin are mainly 
found in the outer membrane while phosphatidylethanolamine and phosphatidylserine (PS) 
are located in the inner plasma membrane. It is known that during the process of apoptosis, 
externalization of PS occurs and this can be used as a biomarker for apoptosis (Bretscher, 
1972). The APOPercentage™ assay makes use of an anionic halogenated fluorescein dye, the 
disodium salt of 3, 4, 5, 6,-tetrachloro-2, 4, 5, 7-tetraiodofluorescein (TCTF), which is taken 
up by apoptotic cells by binding to externalized PS, which gives such cells a purple-red 
appearance that can be analyzed by flow cytometry (Meyer et al., 2008).  
The cells were treated as reported for the trypan blue assay above. Following incubation for 
24 h, floating cells in each respective treatment were transferred to a 15-ml centrifuge tube 
and the adherent cells trypsinized and added to the respective tubes containing floating cells. 
The cells were washed with 1% PBS and resuspended in residual PBS. APOPecerntage dye 
(100 µl) in complete culture medium (diluted 1:160, v/v) was added to the tubes and allowed 
to incubate for 30 min at 37°C in a humidified CO2 incubator. After the incubation, 500 µl of 
1% PBS was added to the tubes containing cells and centrifuged for 5 min at 1,050 x g. After 
the second washing at the same centrifugation speed, the cell pellet obtained was 
resuspended in PBS and analyzed on a Becton Dickinson FACScan instrument (BD 
Biosciences Pharmingen, San Diego, CA, USA) fitted with a 488 nm argon laser. A 
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minimum of 10,000 cells per sample were acquired and analyzed using the CELLQuest 
PRO® software (BD Biosciences). 
3.3.16 Caspase Glo®-3/7 and -9 Assay 
Caspase-3/7 is considered as an executioner caspase and one of the hallmarks of apoptosis 
induction (Kroemer et al., 2009). Caspase-3/7 was estimated by the Caspase-Glo®-3/7 assay 
system kit (Promega, USA). Evaluation of the caspase-3/7 was performed according to the 
manufacturer’s instructions. Briefly, 100 µl of 5 x 104 cells/ml were seeded in a white walled 
96-well microplate for 24 h. The cells were treated with the MLE of Holarrhena floribunda 
(100, 200, 300, 400, 500 µg/ml) for 24 h. After treatment, an equal volume of Caspase-
Glo®-3/7 reagent was added, agitated for 30 sec and the luminescence signal recorded using 
GloMax Multi Detection System (Promega, USA) after incubation for 1 hour. The same 
procedure was followed for the evaluation of caspase-9. 
3.3.17 Annexin/PI Assay  
The Annexin V-FITC apoptosis kit (BD Pharmingen, USA) was used to calculate early and 
late apoptosis with modification to reduce false positive events by fixing the cells with 
paraformaldehyde and addition of RNase to remove cytoplasmic RNA (Rieger et al., 2011). 
The Annexin/PI assay determines if cells are viable, apoptotic and necrotic depending on the 
state of plasma membrane integrity and permeability. Cells undergoing apoptosis are known 
to externalize PS which binds strongly with Annexin V allowing for the evaluation of 
apoptosis (Vermes et al., 1995). PI does not stain live cells with intact plasma membranes, 
but stains cells with compromised plasma membranes in late apoptotic and necrotic states 
(Darzynkiewicz et al., 1992; Kroemer et al., 1998). PI passes through the membrane and 
intercalates into nucleic acids to display red fluorescence (Faleiro and Lazebnik, 2000; 
Rieger et al., 2011). Cells (2 ml) at a density of 5 x 104 were grown in 40-mm petri dishes 
and allowed to attach for 24 h.  
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The cells were treated after 24 hours with MLE test compounds at different time points (12, 
24 and 48 hours at 200 µg/ml extract; 15 µg/ml pure compounds for 12 and 24 h). After the 
treatment, cells were harvested and centrifuged at 335 x g for 10 min. The supernatants were 
washed in 1% PBS and resuspended in Annexin V binding buffer. The cells were centrifuged 
at 335 x g for 10 min and supernatants discarded. Cell extracts were suspended in 100 µl 
Annexin V binding buffer and 5 μl Annexin V Alexa Fluor 488 added and allowed to 
incubate in the dark for 15 min. PI (4 µl) diluted in 1 x Annexin V binding buffer (1:10) was 
added and allowed to incubate for 15 min in the dark at room temperature. Annexin V 
binding buffer (500 µl) was added to wash the Annexin/PI stained cells. The cells were 
centrifuged at 335 x g for 10 min and the supernatants were discarded. The cells were 
resuspended in 500 µl Annexin binding buffer and 500 µl 2% paraformaldehyde to make a 1 
% final solution of paraformaldehyde on ice for 10 min. PBS (1 ml) was added to the cell, 
centrifuged at 425 x g for 8 min and the supernatant discarded. The latter step was repeated 
twice. RNase A (16 µl) at a concentration of 50 µg/ml was added to the cell for 15 min at 
37°C. PBS (1 ml) was added to the cell, gently flicked and centrifuged at 425 x g for 8 min. 
The supernatants from the extract treated cells were discarded and the cells were suspended 
in the residual PBS and analyzed on a Becton Dickinson FACScan instrument (BD 
Biosciences Pharmingen, San Diego, CA, USA) fitted with a 488 nm argon laser while a 
Tali® Image-Based cytometer was used for cells treated with pure compounds. A minimum 
of 10,000 cells per sample were acquired and analyzed using CELLQuest PRO software. 
3.3.18 Cell Cycle Analysis  
Cells were seeded at a density of 2 x 105/well in 6-well plates and incubated for 24 hours at 
37°C in a CO2 incubator to form a monolayer. The cells were treated with 200 µg/ml MLE 
for 12 and 24 h. After treatment, the cells were washed with 2 ml PBS and the cell pellet 
resuspended in 1 ml (1%, w/v) paraformaldehyde in PBS (pH 7.4) on ice for 30 min. The cell 
pellets were washed twice in 5 ml PBS. Slowly, 70% of ethanol was added to the cell while 
vortexing to reduce cell clumping. The cells were stored at -20°C for 48 h, after which they 
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were pelleted at 4000 rpm for 10 min. Cells were washed in 2X PBS and 1 ml of PI master 
mix containing 100 µg/ml RNase and 40 µg/ml in PBS. Cell cycle phase distribution was 
determined using a FACSCalibur Flow Cytometer (BD Biosciences Franklin Lakes, NJ, 
USA). DNA content of 50,000 events was determined by ModFit software (Verity Software 
House, Topsham, ME), which provided histograms to evaluate the cell cycle distribution. 
3.3.19 Bromodeoxyuridine (BrdU) Incorporation Assay  
The BrdU incorporation assay measures cell proliferation by detecting de novo DNA 
synthesis. The assay is based on the incorporation of BrdU as a thymidine analog into nuclear 
DNA that can be tracked with an antibody probe. Cell proliferation was determined by the 
ELISA-BrdU (5-bromo-2’-deoxyuridine) chemiluminescence assay kit (Roche, Germany). 
Briefly, after incubating the cells with IC50 concentrations of the compounds for 12, 24 and 
48 hours in a 96-well microtiter plate, 10 µl BrdU labeling solution (100 μM, final 
concentration) was added, and the plate was incubated for 2 h. The labeling solution was 
removed and the cells were fixed with FixDenat™ solution for 30 min. After removal of the 
FixDenat solution, anti-BrdU-POD (peroxide dismutase) solution was added and further 
incubated for 90 min. This was followed by 3 rinses with washing buffer provided with the 
kit. Then substrate was added for 5 min and the chemiluminescence intensity was determined 
according to the manufacturer’s instruction using GloMax Multi detection system (Promega, 
USA). Cell proliferation was expressed as a percentage relative to the untreated control. 
3.3.20 Evaluation of Reactive Oxygen Species (ROS) 
Detection of reactive oxygen species (ROS) activities within cells can be evaluated using the 
fluorogenic molecular probe 5- (and 6)-chloromethyl-2’, 7’-dichlorofluorescein diacetate 
actyl ester (CM-H2 DCFDA) (Invitrogen). CM-H2DCFDA permeates freely into cells where 
its acetate groups get cleaved by intracellular esterases to a highly fluorescent compound 2, 
7-dichlorofluorescin (DCF). The fluorescent DCF can be detected by flow cytometry or 
fluorescence microscopy and spectroscopy. Briefly, cells were cultured in a 6-well plate at a 
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density of 2 x 105/ml. The cells were treated with 200 µg/ml extract and 15 µg/ml of the pure 
compounds for 12 and 24 hours. After the treatment, cells were washed with PBS and stained 
with 7.5 µM of CM-H2 DCFDA prepared in PBS from a DMSO stock solution and incubated 
for 30 min at 37°C in a humidified CO2 incubator. The cells were washed twice with ice-cold 
PBS following which the cells were acquired and 10,000 events analyzed on a Becton 
Dickinson FACScan instrument (BD Biosciences Pharmingen, San Diego, CA, USA) fitted 
with a 488 nm argon laser. 
3.3.21 Mitochondrial ToxGlo™ Assay  
This assay evaluates biomarkers associated with changes in cell membrane integrity and 
cellular ATP levels relative to vehicle control cells during short exposure periods (Promega, 
2011). Integrity of cell membrane is first assessed by measuring the presence or absence of 
distinct protease activity associated with necrosis using a fluorogenic peptide substrate bis-
AAF-R110 (bis-(Ala-Ala-Phe)-rhodamine 110) to measure dead cell protease (Niles et al., 
2007). ATP is measured by adding ATP detection reagent, resulting in cell lysis and 
generation of a luminescent signal proportional to the amount of ATP present (Promega, 
2011). Breifly, 100 µl cells were plated in a 96-well white walled plate at 5 x 104 /ml in 
galactose fortified glucose and FBS free medium. The cells were treated with the log increase 
concentration of compounds (0.01, 0.1, 1 and 10 µg/ml) for 2 hours before evaluation as 
described above. 
3.3.22 Florescence Microscopic Evaluation of Mitochondrial Status  
The status of mitochondria was analyzed by fluorescence microscopic examination of cells 
stained with the fluorochrome Mito Tracker Red (CMXRos, Lonza Walkersville, USA). Mito 
Tracker Red (CMXRos) is an aldehyde fixable cationic lipophilic fluorochrome that 
passively diffuses through the plasma membrane of viable cells and is selectively sequestered 
in mitochondria with an active membrane potential which allows for the evaluation of 
mitochondrial functional state in adherent cells (Poot et al., 1996). Briefly, to assess the 
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effect of the compounds, the cells were cultured in 6-well plate containing coverslips. 
Twenty minutes to the end of the treatments (3, 6 and 12 h), DAPI (4',6-diamidino-2-
phenylindole) stain (5 µl) was added to each treatment and 100 µl of CMXRos (250 nM) in 
medium was added and incubated for 30 min at 37°C. At the end of the incubation period, 
the media and the CMXRos were aspirated, washed in PBS and coverslips removed for 
visualization by mounting on glass microscope slides. The resultant images were taken using 
a Zeiss Axio-plan 2 fluorescent microscope (Zeiss, Germany) 
3.3.23 Immunofluorescent Staining of Actin Filaments 
The actin cytoskeleton is a network of dynamic assembly of actin polymers and a variety of 
associated proteins. Actin performs essential functions for intra- and extra-cellular movement 
and support in eukaryotic cells. The associated proteins are important for the signalling 
pathways controlling actin assembly (Jung et al., 2012). Therefore, a change to its normal 
functions, organization and regulations may lead to cancer. The immunofluorescent staining 
of actin filaments in the cytoskeleton, focal contacts and nucleus of the cells were evaluated 
using TRITC-conjugated phalloidin, anti-vinculin and DAPI staining kit according to 
manufacturer’s instructions (Merck Millipore, Darmstadt Germany). Briefly, cells were 
cultured on cover slides in 6-well plate and treated for 3 hours and 6 hours. Cells were fixed 
with 4% paraformaldehyde for 15 min followed by washing twice in wash buffer (0.05% 
Tween-20 in PBS). Cells were permeabilized with 0.1% Triton X-100 (in 1% PBS) for 5 min 
followed by washing twice with wash buffer (0.05% tween-20 in 1 x PBS). Blocking solution 
(1% BSA in PBS) was applied for 30 min. Primary antibody (anti-vinculin) (100 µl) was 
added for 1 hour followed by three washes with wash buffer. The resultant images were 
taken using a Zeiss Axio-plan 2 fluorescent microscope (Zeiss, Germany). 
3.3.24 Fluorescence Microscopic Evaluation of ROS  
The cell permeant reagent chloromethyl-2’, 7’-dichlorofluorescindiacetate (CM-H2DCFDA) 
fluorogenic dye was used to measure the induction of ROS in cells. Cells were treated in 6-
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well plates containing coverslips for 3, 6 and 12 h. After treatments, 2 µl of Hoechst 33342 
(NucBlue Live ReadyProbesTM Reagent, USA) was added to the medium and incubated for 
20 min. After the medium was removed, cells were washed with Hank’s balanced salt 
solution (HBSS). CM-H2DCFDA (2 µM) was droppered onto coverslips and incubated at 
37°C for 30 min in the dark. After incubation, cells were washed twice with HBSS and the 
coverslips mounted on the microscope slides. The resultant images were taken using a Zeiss 
Axio-plan 2 fluorescent microscope (Zeiss, Germany) at blue and red fluorescent channels. 
3.3.25 Topoisomerase-I Relaxation Assay  
This assay is based on the inhibition of the relaxation of supercoiled circular DNA by 
topoisomerase-I (Osheroff et al., 1983). Topoisomerase (1 U) will relax 0.5 µg of supercoiled 
pBR322 when incubated in assay buffer in a total reaction of 30 µl at 37°C for 30 min. 
However, any test compound that inhibits the relaxation of the supercoiled plasmid in the 
presence of topoisomerase is considered a topoisomerase inhibitor. Gels were run in the 
absence of ethidium bromide or chloquine. Supercoiled DNA moves faster than 
relaxed/nicked DNA on 1-1.2% agarose gel electrophoresis. A master mix containing 
doubled distilled water (ddH2O), 1X assay buffer (20 mM Tris-HCl (pH7.5), 200 mM NaCl, 
0.25 mM EDTA and 5% glycerol), 0.5 µg supercoiled DNA, 1 U topoisomerase-I enzyme 
and the test compounds were prepared as summarized in the Table 3.2. The stock solutions (5 
µl) of test compounds were added to 30 µl of the total reaction volume to give 15 µg/ml 
concentrations. Preparation was done on ice before incubating the mixtures at 37°C for 2 h. 
After 2 hours of incubation, reactions were terminated with 6 µl 6X Stop buffer (3% SDS, 60 
mM EDTA, 50% glycerol, 0.25% bromphenol blue). The reaction products were determined 
by electrophoresis on 1% agarose gel in TAE (Tris-acetate-EDTA) running buffer at 6.5 
V/cm for 2 h. The gels were stained with ethidium bromide (0.5 μg/ml) for 30 min, and then 
destained in distilled water for 30 min. Gels were directly scanned with an image analyzer 
(Biometra, Germany) for visualization. 
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Table 3.2: Master mix preparation of topoisomerase-I 
Reagent Stock Concentration 1X Concentration Volume (µl)/assay X 40 
Reactions 
H2O   21.4 856 
10X assay buffer 10 X 1 X 3 120 
Supercoiled DNA 50 µg 0.5 µg 0.3 12 
Topo I enzyme 100 U 1 U 0.3 12 
 Reaction volume without test fraction: 25  
 Reaction volume with test fraction: 30  
Master Mix with Topo I + 9.3 mg/ml Camptothecin (Prepared on Ice) 
Reagent Stock Concentration 1X Concentration Volume (µl)/assay X 3 Reactions 
H2O   19.4 58.2 
10X assay buffer 10 X 1 X 3 9 
Supercoiled DNA 50 µg 0.5 µg 0.3 0.9 
Topo I enzyme 100 U 1 U 0.3 0.9 
 Reaction volume without test fraction: 23  
 Reaction volume with test fraction: 30  
 3.3.26 Extraction of Protein  
The treated and untreated cells grown in T-25 cell culture flasks were washed twice with 1X 
PBS following the addition of 500 µl Cytobuster (Novagen) for 5 min at room temperature. 
Cells were harvested with a cell scraper and transferred to a microcentrifuge tube and 
centrifuged for 5 min at 16,000 x g at 4°C. The supernatant was transferred to a sterile 
microcentrifuge tube and stored at -20°C. 
3.3.27 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
3.3.27.1 Preparation of Protein Samples  
The Bradford assay was used to evaluate protein concentration of cell samples. The protein 
samples were loaded onto gels at 1 µg/µl following heating at 95°C for 10 min. 
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3.3.27.2 SDS Gel Preparation  
Proteins were separated by denaturing SDS-PAGE under reducing conditions (Laemmli, 
1970). Briefly, gels were prepared from 40% stock of premixed 37:5:1 acrylamide: 
bisacryamide and consisted of separating and stacking gels which were poured between two 
assembled glass plates separated by a 1.5 mm thick comb spacer. The gels were prepared in 
1.5 mm Hoeffer dual gel caster and about 10 ml were enough for one gel. The separating gel 
was poured about 1 cm below the wells of the comb and about 1 ml water saturated 1-butanol 
was overlaid on top of the separating gel and left to set. Afterwards, the butanol was poured 
off the gel and rinsed with deionized water. Stacking gel (≈ 5 ml) was poured over the 
running gel. The comb was immediately inserted into the stacking gel to make wells and 
allow stacking gel to set. After, the comb was removed, the gel transferred to the Mighty 
Small apparatus (Hoeffer) containing running buffer. 
3.3.27.3 Loading and Electrophoresis of Samples  
Two equal volumes of samples were loaded into two different gels and electrophoresed at 100 
V/cm until the loading dye barely leaked out of the gel into the running buffer. One of the 
gels was blotted onto nitrocellulose paper membrane while the other was stained with 
Coomasie stain. 
3.3.27.4 Staining and Destaining of SDS-PAGE Gel  
The gel was stained with Coomasie blue solution for 30 min. Destaining was done by several 
washes with the SDS-PAGE destaining solution on a shaker. 
3.3.28 Western Blot Analysis 
A ‘wet’ system of transfer proteins separated by SDS-PAGE onto nitrocellulose membrane 
was used. Gels, sponges, and Whatman filter paper were equilibrated in pre-chilled transfer 
buffer for 30 min. Cellulose membranes were immersed in 100% methanol for 15 to 20 sec 
and 30 min allowed for equilibration. Transfer apparatus was assembled by placing the 
 
 
 
 
CHAPTER 3 | 3.3.29 OXYGEN RADICAL ABSORPTION CAPACITY (ORAC) 
75 
sponge on the black side of transfer cassette followed by Whatman paper, the gel, cellulose 
membrane, Whatman paper and lastly the sponge at the second end and making sure bubbles 
were squeezed out. The cassette was placed into a wet tank with the black side of the cassette 
correspondingly placed on the black side of the tank. Pre-chilled transfer buffer was added 
with a magnetic stirrer to mix the buffer to maintain constant buffer temperature. The protein 
was electro-blotted onto the membrane at 100 V for 90 min. After blotting, the membrane was 
blocked with 5% milk in TBST (Tris, NaCl and Tween 20; pH 7.8) at room temperature for 
an hour. The membrane was immediately incubated in 1:1000 dilution of the primary 
antibody in TBST overnight at 4°C on a shaker. The membrane was later rinsed thrice with 
TBST for 5 min each. Thereafter, the membrane was incubated with secondary antibody (1: 
10,000 in TBST) at room temperature for an hour. The membrane was rinsed with TBST 
twice at 5 min each. Then, Super Signal West Pico chemiluminescent substrate was prepared 
by mixing solutions A and B (1:1, v/v) according to the manufacturer’s instructions (Thermo 
Scientific) and the substrate mixture was placed on the membrane. The blot was stripped for 
another primary antibody. The stripping was performed by pre-wetting the membrane in 
methanol for a few seconds, then washed in distilled water for 5 min and incubation of the 
membrane in 0.2 M NaOH for 5 min. This was followed by a 5 min wash in distilled water 
and finally in TBST for another 5 min. The membrane was then blocked with blocking buffer 
(5% milk in TBST) for another round of protein evaluation (actin antibody). 
3.3.29 Oxygen Radical Absorption Capacity (ORAC) 
The ORAC assay is used to measure the scavenging potential of antioxidant compounds 
against the peroxyl radical (Cao et al., 1993). ORAC generates both qualitative and 
quantitative measures which present fast- and slow-acting antioxidant activity of a test 
compound (DeLange and Glazer, 1989). The assay is based on the inhibition of the peroxyl-
radical-induced oxidation initiated by thermal decomposition of azo-compounds like 2, 2’-
azobis (2-amidino-propane) dihydrochloride (AAPH) (Prior et al., 2003). Briefly, 12 µl of 
test sample was combined with 138 µl of fluorescein working solution. The reaction was 
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started by addition of 50 µl AAPH (150 mg/6ml of phosphate buffer) in a 96-well plate. The 
absorbance was measured with a Fluoroskan Spectrum microplate reader with excitation 
wavelength set at 485 nm and emission wavelength 530 nm at a temperature of 37°C against 
a reagent blank prepared with phosphate buffer. Trolox solution was used as a standard 
calibration curve with concentration ranges from 83-417 µM. ORAC values were calculated 
using a regression equation (y=a+bx+cx2) and expressed as micromoles of Trolox 
equivalents (TE) per milligram of test sample. In this assay, three different reactive species 
were used to assess antioxidant and prooxidant activity of the antioxidants: (1) AAPH (4 
mM) as a peroxyl radical generator, (2) H2O2-Cu2+ (H2O2, 0.6%; Cu2+ as [CuSO4] 18 µM) as 
mainly a hydroxyl radical generator (ORACOH assay) or (3) Cu2+ as (CuSO4 ) (18 µM) as a 
transition metal oxidant (Cao et al., 1997). 
3.3.30 Ferric Reducing Antioxidant Power (FRAP) 
FRAP evaluates the potential of a test compound to reduce ferric iron (Fe3+, oxidant in 
system) to ferrous iron (Fe2+). This redox-linked colorimetric assay incorporates antioxidants 
as reductants, where the reduction of FeIII-Tris (2-pyridyl)-S-triazine) (TPTZ), which is 
known to have a deep indigo/blue colour (Benzie and Strain, 1996). FRAP is a single 
electron transfer reaction from the antioxidant molecule to the oxidant. The change in 
absorbance value of either oxidant or antioxidant is a measure of reducing capability of the 
antioxidant (Ou et al., 2002). A working FRAP reagent was prepared as required by mixing 
30 ml of 300 mM acetate buffer (pH 3.6) with 3 ml of 10 mM 2,4,6 tripyridyl-S-triazine 
(TPTZ) solution in 40 mM HCl and 3 ml of 20 mM FeCl36H2O solution. Trolox standard 
was used as illustrated in Table 3.3. The standard and samples (100 µl) were prepared in 
triplicate followed by the addition of 3 ml freshly prepared FRAP reagent. Then, reaction 
mixture was incubated at 37°C for 4 min. Absorbance was read at 593 nm against a blank 
prepared with distilled water. 
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Table 3.3: Preparation of FRAP assay standard 
Tube Trolox (µM) Volume of Stock 
(µl) 
Phosphate Buffer 
(µl) 
Final Volume (µl) 
S1 0 0 750 750 
S2 83 125 625 750 
S3 167 250 500 750 
S4 250 375 375 750 
S5 333 500 250 750 
S6 417 625 125 750 
3.3.31 Trolox Equivalent Antioxidant Capacity (TEAC) 
The TEAC assay estimates inhibition of radical cation production by the antioxidant in the 
sample. The concentration of antioxidant in the sample is inversely proportional to the 
absorbance of the radical cation produced by 2, 2’-azo-bis- (3-ethyl benzothiozoline-6-
sulfonate) (ABTS) (Gupta et al., 2009).  
The TEAC assay is useful assay for tracking unknown antioxidants in a complex mixture 
(Arts et al., 2004). Potassium peroxodisulphate solution (8 µl) was added to 5 ml of 7 mM of 
ABTS and kept in the dark for 24 hours before use. Trolox (6-hydroxy-2, 5, 7, 8-tetramethyl 
chroman-2-carboxylic acid) (1 mM) was dissolved in 50 ml of ethanol. Trolox concentration 
ranged between 50-500 µM. Briefly, 25 µl of test sample was added to 300 µl of ABTS (1 ml 
of ABTS in 20 ml ethanol) in triplicate. The reaction mixture was incubated for 30 min. 
Absorbance of the reaction was measured with a Multiskan Spectrum Plate Reader at a 
wavelength of 734 nm and temperature set at 25°C against a blank prepared with ethanol. 
The TEAC values were estimated using a linear equation (y=mx+c) between ABTS 
scavenged (y in mM) and the ABTS concentration (x in µM). Results were expressed as 
µmole Trolox equivalents per milligram dry weight of test sample. 
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3.3.32 Inhibition of Fe (II)-Induced Microsomal Lipid Peroxidation  
Endogenous and exogenous factors such as metabolism, chemicals and ionizing radiation are 
linked to the induction of free radical in biological tissues (Iqbal et al., 2003). Iron is known 
to be involved in the generation of reactive oxygen species (ROS) in vivo such as H2O2 
which may attack lipids to form damaged products (Imlay and Linn, 1988; Aruoma et al., 
1989). Lipid peroxidation is an important product of the reaction between free radicals and 
lipid (D'Souza and Prabhu, 2006). The ability of an agent to protect lipid from peroxidation 
by ROS can be related to the antioxidant capacity of the agent. Liver microsomes were 
prepared from male Fischer 344 rats. Rat livers were homogenized in 0.15 M KCl containing 
10 mM potassium phosphate buffer (pH 7.4) and centrifuged at 9000 x g. The supernatant 
fraction (S9) was stored at -80°C until ready to use.  
Microsomes were purified on a Sepharose-2B column as described previously (Gelderblom 
et al., 1984). Inhibition of FeII-induced microsomal lipid peroxidation was determined by the 
method described by (Snijman et al., 2009). The reaction mixture contained microsomes (1 
mg of protein/ml in 0.01 M potassium phosphate buffer pH 7.4, supplemented with 1.15% 
KCl). The samples (100 µl) were pre-incubated with 500 µl microsomes at 37°C for 30 min 
in a shaking water bath. KCl buffer (200 µl) was added, followed by 2.5 mM ferrous sulphate 
(200 µl) and incubated for an hour in a shaking water bath. The reaction was terminated with 
1 ml 10% trichloroacetic acid (TCA) containing 0.01% butylated hydroxytoluene (BHT) and 
1 mM EDTA. Samples were centrifuged at 2000 rpm for 15 min. Supernatant (1 ml) was 
mixed with 1 ml of 0.67% thiobarbituric acid (TBA) solution and incubated in a water bath at 
90°C for 20 min. The absorbance was read at 532 nm. The percentage of inhibition of 
TBARS formation relative to the positive control was calculated by: 
control sample
control
A -A% Inhibition of TBARS formation = X 100%A  
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3.4 Statistical Analysis  
Data are expressed as means ± SD of experiments performed in triplicate. The values were 
analyzed by Two-Way ANOVA, followed by Tukey’s multiple comparism test using 
GraphPad Prism version 6.05 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com). 
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CHAPTER 4 
ANTI-PROLIFERATIVE AND APOPTOSIS INDUCTION 
POTENTIAL OF THE METHANOLIC LEAF EXTRACT 
OF HOLARRHENA FLORIBUNDA 
4.1 Introduction  
Cancer remains the leading cause of mortality and morbidity in the world. Newly diagnosed 
cancer cases are about 10 million with 6 million deaths reported worldwide annually (Parkin 
et al., 2001). In addition, about 1.6 million new cases and 6 hundred thousand deaths are 
predicted for 2013 in the USA alone (Siegel et al., 2013). Chemotherapy is a major mode of 
treatment of various cancers, but its success is marred by the attendant toxicity and drug 
resistance (Yaacob et al., 2010; Leonard et al., 2009; Wonders and Reigle, 2009). Traditional 
uses of natural plants to treat different diseases, including cancer, and scientific isolation of 
effective drugs against cancer from plants give credence to their importance. The reason for 
the viable source of therapeutic agents from nature might not be unconnected with the 
structural diversity inherent in over a million of species of plants and microorganisms that 
still remain beyond the comprehension of man (da Rocha et al., 2001).  
Drugs currently in use as anticancer agents have over 60% of their origin from natural 
products (Cragg et al., 2009). Vinblastine (Velban®), vincristine (Oncovin®), vinorelbine 
(Navelbine®), etoposide (VP-16®), teniposide (VM-26®), paclitaxel (Taxol®), docetaxel 
(Taxotere®), topotecan (Hycamptin®), and irinotecan (Camptosar®) are some of the 
examples of anticancer drugs that had passed through different stages of pre-clinical and 
clinical trials and hence approved for clinical use (Wang et al., 1997; Lee, 1999). Holarrhena 
floribunda (G. Don) is a tree that belongs to the Apocynaceae family, a family of plants 
 
 
 
 
CHAPTER 4 | 4.2 CYTOTOXICITY OF THE METHANOLIC LEAF EXTRACT 
81 
known to be rich in alkaloids. Alkaloids are compounds found to be responsible for the 
anticancer activity of the Camptotheca acuminata plant from which one of the currently used 
anticancer drugs (camptothecin) is isolated.  
The leaves of the plant—Holarrhena floribunda—evaluated in this study, are used in 
folklore medicine as an anti-malarial in Ghana (Bouquet and Debray, 1974). The bark is put 
to use in the Ivory Coast as a treatment for diarrhoea and the leaves for the amenorrhea 
(Kerharo and Adam, 1974). The root is boiled in milk and used to bathe boys attaining 
puberty and it is also used as a cure for snakebites and venereal disease (Iwu, 2014). It has 
been shown to exhibit significant cytotoxicity activity out of some plant extracts screened 
(Abreu et al., 1999). Its antioxidant, antimutagenic and lipid peroxidation inhibition 
properties have been reported (Badmus et al., 2010). The present study aimed to evaluate the 
antiproliferative, apoptosis and reactive oxygen species inducing activities of the MLE of 
Holarrhena floribunda in breast cancer carcinoma cell (MCF-7), colon cancer (HT-29), 
cervical cancer (Hela) and normal fibroblasts (KMST-6) as control. 
4.2 Cytotoxicity of the Methanolic Leaf Extract  
The cytotoxic effect of the MLE of Holarrhena floribunda was evaluated on HT-29, HeLa, 
MCF-7 and KMST-6 using MTT assays. Figure 4.1 shows a log dose-response curve to 
calculate half-maximal (IC50) cytotoxic effects of the MLE on the cell lines. Table 4.1 depicts 
IC50 values for 24-, 48- and 72-hour treatments. The results showed that all the cells 
responded to the cytotoxicity effect of the MLE in a dose- and time-dependent manner. The 
HeLa cancer cells, however, were more sensitive to the plant extract as shown by its IC50 
values for 24, 48 and 72 hours (182.6, 127.4 and 106.7 µg/ml, respecively). Moreover, the 
extract exhibited a selectively lower cytotoxicity to normal KMST-6 fibroblasts with higher 
IC50 values of 376.9, 428.2 and 342.3 for the 24-, 48- and 72-hour exposure times, 
respectively.  
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Cell viability in respect of MLE doses ranging from 100 - 500 µg/ml was evaluated using the 
trypan blue dye exclusion assay. The assay further reaffirms the sensitivity of the cancer cell 
lines compared to the non-cancerous KMST-6 cells (Figure 4.2).  
 
 A 
                                         
      B 
 C D 
Log dose (µg/ml) effects of extract after 24, 48 and 72 hours exposure of cells specified. MTT assay was employed to assess the 
cytotoxic effect of the extract and the graphs were prepared using Graphpad Prism 6 statistical software. 
Figure 4.1: Cytotoxic effects of the MLE on HT-29, HeLa, MCF-7 and KMST-6 cells 
The antiproliferative activity of the extract was further evaluated using clonogenic survival 
assay. The assay measures the potential of cells to grow into colonies after treatment in a 
manner unrestricted by growth contact inhibition as found in normal growing cells. 
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As presented in Figures 4.3 and 4.4, colony formation decreases with an increase in the 
concentration of the extract. Remarkably, MCF-7 and HeLa cell lines displayed no colony 
forming units at MLE concentrations of 400 and 500 µg/ml. 
Table 4.1: IC50 values of the MLE of Holarrhena floribunda for HT-29, Hela, MCF-7 and KMST-6 
cell lines for the 24-, 48- and 72-hour treatments 
 IC50* (µg/ml) values for cell lines exposed to the MLE of Holarrhena floribunda 
Time (h) HT-29 colon cancer HeLa cervical cancer MCF-7 breast 
cancer 
KMST-6 
fibroblasts 
24 349.2 182.6 357.6 376.9 
48 217.5 127.4 244.3 428.2 
72 159.4 106.7 126.7 342.3 
*IC50 values were obtained from non-linear regression analysis of the log dose cytotoxic effects of the MLE, using 
Graphpad Prism 6 statistical software. 
 
 
The trypan blue dye exclusion assay as assessed with the BioRad TC-20 cell counter was used as described in Chapter 3. 
Figure 4. 2: Effects of MLE on the viability of HT-29, MCF-7, HeLa and KMST-6 cells  
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Paraformaldehyde fixed cells were stained with 0.5% crystal violet dye and colonies formed were counted using a colony 
counter. Colony formation inhibition at each concentration of the extract is expressed in terms of percent of control and 
reported as the means ± SD. 
Figure 4.3: Percentage colonies formed after a 24-hour MLE treatment of HT-29, MCF-7, HeLa and 
KMST-6 cells 
4.3 Apoptotic Effects of the Methanolic Leaf Extract 
Apoptotic effects of the MLE was explored by staining the cells with APOPercentageTM dye 
and evaluated by flow cytometry. The results showed that the induction of cytotoxicity 
occurs through the mechanism of apoptosis. The MLE induced apoptosis in a concentration 
dependent manner (Figure 4.5). The HeLa cell line was significantly (P<0.0001) more 
sensitive to the MLE when compared with other cell lines. The sensitivity of the KMST-6 
cell line to the apoptosis inducing ability of the MLE was also low compared to other cell 
lines. The apoptosis inducing ability of the extract was further tested using the Annexin-V 
FITC/propidium iodide double staining flow cytometric assay. Cells were exposed to the 
extract at 200 µg/ml concentration for 12, 24 and 48 h, as presented in Table 4.2. HT-29 
colon cancer cells at 24 hours exihibited significant early apoptosis, Hela cervical cancer 
cells were in the late apoptotic stage at 48 hours while MCF-7 breast carcinoma cells showed 
significant necrotic cell death at 48 h. 
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  Control 100 µg/ml 200 µg/ml 300 µg/ml 400 µg/ml 500 µg/ml 
KMST-6 
fibroblasts 
           
HeLa 
cervical cancer 
           
HT-29  
colon cancer 
           
MCF-7  
breast cancer 
           
Pictures were taken using a ZEISS Primo Vert microscope and the colonies were counted with colony counter. 
Figure 4.4: Photomicrographs of colonies of cells following 24-hour treatment with the MLE at the indicated concentrations 
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Cells were stained with the APOPercentageTM dye and evaluated using a flow cytometer. 
Figure 4.5: Apoptotic effects of the MLE on HT-29, MCF-7, HeLa and KMST-6 cells 
4.4 Effect of Methanolic Leaf Extract on Caspase-3/7 and -9 Activities 
The activation of caspase 3/7 and -9 were evaluated to establish the cell death pathway induced 
by the MLE. As shown in the Figure 4.6, HeLa cells exhibited a concentration dependent fold 
increase in caspase-3/7 activity. However, MCF-7 and HT-29 cells show a significant 
concentration dependent decrease in caspase-3/7 activities. Caspase-9 activities in all the cells 
followed the same pattern. It was observed that the extract caused a decrease in the activities in 
caspase-9 in all the cells treated (Figure 4.7).  
4.5 Effects of Methanolic Leaf Extract on Cell Cycle and ROS Induction  
The effects of the extract on the phases of the cell cycle using flow cytometry in cancer cells 
treated with 200 µg/ml MLE for 12- and 24-hour periods. Representative cell cycle distribution 
histograms of HeLa cell were presented in Figures 4.8 and 4.9 shows the percentage of cells in 
different cell cycling stages for HeLa, MCF-7 and HT-29 cells at 12 and 24 h. 
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Table 4.2: Percentage of live, apoptotic and necrotic cell populations following exposure to the MLE 
Cell Line HeLa MCF-7 HT-29 
Exposure Times 12 h 24 h 48 h 12 h 24 h 48 h 12 h 24 h 48 h 
Live 92.41±0.03 84.94±0.69 19.05±0.51 95.22±1.36 92.15±1.77 7.1±1.23 94.22±2.23 78.45±2.25 83.43±4.61 
Early Apoptosis 3.41±0.32 6.26±0.50 3.41±0.36 4.69±1.27 6.11±0.34 0.15±0.01 4.56±1.60 16.72±1.64 0.01±0.01 
Late Apoptosis 3.53±0.12 6.53±0.78 33.47±1.90 0.18±0.02 0.52±0.19 3.93±1.58 0.26±0.04 4.46±0.70 0.46±0.16 
Dead 0.66±0.23 1.38±1.20 43.60±1.75 0.03 ± 0.02 0.16±0.03 87.60±1.17 0.05±0.01 0.07±0.01 16.42±1.73 
Cells were evaluated by double staining in Annexin V-FITC/propidium iodide using the flow cytometric assay as described in Chapter 3. 
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Caspase-3 activity was evaluated after 24-hour exposure of cells to the MLE, using the Caspase-Glo® 3/7 luminescent 
assay kit (Promega) as described in Chapter 3. 
Figure 4.6: Effects of the MLE on caspase-3 activation in HT-29, MCF-7 and HeLa cell.  
 
 
Caspase-9 activity was evaluated after 24-hour exposure of cells to the MLE, using the Caspase-Glo® 3/7 luminescent 
assay kit (Promega) as described in Chapter 3. 
Figure 4.7: Effects of the MLE on caspase-9 activation in HT-29, MCF-7 and HeLa cells. 
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The results show that the MLE induced a significant accumulation of cells in G0/G1 phases 
and reduced the number of proliferating cells as shown by low S-phase at both 12- and 24-
hours for all the cells. Also, the ability of the MLE (200 µg/ml) at 12- and 24-hours to induce 
ROS was evaluated using the cell permeant dye chloromethyl-2’, 7’-
dichlorofluorescindiacetate (CM-H2DCFDA). As shown in Figure 4.10, MLE-treated cells 
(black panel) showed an increase in ROS concentration compared to the untreated control 
(pink panel) in a time-dependent manner. The ROS induction effect of the extract was 
significantly pronounced in HeLa cells. 
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A: 12-hour Control 
 
B: Hela cells treated for 24-hour 
with 200 µg/ml MLE 
 
C: 24-hour Control 
 
D: Hela cells treated for 12-hour 
with 200 µg/ml MLE 
Figure 4.8: Representative histograms of DNA content in cell cycle phases of HeLa cells 
 HeLa  MCF-7 HT-29 
Values are representative of means ± SD of three separate experiments. 
Figure 4.9: Percentage of cells in the G0/G1, S and G2/M phases after a 12- and 24-hour exposure to 200 µg/ml MLE 
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 MCF HT-29 HeLa 
12 h 
   
 
24 h 
    
 The pink histogram depicts stained control cells while black shows the cells treated with the extract at 12 and 24 h. 
Figure 4.10: Representative histograms of cells stained with CM-H2DCFDA dye and evaluated by flow cytometry 
 
 
Values are means ± SD of three separate experiments evaluated using flow cytometry. 
Figure 4.11: Fold increase in mean florescence intensity (MFI) of cells undergoing induction of ROS following treatment with MLE for 12 and 24h 
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CHAPTER 5 
BIOACTIVITY-GUIDED FRACTIONATION AND 
CYTOXICITY SCREENING OF THE METHANOLIC 
LEAF EXTRACT OF HOLARRHENA FLORIBUNDA 
5.1 Background  
Plants provide a reservoir of chemical diversity that provides leads for the discovery of new 
drugs against human diseases (Newman and Cragg, 2007). The usage of folklore medicine 
worldwide demonstrates its importance as a reliable source of bioactive antitumour, 
antioxidant and antimicrobial compounds (Jung, 2014). Assessing plants used in traditional 
medicine for various biological capabilities is a necessary step in the isolation and 
characterization of bioactive components inherent in plants for drug development. The 
African continent lays claim to about 45,000 plant species of which 5,000 are used for 
medicinal purposes (van Wyk, 2008). Despite the huge potential this number of species 
presents, only 83 out of 1100 potential drugs coming out of the African continent have been 
selected as candidates for preclinical development and screening platforms (van Wyk, 2008). 
Only 1-10% of plants have been scientifically evaluated out of the colossal number of 
250,000-500,000 world floral species (Verpoorte, 2000). There is a huge gap between the 
natural endowment and human potential to stem the tide of avalanche of drugs that present 
with adverse reactions, especially against cancer. The medicinal constituents derived from 
plants are not only important as therapeutic agents, but can also serve as templates for the 
synthesis of active drugs with required therapeutic properties (Mukherjee, 2003). This has 
opened new vistas for the importance of the structures of bioactive components of plants 
such as camptothecin, which has been developed into different analogues (topotecan, 
irinotecan, belatecan and 9-aminocamptothecin). 
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Holarrhena floribunda is a plant with an approximate height of 17 m and girth of 1 m. The 
plant belongs to the family of Apocynaceae and commonly found in secondary regeneration 
in deciduous forests, savanna woodlands in Senegal, Nigeria and Congo basin. Apocynaceae, 
the dogane family of flowering plants includes more than 250 genera and 2,000 species of 
trees, shrubs, woody vines and herbs distributed primarily in tropical and subtropical areas of 
the world (Wiart, 2006). All the members of the family are known to produce abundant 
milky latex; simple, opposite and whorled leaves; slightly fragrant, colourful and large 
flowers with five contorted lobes; and with paired fruits (Wiart, 2006). The most commonly 
medicinal contents of the family are alkaloids, steroidal alkaloids, cardiotonic glycosides, 
saponin, and iridoids (Wiart, 2006). Some bioactive natural products from the family are 
vinblastine, quabain, reserpine and ibogaine. Alkaloids contents of the family has been 
historically useful to treat cancer with many other compounds awaiting discovery (Wiart, 
2006). Some of Apocynaceae members reported to have anticancer properties are Alstonia 
macrophylla (Keawpradub et al., 1999), Nerium oleander (Siddiqui et al., 1995), Cerbera 
manghas (Chang et al., 2000) and Calotropis gigantea (Lhinhatrakool and Sutthivaiyakit, 
2006). The objective of this work was to isolate, purify and characterize bioactive 
components with antiproliferative activity from the MLE of H. floribunda using bioactivity-
guided fractionation, and to profile cytotoxicity, cell cycle and DNA synthesis effects on 
HeLa, MCF-7, HT-29 cancer cells and KMST-6 normal fibroblasts of the isolated 
compounds. 
5.2 Bioassay-Guided Fractionation  
The cytotoxic potential of the total extract as presented in Chapter 4 led to further interest to 
isolate the compounds in the leaves responsible for the observed effects. The isolation of 
compounds involved the use of silica gel and alumina packed column chromatography 
coupled with cytotoxicity evaluation of sub-fractions using the MTT assay as presented in 
Figure 5.1.           
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Figure 5.1: Schematic diagram showing purification steps of alkaloids from the MLE 
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The ground, air-dried leaves, weighing 1.748 kg were soaked in 5.25 L of methanol. The 
mixture was thoroughly mixed and filtered after 48 hours using a Buchner vacuum filter. The 
filtrate was evaporated to dryness with Rotary evaporator. The fractionation of the MLE (175 
g) was carried out by using a silica gel packed column with gradient mixture of increasing 
polarity of ethyl-acetate and methanol as mobile phase. The fractions were combined 
together according to their TLC profiles to yield 18 fractions. 
The eighteen fractions (Table 5.1) obtained from the methanolic extract were subjected to 
bioassay-guided fractionation using tetrazolium salt 3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTT) cytotoxicity assay to check for potential fractions that 
can be further purified for anticancer activity. Bioassay-guided fractionation led to 
identification of three sub-fractions with strong cytotoxicity. The three cytotoxic sub-
fractions were found to be similar on TLC plate and one of the three (sub-fraction 17) was 
selected for further purification by alumina packed column chromatography. 
The purification of sub-fraction 17 (0.6 g) on alumina column chromatography afforded 21 
sub-sub fractions. The NMR characterization and identification of the isolated compounds 
were done on 200 MHz Unity Inova spectrometer (Mercury 200) as stated in Chapter 3. 
Compound 1 obtained weiged 49.5 mg and compound 2 weighed 20.2 mg. 
5.3 NMR Data of the Isolated Alkaloids  
The NMR spectra of the purified alkaloids is shown in the Figures 5.2 to 5.5. 
Compound 1: colourless crystals; 1H NMR (200 MHZ, CDCl3): δH 5.38 (H-6); 3.12 (H-3); 
2.54 (H-17); Me 2.10 (Me-21); 0.97 (Me-19); 0.63 (Me-18). 13C NMR (200 MHZ, CD3OD): 
δC 209.6 (C-20); 139.0 (C-5); 122.8 (C-6); 63.6 (C-17); 56.8 (C-14), 50.2 (C-9); 46.7 (C-3); 
43.9 (C-13); 40.0 (C-7); 38.7 (C-12); 37.3 (C-10); 33.0 (C-1); 31.78 (C-8); 31.74 (C-7); 31.5 
(C-21); 29.4 (C-2); 24.4 (C-15); 22.7 (C-16); 20.7 (C-11); 18.8 (C-19); 13.1 (C-18).
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Table 5.1: The weight and the IC50 cytotoxicity activities of sub-fractions from MLE on HeLa cells 
Fraction Weight (g) IC50 (µg/ml) 
1 7.50 >500 
2 2.12 100 
3 5.38 >500 
4 1.59 >500 
5 1.92 >500 
6 0.91 >500 
7 0.24 >500 
8 0.44 >500 
9 0.84 >500 
10 0.31 >500 
11 0.16 >500 
12 6.10 >500 
13 14.45 >500 
14 9.04 >500 
15 39.63 <30 
16 23.80 <30 
17 16.40 <30 
18 6.17 >500 
 
Compound 2: colourless crystal: 1H NMR (200 MHZ, CDCl3): δH 3.15 (H-3), 2.48 (H-17); 
2.06 (Me-21); 0.73 (Me-19) and 0.55 (Me-18). 13C NMR (200 MHZ, CD3OD): δC 209.8 (C-
20); 63.8 (C-17); 56.7 (C-14); 54.2 (C-9)?; 45.2 (C-3); 44.2 (C-13) 39.0 (C-5, -12); 36.3 (C-
10); 35.9 (C-8); 35.4 (C-4); 32.0 (C-1); 31.9 (C-21); 29.8 (C-2); 28.8 (C-7); 28.5 (C-6); 24.3 
(C-15); 22.7 (C-16); 20.7 (C-11); 13.4 (C-18); 11.3 (C-19).
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Figure 5.2: 1H NMR spectrum of isolated alkaloids (compound 1) from the MLE 
 
O
H2N Compound 1, (Holamine)
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Figure 5.3: 13C NMR spectrum of isolated alkaloids (compound 1) from the MLE 
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Figure 5.4: 1H NMR spectrum of isolated alkaloids (compound 2) from the MLE 
 
O
H2N
Compound 2, Funtumine
 
 
 
 
CHAPTER 5 | 5.3 NMR DATA OF THE ISOLATED ALKALOIDS 
100 
 
 
Figure 5.5: 13C NMR spectrum of isolated alkaloids (compound 2) from the MLE 
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5.4 Cytotoxicity of Isolated Compounds  
The cytotoxicity of compounds 1 and 2 were tested on HT-29 (colon cancer), MCF-7 (breast 
cancer), HeLa (cervical cancer) and KMST-6 (normal fibroblast cell). Figure 5.6 shows the log 
dose-response curve of the isolated compounds and standard anticancer drugs (cisplatin and 
doxorubicin) in the cancer and normal cell lines. Table 5.2 depicts the IC50 values of the isolated 
compounds and standards while Table 5.3 shows the selectivity index. The cytotoxicity result 
shows that compound 1 induced significant cytotoxicity on HT-29 cancer cell compared with 
other cancer cell lines with lowest IC50 of 31.06 µM followed by MCF-7 (42.82µM), HeLa 
(51.42 µM) and KMST-6 (102.95 µM). The cytotoxicity effect of compound 1 is closely similar 
to that of compound 2. Compound 2 also shows cytotoxicity against HT-29 as the most sensitive 
with IC50 of 22.36 µM followed by HeLa (46.17 µM), MCF-7 (52.69 µM) and KMST-6 (85.45 
µM). Cisplatin and doxorubicin showed significant indiscriminate cytotoxicity activities against 
cancer cells and normal cell line as presented in Table 5.3. The selectivity index as presented in 
Table 5.4 shows that the isolated compounds are more selective towards cancer cells than the 
normal cell line as opposed to the standard anticancer drugs with low selectivity index. 
5.5 Cell Cycle Effects of the Isolated Compounds  
The effects of the IC50 concentrations of the isolated compounds calculated from cytotoxicity 
assays were tested on the cell cycle phases of the cancer cell lines used in this study. Cancer cells 
were stained with propidium iodide (PI) and evaluated using flow cytometry. The cell cycle 
phases (G0/G1, S, G2/M) were evaluated at 12 and 24-hour time points as presented in Figures 
5.7 and 5.8. The results showed that the compounds induced significant increase (P<0.0001) in 
cell populations in G0/G1 and G2/M phases with concomitant reduction in S-phase of HT-29 cell 
at both time points. 
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Figure 5.6: Cytotoxic effects of isolated compounds (1 and 2) and standard compounds (cisplatin and doxorobucin) on cancer cells and normal fibroblasts 
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Table 5.2: IC50 values for cancer cell lines treated for 24-hour with compounds 1, 2, cisplatin and 
doxorubicin 
Drug 
IC50 (µM) determined by non-linear regression of MTT assay dose-response data  
Cell Line 
HT-29 HeLa MCF-7 KMST-6 
Compound 1 31.06 51.42 42.82 102.95  
Compound 2 22.36 46.17 52.69 85.45 
Cisplatin 7.07 2.91 10.58 6.14 
Doxorubicin 17.38 3.57 8.20 4.68 
 
Table 5.3: Selectivity index of isolated compounds and standard drugs in normal and cell cancer cells 
Drug 
Cell Line 
HT-29 HeLa MCF-7 
Compound 1 3.31 2.00 2.00 
Compound 2 3.82 1.62 1.85 
Cisplatin 0.87 2.11 0.58 
Doxorubicin 0.27 1.31 0.57 
 
A significant increase was observed in the G0/G1 phase with reduction in S-phase in HeLa cell 
treated with both compounds while significant increase (P<0.01) in G2/M-phase was only 
observed at 24-hour for the compound 1. MCF-7 cells showed a significant increase (P<0.0001) 
in cell populations at G0/G1 phase and reduction in S-phase. Treatment of MCF-7 cells with 
compound 2 resulted in a significant increase (P<0.0001) in the G2/M-phase at both time points 
while compound 1 only caused a significant increase (P<0.0001) at the 12-hour time point. 
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5.6 Effects of Isolated Compounds on DNA Synthesis  
The effects of the isolated compounds on DNA synthesis was tested using BrdU 
chemiluminescent ELISA kit by treating the cells (HeLa, MCF-7 and HT-29) with the respective 
IC50 concentrations determined for the periods of 12, 24 and 48 hours in relation to untreated 
control cells (KMST-6). The results as presented in Figure 5.9 show that the two compounds 
significantly reduced DNA synthesis in all the cells. Compound 1 showed significant reduction 
(P<0.0088) between 24 and 48 hours while compound 2 displayed significant reduction 
(P<0.0001) in DNA synthesis between 12 and 24 hours in HeLa cell. MCF-7 cells showed 
significant reduction (P<0.0030) in DNA synthesis when treated with compound 1 between 12 
and 24 hours while compound 2 significantly (P<0.05) reduced the DNA synthesis between the 
24 and 48 hours. Compound 1 only showed significant reduction (P<0.0001) at 12 and 24 hours 
treatment of HT-29 cell while compound 2 showed significant reduction between 12 and 24 
hours (P<0.05) and between 24 and 48 hours (P<0.001). 
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Figure 5.7: Effects of compound 1 on cell cycle progression of HT-29, HeLa and MCF-7 cells stained with PI and evaluated using flow cytometry 
 
Figure 5.8: Effects of compound 2 on cell cycle progression of HT-29, HeLa and MCF-7 cells stained with PI and evaluated using flow cytometry 
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Hela MCF-7 HT-29 
Figure 5.9: Effects of IC50 concentrations of compounds 1 and 2 on DNA synthesis at 12, 24 and 48 hours based on the chemiluminescent BrdU ELISA assay 
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CHAPTER 6 
TWO STEROIDAL ALKALOIDS FROM HOLARRHENA 
FLORIBUNDA LEAVES INDUCE APOPTOSIS IN CANCER 
CELLS 
6.1 Background  
Apoptosis is a gene-regulated autonomous process of cell component removal without induction 
of end-point inflammatory effects on surrounding cells (Gallardo-Escarate et al., 2007). It is an 
important physiological event for the maintenance of tissue homeostasis for all organ systems in 
the human body (Kumar et al., 2012). Deregulation of apoptosis is linked to several pathogenic 
conditions such as stroke, neurodegenerative diseases and cancer (Thompson, 1995). Several 
lines of evidence have shown that chemoprevention and chemotherapeutic agents stimulate 
induction of apoptosis suggesting its importance in cancer treatment (Al Dhaheri et al., 2013). 
Cancer cells possess several mechanisms of resisting programmed cell death (PCD) and potential 
of natural products to induce the process of apoptosis is a crucial step in anticancer activity 
(Fulda, 2010b) and an important approach to treat cancer (Dixon et al., 1997).  
An ideal therapeutic goal for cancer treatment is to trigger apoptotic death selectively in tumour 
cells (Ganesh et al., 2014). Cytotoxic effects of medicinal plant products can be mediated 
through the stimulation of apoptotic pathways (Mehta et al., 2010) and a number of them have 
the ability to induce apoptosis (Parsaee et al., 2013a). It is, however, essential to screen 
anticancer agents from natural products for their ability to induce apoptosis (Taraphdar et al., 
2001). Previous chapters show that the methanolic extract of Holarrhena floribunda leaves and 
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the two steroidal alkaloids (holamine and funtumine) isolated from the leaves have cytotoxicity 
against the panel of cancer cells used in this study. In addition, Holarrhena floribunda used in 
this study has been extensively reviewed in the previous chapters. Cytotoxic and apoptotic 
effects of alkaloids in general and steroidal alkaloids in particular are well documented in the 
scientific literature (Rosenkranz and Wink, 2008; el-Shazly and Wink, 2008; Dassonneville et 
al., 2000). Holamine and funtumine exert cytotoxic and apoptotic effects on the cell lines studied 
and their modes of action need to be elucidated. The present study sought to evaluate the effects 
of the steroidal alkaloids with regard to apoptosis induction, reactive oxygen species production, 
mitochondrial depolarization, actin filament expression and inhibition of topoisomerase-I. 
6.2 Viability and Cytotoxicity of Holamine and Funtumine 
The previous chapter evaluated the cytotoxicity of the isolated compounds using the MTT assay. 
The present section sought to evaluate the cytotoxicity and viability of the compounds by using 
the CytoTox-GloTM cytotoxicity assay (Promega) to further confirm the activities of the 
compounds against cancer cells and the normal fibroblast cell line (control). Figure 6.1 and 6.2 
shows the cytotoxicity and viability effects of the compounds on the cancer and normal cell 
lines. The results show that the two compounds are significantly more toxic to the cancer cell 
lines compared with normal fibroblasts.  
Holamine and funtumine showed significant cytotoxicity (P<0.0001) to MCF-7 and HT-29 
compared to KMST-6 while a P<0.01 was observed when KMST-6 was compared with HeLa 
cells treated with holamine and P<0.001 when treated with funtumine. There was no significant 
difference in sensitivity among the cancer cells treated with the holamine. Funtumine, however, 
showed significant cytotoxicity towards MCF-7 (P<0.5) and HT-29 (P<0.01) compared with 
HeLa cells. 
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A—HT-29, B—MCF-7, C—HeLa and D—KMST-6 cells 
Figure 6.1: Effects of holamine on cells evaluated with the CytoTox-Glo™ cytotoxicity assay
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E—HT-29, F—MCF-7, G—HeLa and H—KMST-6 cells 
Figure 6.2: Effects of funtumine on cells evaluated with the CytoTox-Glo™ cytotoxicity assay 
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6.3 Apoptotic Effects of Holamine and Funtumine  
The apoptotic effects of the compounds were evaluated by the APOPercentage™ dye using flow 
cytometry and the Annexin-V/PI double staining using Tali® Image-Based Cytometer. Figure 6.3 
and 6.4 shows the apoptotic effects of the two compounds on HT-29, HeLa and MCF-7 cancer 
cells. The Apopercentage assay results show that the cancer cell lines used in this study are 
significantly (P<0.0001) sensitive to the apoptotic effects of holamine when compared with 
normal KMST-6 fibroblasts.  
Likewise, cancer cells were significantly sensitive to funtumine-induced apoptosis compared 
with KMST-6 control. HeLa cells are more sensitive to the apoptotic effect of holamine while 
MCF-7 cells are more sensitive to funtumine. The results of Annexin-V/PI staining presented in 
the Figure 6.4 indicate that the two compounds induced significant late stage apoptosis compared 
with the early stage. Holamine induced significant late stage apoptotic effects in HeLa cells 
while funtumine showed a greater effect in HT-29 cancer cells. 
6.4 Effects of Holamine and Funtumine on Caspase-3/7 Activity 
The ability of the compounds to induce caspase-3/7 in cancer cell lines (HeLa, MCF-7 and HT-
29) treated for 12- and 24-hour periods is presented in Figure 6.5. Caspase-3/7 activity was 
evaluated using Caspase-3/7 Glo™ assay kit. The results show that the two compounds induced 
significant caspase-3/7 activity following exposure of cells to concentrations of 15 µg/ml and 30 
µg/ml for 24 and 12 hours respectively. The results reveal that the two compounds induced 
significant caspase-3/7 activity in the HeLa cancer cell line compared with the MCF-7 and HT-
29 cancer cell lines (P<0.0001). 
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Cells were stained with Apopercentage™ dye and evaluated by flow cytometry. Panel A represents the apoptotic effects of holamine and panel B those of funtumine. 
Figure 6.3: Apoptotic effects of holomine and funtumine on HT-29, MCF-7, HeLa and KMST-6 cells 
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 Cells were stained with Annexin-V FITC/PI and evaluated on a Tali® image-based flow cytometer. Panel A represents the apoptotic effects of 15 µg/ml holamine while panel B shows the apoptotic 
effects of 15 µg/ml funtumine, following exposure of cells for 24 hours to the compounds. 
Figure 6.4: Apoptotic effects of each holamine and funtumine on HT-29, MCF-7 and HeLa cell lines  
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Panel A represents holamine at 12 hours, B represents funtumine at 12 hours while C and D represent compounds 1 and 2 at 24 hours, respectively. Caspase-3 activity was evaluated using Caspase-
Glo®-3/7 luminescent assay kit (Promega). 
Figure 6.5: Effects of holamine and funtumine on the induction of caspase-3/7 in cancer cell lines (MCF-7, HeLa and HT-29) treated for 12 and 24 hours.
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6.5 Effects of Holamine and Funtumine on ROS Induction 
The induction of reactive oxygen species (ROS) by the two compounds were assessed by 
staining the cancer cells with the cell permeant dye chloromethyl-2’, 7’-
dichlorofluorescindiacetate (CM-H2DCFDA) and the results were evaluated by flow cytometry. 
The cells were treated with 15 µg/ml of the compounds for 12- and 24-hour periods. The 
concentration used was based on the effective concentration of the compounds that induced 
caspase-3/7 activity in the cancer cells. The results as presented in Figures 6.6 and 6.7 and show 
that the two compounds induced significant ROS in all the cell lines at both 12 and 24 hours.  
Holamine and funtumine show significant (P<0.0001) induction of ROS between 12 and 24 
hours for both HT-29 and HeLa cell lines while a significant difference in MCF-7 was not 
observed for these periods of exposure. Holamine and funtumine induced different levels of ROS 
in the cell lines. There was, however, no significant difference in ROS induction by funtumine 
between HT-29 and HeLa cell lines. 
6.6 Effects of Holamine and Funtumine on Mitochondrial ATP Production 
The effects of the compounds on mitochondrial ATP production in cells were evaluated with the 
mitochondrial ToxGlo™ assay according to the manufacturer’s instructions. The cells were 
treated with log increments in concentration of the compounds (0.01, 0.1, 1 and 10 µg/ml) for 2 
hours. The results are summarized in Figure 6.8.  
The different cancer cell lines differed in their responses to the effects of the two compounds, 
suggesting that the cell cytotoxicity induced by these compounds might not be isoeffective or 
involve the same mechanisms of action. The results show that holamine-induced cytotoxicity is 
mitochondrial specific in HeLa and HT-29 cells, but not in MCF-7 while funtumine induced 
mitochondrial cytotoxicity in HeLa and MCF-7, but not in HT-29. 
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Cells were treated for 12- and 24-hour periods with holamine (A) or funtumine (B), and thereafter stained with CM-H2DCFDA and the results were evaluated using a flow cytometer. MFI—Mean 
florescence intensity. 
Figure 6.6: Induction of ROS in HT-29, MCF-7 and HeLa cancer cell lines treated with holamine and funtumine  
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HT-29 MCF-7 HeLa 
Cells were stained with CM-H2DCFDA dye. The black histogram depicts stained control cells while the red and blue represent the cells treated with holamine and 
funtumine, respectively. 
Figure 6.7: Representative flow cytometry histograms of ROS production in HT-29, MCF-7 and HeLa cancer cell lines  
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The effects of holamine and funtumine were evaluated using the mitochondrial ToxGlo assay kit and recorded with a GLOMAX 
Multi detection system (Promega, USA). 
Figure 6.8: Effects of holamine and funtumine on mitochondrial ATP production in HeLa, HT-29 and 
MCF-7 cancer cells 
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6.7 Evaluation of Cell Morphology by Fluorescence Microscopy  
The morphology of HeLa cells was observed under a fluorescence microscope after treatment 
with the two compounds (15 µg/ml) and staining with tetramethylrhodamine (TRITC)-
conjugated phalloidin for the detection of F-actin cytoskeleton, 5-(and-6)-chloromethyl-2’, 7’-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) dye for detection of ROS induction and 
Mitotracker Red™ for the evaluation of cell mitochondrial status.  
DAPI (4', 6-diamidino-2-phenylindole) was used to counterstain cell nuclei in each experiment 
and merged images show co-localization of F-actin (red) and nuclear stain (blue), ROS induced 
cell (green) and nuclear stain (blue) and mitochondria (red) and nuclear stain (blue) (Figures 6.9 
to 6.14). The results show that the two compounds induced alterations of actin organization by 
decreasing actin at the edges of cell–cell contacts leading to reduced cellular contact between 
adjacent cells compared with the control with well-defined actin stress fibres as presented in 
Figure 6.9. 
Figure 6.10 shows increased fluorescence intensity of the cells treated with the two compounds 
after 12 hours treatment compared with the control cells. The increased intensity was not 
observed at 6 hours treatment with the compounds. Furthermore, the Mitotracker Red revealed 
evenly distributed mitochondria in the control cells. The fluorescence intensity in the 
mitochondria of treated cells was lower compared with the treated cells (Figure 6.11). 
6.8 Evaluation of Cell Morphology by Light Microscopy  
The morphological changes in MCF-7, HeLa and HT-29 cells were observed under the light 
microscope after the cells were exposed to 15 µg/ml of holamine and funtumine for 24 hours. As 
presented in Figure 6.15, it is clear that untreated control cells exhibit a normal shape while the 
treated cells show loss of cell adhesion, cell shrinkage, and reduced cell density. 
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HeLa cells were treated with 15 µg/ml holamine for 3 and 6 hours. Cells were fixed and stained with TRITC-conjugated phalloidin and viewed under a fluorescence microscope (x400) to visualize F-
actin cytoskeleton.  
Figure 6.9: Effects of holamine on HeLa cell F-actin cytoskeleton
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HeLa cells were treated with 15 µg/ml funtumine for 3 and 6 hours. Cells were fixed and stained with TRITC-conjugated phalloidin and viewed under a fluorescence microscope (x400) to visualize F-
actin cytoskeleton.  
Figure 6.10: Effects of funtumine on HeLa cell F-actin cytoskeleton 
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HeLa cells were treated with 15 µg/ml holamine and funtumine for 6 hours to induce ROS production. Cells were stained with 2 µM CM-H2DCFDA and DAPI dye and viewed under a fluorescence 
microscope (x400). 
Figure 6.11: Induction of ROS production after exposure of HeLa cells to 15 µg/m holamine or funtumine for 6 hours 
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HeLa cells were treated with 15 µg/ml holamine and funtumine for 6 hours to induce ROS production. Cells were stained with 2 µM CM-H2DCFDA and DAPI dye and viewed under a fluorescence 
microscope (x400). 
Figure 6.12: Induction of ROS production after exposure of HeLa cells to 15 µg/m holamine or funtumine for 12 hours
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HeLa cells were treated with 15 µg/ml holamine and funtumine for 6 hours to evaluate their effects on cell mitochondria. The cells were stained both Mitotracker red (red) and DAPI (blue) and viewed 
under fluorescence microscope (x400). 
Figure 6.13: Effects of a 6-hour exposure to 15 µg/ml holamine and funtumine on HeLa cell mitochondria
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HeLa cells were treated with 15 µg/ml holamine and funtumine for 12 hours to evaluate their effects on cell mitochondria. The cells were stained both Mitotracker red (red) and DAPI (blue) and viewed 
under fluorescence microscope (x400). 
Figure 6.14: Effects of a 12-hour exposure to 15 µg/ml holamine and funtumine on HeLa cell mitochondria
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MCF-7, HT-29 and HeLa cells were treated with 15 µg/ml holamine and funtumine for 24 hours and morphological changes assessed. Images were visualized and captured with a Ziess microscope at 
x200 magnification. 
Figure 6.15: Morphological changes in MCF-7, HT-29 and HeLa cells after 24 hours exposure to 15 µg/ml holamine and funtumine 
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6.9 Effects of Holamine and Funtumine on Topoisomerase-I Inhibition  
The topoisomerase-I inhibition assay is based on the inhibition of relaxation of supercoiled 
circular DNA as described by (Osheroff et al., 1983). Figure 6.16 shows topoisomerase-I, 
supercoiled DNA after treatment with the compounds and electrophoresed on 1% agarose gels 
stained with 0.5 µg/ml ethidium bromide in Tris-acetate EDTA (TAE) at 6.5 V/cm for 2 hours. 
Gels were directly scanned with an image analyzer (Biometra, Germany) for visualization. The 
results shows that the two compounds (holamine and funtumine) inhibited the topoisomerase-I 
enzyme. 
 
Lane 1 represents supercoiled DNA, lane 2, 3, 4 and 5 represent supercoiled DNA and topoisomerase-I (2 U), camptothecin 
(9.3 mg/ml; as standard), 15 µg/ml of holamine and funtumine, respectively. 
Figure 6.16: DNA relaxation effects of holamine and funtumine on topoisomerase-I 
6.10 Effects of Holamine and Funtumine on the Expression of PARP-1 
The expression of PARP-1 was evaluated in the HeLa cell line treated with 15 ug/ml each of 
holamine and funtumine. The cells were treated at different time intervals of 6, 12 and 24 hours 
with both compounds. Figure 6.17 represents proteins obtained from the treated cells resolved on 
12% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at a constant 
voltage of 200 V and stained with Coomassie Blue to determine whether proteins were present in 
the cell lysates.  
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Figure 6.17 illustrates the expression of low and high molecular weight protein profiles of the 
cells. 
 
Equal amounts of 20 µg were separated on a 12% SDS polyacrylamide gels stained with Comassie brilliant blue and 
destained. Lanes A and B show 24-hour treatment with funtumine and holamine while C and D, E and F, G and represent 6- 
and 12-hour treatment with funtumine and holamine respectively. Lane I shows the molecular weight standards. The stained 
gel was photographed with a UVP-Bioimaging System. 
Figure 6.17: SDS-PAGE profile of lysates of HeLa cells treated with or without 15 ug/ml holamine and 
funtumine for 6, 12 and 24 hours 
Figure 6.18 depicts the expression of PARP-1 protein by cells treated with the compounds for 6-, 
12- and 24-hour time periods. Electrobloting of the gel onto a nitrocellulose membrane shows 
that PARP-1 was activated at 12- and 24-hour treatments with both compounds. 
 
Lane 1 represents untreated control while lanes 2, 3, 4, 5, 6 and 7 represent holamine treatment (6 hours), funtumine (6 hours), 
holamine (12 hours), funtumine (12 hours), holamine (24 hours) and funtumine (24 hours), respectively. The image was taken with 
UVP-Bioimaging System. 
Figure 6.18: Western blot showing the expression of both active PARP-1 and cleaved PARP-1 
(inactivated) of HeLa cells treated with 15 ug/ml holamine and funtumine 
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CHAPTER 7 
ANTIOXIDANT ACTIVITY OF FLAVONOIDS ISOLATED 
FROM HOLARRHENA FLORIBUNDA LEAVES 
7.1 Introduction 
Flavonoids are low molecular weight, structurally related compounds with basic features of the 
2-phenyl-benzo-γ-prone nucleus consisting of two benzene rings linked through a heterocyclic 
pyran ring (Cushnie and Lamb, 2005). The broad pharmacological activity and protective health 
benefits of natural flavonoids have led to increased interest among scientists with a bias toward 
functional foods (Kahkonen et al., 1999). Flavonoids and other phenolic compounds with 
antioxidant activities are reputed to play a preventive role in the development of reactive oxygen 
species (ROS)-related diseases like cancer (Kahkonen et al., 1999). ROS produced during 
normal metabolism or induced by exogenous damage have been implicated in several human 
diseases (Tapas et al., 2008).  
ROS is known to contribute to cellular aging, mutagenesis, carcinogenesis and coronary heart 
diseases (Sastre et al., 2000; Takabe et al., 2001; Kawanishi et al., 2001). The scavenging ability 
of ROS by flavonoids is essential in preventing impending lesions to the cellular components 
such as DNA, proteins and lipids (Suganya et al., 2007b). Oxidation of lipid, for example, leads 
to lipid peroxidation, which is a free-radical-mediated propagation oxidative insult to 
polyunsaturated fatty acid components of cell membranes (Heim et al., 2002). The potential of 
the health benefits of these compounds for the prevention and therapeutic use has led to the 
investigation and identification of a wide range of bioactive principles that include flavonoids 
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and phenolic compounds in plants (vegetables, fruits, leaves, seeds cereals, roots, spices and 
herbs) (Suganya et al., 2007b). The protective effects of flavonoids are attributed to their ability 
to transfer electrons, chelate metals, activate antioxidant enzymes, reduce alpha tocopherol 
radicals and inhibit oxidases (Heim et al., 2002). Anti-inflammatory, anti-diarrhoeal, anti-ulcer, 
anti-viral, anti-allergic and vasodilatory actions are also attributed to these compounds (Proestos 
and Komaitis, 2006). The methanolic extract and sub-fractions isolated from the Holarrhena 
floribunda leaves have been reported to have strong antioxidant activity (Badmus et al., 2010; 
Badmus et al., 2013). The present work sought to isolate and characterize the flavonoids 
responsible for the antioxidant activities attributed to the leaves. 
7.2 Characterization of Flavonoids from MLE of Holarrhena floribunda 
Thin layer chromatography (TLC) screening of different fractions from the MLE of Holarrhena 
floribunda showed that sub-fractions 13 and 14 were rich in flavonoids, which were submitted 
for further chromatographic purification using a combination of silica gel and Sephadex column 
chromatography and high performance liquid chromatography (HPLC). Figure 7.1 shows the 
flowchart of the isolation of flavonoids. Sub-fraction 13 was subjected to silica gel 
chromatography to obtain 46 fractions which were combined according to their TLC profiles 
(TLC plates were developed using 10% dichloromethane (DCM):methanol and 
EtOAc:Acetic:formic acid:H2O (30:2:2:2, v/v). Next, 2 of the 8 sub-fractions were further 
subjected to Sephadex column chromatography using 100% ethanol.  
The flavonoid-rich fractions were purified by HPLC as described in Chapter 3 which led to the 
isolation of four pure flavonoid compounds (Figures 7.2 to 7.5). The nuclear magnetic resonance 
(NMR) spectra for the four flavonoid compounds are depicted in Figures 7.6 to 7.13 and 
summarized in Table 7.1. Sub-fraction 14 was also passed through the same process and led to 
the isolation of similar flavonoid compounds isolated from fraction 13. Compound 1 yielded 
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17.6 mg while compounds 2, 3 and 4 yielded 14.7, 12.3 and 17.3 mg, respectively. These 
flavonoids were further subjected to antioxidant tests: oxygen radical absorbance capacity 
(ORAC), ferric reducing/antioxidant power (FRAP), Trolox equivalent antioxidant capacity 
(TEAC) and lipid peroxidation inhibition. 
 
Figure 7.1: Flowchart of the isolation of flavonoids from the methanolic extract of H. floribunda leaves
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Figure 7.2: HPLC chromatogram of compound 1 at λ=240, Rt=33.169 
 
Figure 7.3: HPLC chromatogram of compound 2 at λ=240, Rt=31.926 
 
Figure 7.4: HPLC chromatogram of compound 3 at λ=240, Rt=31.765 
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Figure 7.5: HPLC chromatogram of compound 4 at λ=240, Rt=34.565 
7.3 Evaluation of Oxygen Radical Absorbance Capacity (ORAC) 
The antioxidant evaluation of flavonoids using ORAC assay in the presence of AAPH, Cu2+-
H2O2 and Cu2+ show that the entire isolated flavonoids and total extract have remarkable ORAC 
activities against the oxidants 2, 2’-azobis (2-amidino-propane) dihydrochloride (AAPH) and 
Cu2+-H2O2 as shown in the Figures 7.14 and 7.15. However, ORAC values for compounds 2 and 
3 were significantly higher compared with those for compounds 1 and 4 and the total extract in 
the AAPH and Cu2+-H2O2 systems. Figure 7.16 shows the percentage pro-oxidant ability of the 
compounds in the presence of Cu2+. The results in Figure 7.16 further reveal that none of the 
isolated compounds and the total extract act as a pro-oxidant in the presence of Cu2+. 
7.4 Evaluation of Ferric Reducing Antioxidant Power (FRAP) 
The ability of compounds to reduce Fe3+ to Fe2+ was evaluated using the established method of 
FRAP. Figure 7.17 shows the ability of each compound and the total extract to reduce the Fe3+ to 
Fe2+ calculated as µmole Trolox equivalent per gram (µmole TE/g). The results show that 
compounds 2, 3 and extract have significant (P< 0.0001) Trolox equivalent per gram when 
compared with compounds 1 and 4. 
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Figure 7.6: 1H-NMR spectrum of compound 1 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.7: 13C-NMR spectrum of compound 1 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.8: 1HNMR spectrum of compound 2 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.9: 13C-NMR spectrum of compound 2 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.10: 1H-NMR spectrum of compound 3 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.11: 13C-NMR spectrum of compound 3 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.12: 1H-NMR spectrum of compound 4 isolated from the methanolic extract of H. floribunda leaves 
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Figure 7.13: 13C-NMR spectrum of compound 4 isolated from the methanolic extract of H. floribunda leaves 
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Table 7.1: NMR spectroscopic data (400 MHz, DMSO-d6) of compounds 1-4 
 
O
O
O
HO
OH
O
OH
CH2
OH
OH
HO
O
O
CH3
OH
OH OH  
Mixture of quercetin-3-O-glucoside 
and 3-O-galactoside 
O
O
O
HO
OH
O
OH
CH2OH
OH
OH
HO
OH
O
O
O
HO
OH
O
OH
CH2OH
OH
OH
HO
 
Position  C1 C2 C3 C4 
 13C 1H 13C 1H 13C 1H 13C 1H 
2 156.6  156.9  156.5  156.6  
3 133.6  133.8/133.6  133.7  133.6  
4 177.9  177.6  177.8  177.9  
5 161.6  161.6  161.7  161.6  
6 99.2 6.21 99.5  99.2 6.20 s 99.2 6.21 s 
7 164.8  165.0  165.5  164.8  
8 94.2 6.44 94.1  94.0 6.40 s 94.2 6.44 s 
9 156.8  156.4/156.3  156.8  156.8  
10 104.3  103.9/103.8  104.3  104.3  
1’ 121.3  121.5/121.4  121.6  121.3  
2’ 131.3  115.6  115.6 7.54 brs 131.3 8.05 d (8.4 Hz) 
3’ 115.5  149.1  148.9  115.5 6.89 d (8.4 Hz)) 
4’ 160.4  145.3  145.2  160.4  
5’ 115.5  116.5/116.2  116.8 6.85 d (4.4 Hz) 115.5 6.89 d (8.4 Hz)) 
6’ 131.3  122.4/122.0  122.0 7.54 brs 131.3 8.05 d (8.4 Hz) 
Glucose moiety Glucose 
moiety 
 Glucose/ 
Galactose moiety 
 Glucose moiety    
1’’  5.97 d (7.2 Hz) 100.69/102.00  101.3  
 
 
3.00-3.70 
101.3 5.97 d (7.2 Hz) 
2’’ 74.6  74.19/71.38  74.5 74.6  
 
3.19-3.70 
3’’ 76.8  76.49/73.30  78.0 76.8 
4’’ 70.3  70.19/68.11  70.3 70.3 
5’’ 77.9  77.76/75.99  76.9 77.9 
6’’ 61.3  61.46/60.33  61.4 61.3 
Rhamnose 
1``` 
2``` 
3``` 
4``` 
5``` 
6``` 
 
OH-5 
 
 
73.9 
70.3 
71.0 
72.2 
68.7 
18.2 
 
     
 
 
 
 
 
 
 
12.64 s 
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AAPH was used as an oxidant against the compounds. TE/g = Trolox equivalent per gram. Note that standard deviation is very low 
and as such is not showing in the figure. 
Figure 7.14: ORAC values of isolated flavonoids and the total extract from Holarrhena floribunda leaves  
 
Cu2+-H2O2 was used to generate OH radical as an oxidant against the compounds and the extract in the ORAC assay reaction 
system. TE/g = Trolox equivalent per gram. Note that standard deviation is very low and as such is not showing in the figure. 
Figure 7.15: ORAC values of isolated flavonoids and the total extract from H. floribunda leaves 
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Pro-oxidant induction in the presence of Cu2+ evaluated using ORAC assay. The values were calculated as percentage decrease of 
area under the curve of the treated in relation to the untreated control. 
Figure 7.16: Pro-oxidant induction in relation to untreated control  
 
Trolox equivalent per gram (µmole TE/g); Ferric reducing antioxidant power assay (FRAP). 
Figure 7.17: Trolox equivalent of the compounds and extract evaluated using FRAP 
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7.5 Trolox Equivalent Antioxidant Capacity (TEAC) 
Trolox equivalent antioxidant capacity of the compounds and the total extract of Holarrhena 
floribunda are presented in Figure 7.18. The results indicate that compounds 2, 3 and the extract 
expressed significant (P< 0.0001) levels of Trolox equivalent capacity compared with the 
compounds 1 and 4. 
C 1 C 2 C 3 C 4
Tot
al e
xtra
ct
0
500
1000
1500
2000
C 1
C 2
C 3
C 4
Total extract
 
Trolox equivalent capacity (TEAC); values of the isolated flavonoids and the total extract in µmole trolox equivalent per gram. 
Figure 7.18: Trolox equivalent capacity values of the isolated flavonoids and the total extract 
7.6 Inhibition of Fe-Induced Lipid Peroxidation in Rat Liver Microsomes 
The potential inhibitory effects of the compounds and the total extract on lipid peroxidation were 
evaluated in S9 rat liver fractions. The IC50 values were calculated using GraphPad Prism 6 
statistical software. The IC50 values are summarized in Table 7.2 which shows that compound 2 
has a value of 9.8 µg/ml while compounds 3 and the extract have values of 10.4 and 7.2 µg/ml, 
respectively. Values for compounds 1 and 4 could not be determined because their lipid 
peroxidation inhibitory values did not reach 50% at the concentrations used in this study. 
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Table 7.2: Inhibition of Fe-induced lipid peroxidation by isolated compounds and the total extract in rat 
liver microsomes 
Compound Concentration (µg/ml) % Inhibition IC50 (µg/ml) Regression Equation 
1 
0.67 4.50±0.37 ND Y = 0.4353*X + 3.093 
6.67 6.00±1.76  R2 =0.8370 
13.40 7.55±1.86   
16.70 9.27±2.19   
26.70 16.06±0.98   
     
2 
0.67 8.58±0.64 9.8 Y = 2.333*X + 14.05 
6.67 31.11±2.74  R2 =0.9074 
13.40 50.67±0.81   
16.70 61.21 ±1.27   
26.70 68.34±0.47   
     
3 
0.67 11.59±1.62 10.4 Y = 2.202*X + 13.13 
6.67 20.44±9.98  R2 =0.8193 
13.40 55.52±0.81   
16.70 55.37±1.27   
26.70 63.94±6.45   
     
4 
0.67 0.43±0.7 ND Y = 0.4822*X - 0.8752 
6.67 0.44±0.4  R2 =0.6700 
13.40 4.58±2.14   
16.70 9.75±1.11   
26.70 11.34±0.55   
     
Extract 
0.67 2.14±1.70 7.2 Y = 2.742*X + 3.333 
6.67 17.33±5.77  R2 =0.9369 
13.40 50.13±1.68   
16.70 52.20±0.84   
26.70 70.70±0.82   
     
Quercetin 
0.27 5.31±1.73 2.95 Y=3.909*X + 11.80 
0.53 26.00±1.70  R2 =0.8739 
1.13 23.53±1.73   
2.26 51.23±0.83   
4.53 65.28±0.99   
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CHAPTER 8 
GENERAL DISCUSSION 
 
8.1 Introduction  
The use of plants as a source of human therapeutic medicine is as old as recorded history. The 
importance of plant components as therapeutic agents is increasingly being recognized in line 
with current advances in technology. Globally, natural plant compounds have attracted attention 
as alternative therapeutic strategies in the fight against diseases, primarily because of their low 
toxicity and high therapeutic index (Sanchez-Gonzalez et al., 2011; Jung, 2014). Many existing 
and contemporary drugs in clinical use derive from the natural plants (Cragg et al., 2009). 
Holarrhena floribunda leaves are an important source of drugs used in traditional medicine to 
cure different diseases, including diabetes, malaria, cancer and oxidant damage-related diseases 
(Badmus et al., 2013; Fotie et al., 2006). 
8.2 Anti-Proliferative and Apoptosis Induction Potential of the Methanolic 
Leaf Extract of Holarrhena floribunda 
The present study evaluated the anticancer activity of the Holarrhena floribunda MLE in breast 
cancer (MCF-7), colon cancer (HT-29), cervical cancer (HeLa) and normal human fibroblast 
(KMST-6) cell lines. The results of this study show that the extract exhibited cytotoxic effects 
towards all the cancer cell lines in a dose- and time-dependent manner. The IC50 values obtained 
for the various treatment protocols demonstrate that HeLa cells are more sensitive to the 
cytotoxic activity of the plant while KMST-6, a normal human fibroblast cell line, showed lesser 
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sensitivity to the extract. The potential of the anticancer activity of the extract to discriminate 
between normal and cancer cells is an important paradigm in the design and discovery of 
chemotherapeutic agents. Consistent with this concept, trypan blue dye exclusion and colony 
formation assays confirm the antineoplastic activities of the extract against cancer cell lines 
compared to the normal KMST-6 human fibroblast cell line.  
Holarrhena floribunda is known to be rich in several phytochemicals like alkaloids, flavonoids, 
tannins and cardiac glycosides. Some of these phytochemicals have been reported to possess 
antineoplatic activities against different cancer cell lines. Several reports, for example, 
underscored that the antiproliferative activities of Perganum harmala seeds and Cassytha 
filiformis, respectively, were due to their alkaloids constituents (Lamchouri et al., 2013; Hoet et 
al., 2004). Flavonoid activities against various cancers have also been reported (Yadegarynia et 
al., 2012; Matsuo et al., 2005; Li et al., 2014).  
To further elucidate the pathways of the cell death induced by the extract, phosphatidylserine 
(PS) flipping was evaluated using the APOPecerntage™ and Annexin/PI flow cytometric assays. 
Exposure of PS on the external surface of the cell membrane is generally accepted as one of the 
biomarkers of apoptosis (Fadok et al., 1992). The results demonstrated the concentration-
dependent apoptotic inducing potential of the extract. As a necessary corollary of the results of 
the cytotoxicity assay, HeLa cells showed a significant sensitivity towards the extract compared 
to the other cell lines tested. The Annexin/PI assay also confirmed the ability of the extract to 
induce early and late apoptosis.  
Unlike necrosis, apoptosis is an important cell death mechanism that does not trigger an 
inflammatory response that occasions collateral destruction of normal cells in the surrounding 
microenvironment (Elmore, 2007). Thus, apoptosis is a protective mechanism that maintains 
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tissue homeostasis by removing ailing cells (Fan et al., 2005). Cancer cells, however, exhibit 
resistance to apoptosis in order to sustain their uncontrolled proliferation signature and, 
therefore, any apoptosis modulating compound is desirable as a plausible chemotherapeutic 
agent against cancer (Tor et al., 2014). 
Two basic processes involved in apoptosis are the intrinsic (mitochondrial) and extrinsic (death 
receptor) pathways (Hsu et al., 2009). Caspase-3/7 is one of the effector caspases that is involved 
in the final execution of dying cells while caspase-9 is an initiator caspase that involves the 
intrinsic pathway (Fan et al., 2005). To understand the mechanism of action induced by the 
extract, caspase-3/7 and caspase-9 activities were evaluated. The results showed that the extract 
induced concentration-dependent increases in caspase-3 activity in HeLa cells while in contrast, 
a concentration-dependent decrease in such activity was observed in MCF-7 and HT-29 cells. 
The caspase-9 results showed a similar trend of decrease in activities in all the cell lines. The 
possible reason for these observed results can be explained in two ways. The first is that the 
increased caspase-3 activity observed in HeLa cells suggests that the extract induced apoptosis is 
a caspase-dependent manner while the decrease in caspase activities in MCF-7 and HT-29 cells 
presumably involves degradation of the protease, although the exact mechanisms of apoptosis 
induction need to be clarified. 
However, in agreement with antiproliferative activity of the extract, the results of the cell cycle 
evaluation confirmed that the extract arrested cell cycle progression by significantly restricting 
cells in G0/G1 phase. This implies that the extract perturbs protein synthesis which is vital to cell 
progression from G1 to S-phase. It is known that p53 and MDM2 proteins are important role 
players in progression through the cell cycle at G0/G1 (Plasencia et al., 2005; Tang et al., 2010). 
It may be possible that the extract interferes with these proteins, but this aspect was not 
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investigated in this study. Also, the effects of the extract on cell cycle progression may be due to 
its phytochemical constituents such as flavonoids and alkaloids. 
Cells are known to thrive in low levels of reactive oxygen species (ROS), but a relative increase 
in ROS induces cell cycle arrest and apoptosis (Li et al., 2014). ROS-modulating drugs are, 
however, being proposed as therapeutic strategies to selectively target the destruction of cancer 
cells (Lampiasi et al., 2009). The results of this study indicate that the extract induced a time-
dependent increase in ROS production. ROS production due to extract (200 µg/ml) treatment for 
12 and 24 hours was more evident in HeLa cells, which may explain why this cell line exhibited 
greater sensitivity to the extract with regard to its antiproliferative, apoptotic and cell cycle arrest 
effects. 
8.3 Isolation, Characterization, Cytotoxicity, Cell Cycle and DNA Synthesis 
Inhibition of Compounds from the Methanolic Leaf Extract of H. 
Floribunda 
Phytochemical studies of the cytotoxic fractions of Holarrhena floribunda resulted in two major 
amino steroidal compounds identified as holamine and funtumine. The two steroidal alkaloids 
were identified based on their NMR spectra (1H and 13C) which were judged against existing 
literature profiles (Kam et al., 1998). Holamine is a major steroidal alkaloid from the genus 
Holarrhena because almost all the isolates from the genus led to the identification of the 
compound (Kam et al., 1998; Dadoun and Cave, 1978; Dodoun et al., 1973). To the best of our 
knowledge this is the first time funtumine has been isolated from Holarrhena floribunda leaves. 
It has been previously isolated from Holarrhena and Funtumia genera such as Holarrhene 
febrifuga, Holarrhena wulfsbergii and Funtumia latifolia (Dodoun et al., 1973; Nelle et al., 
1970; Blanpin and Quevauvillier, 1960).  
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Alkaloids are widely distributed secondary metabolites derived from plants and well known for 
their diverse pharmacological efficacies (Patel et al., 2012). Fungicidal, anti-inflammatory and 
antibacterial activities of aminosteroids have been previously described (Griggs and King, 1978; 
Szendi et al., 1996). Steroidal alkaloids are useful as starting materials for pharmaceuticals or 
important semi-synthetic drugs (Kanika et al., 2013). Holamine derivatives were used as starting 
material for the synthesis of immune stimulating aminopregnenes-I and active adjuvant 
anaphylactic glycinamide-II (Torelli et al., 1984). Funtumine derivates substituted with a 
guanylhydrazone moiety have also been shown to interact selectively with the telomeric G-
quadruplex in vitro (Brassart et al., 2007). The potential for steroidal alkaloids to be used as 
starting material shows that apart from being candidates for anticancer drug discovery, they can 
be used as templates for the synthesis of anticancer drugs of desirable characteristics. 
The cytotoxic activities of the isolated compounds were evaluated using the thiazolyl blue 
(MTT) assay. MTT is a colorimetric enzymatic reduction assay in living metabolic competent 
cells based on the reduction of the tetrazolium salt, but not in compromised dead cells (Ribeiro et 
al., 2012). It is widely applied to evaluate cytostatic and/or cytotoxic potential of medicinal 
agents (Karikas, 2010). The cytotoxic effects of these compounds against cancer cells (HT-29, 
MCF-7 and Hela) were compared with normal fibroblast cells (KMST-6). The IC50 values 
presented in Table 5.2 show that the isolated compounds are significantly selective towards the 
cancer cells than the normal cell compared with the standard drugs (cisplatin and doxorubicin) 
used in this study. The assay showed that HT-29 is more sensitive to the cytotoxic effects of both 
compounds 1 and 2 with IC50 values of 9.80 and 7.10 µg/ml, respectively. Furthermore, 
compound 1 showed IC50 values of 13.51 and 16.22 µg/ml and compound 2 16.73 and 14.66 
µg/ml for MCF-7 and HT-29, respectively. This is the first cytotoxicity report on the isolated 
compounds against this panel of cancer cells. The cytotoxic effect of compound 1 isolated from 
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Holarrhena curtisii have been tested previously on HL-60 and P-388 (Kam et al., 1998) while 
compound 2 was shown not to display cytotoxicity at a neuro-active concentration (Libor et al., 
2004). 
Furthermore, most anticancer agents are reported to play roles in cell cycle arrest and cellular 
demise (Hadfield et al., 2003). Cell cycle transitions were evaluated in this study using flow 
cytometric analysis of PI stained cells. The results showed that compounds 1 and 2 induced a 
significant increase in the population of cells in G0/G1 phase and reductions in S-phase in the 
entire cell treated with corresponding IC50 concentration. Moreover, a significant increase was 
also observed in the population of cells in G2/M phase for both compounds 1 and 2 at 12 and 24 
hours for HT-29 cells. The significant increase in G2/M phase was observed only at 12 hours, 
but not 24 hours for compound 1 while compound 2 produced a significant increase for both time 
periods in MCF-7 cells.  
A significant increase in G2/M phase was observed in HeLa cells treated with compound 1 at 24 
hours, but not at 12 hours while no significant increase was observed for compound 2 at both 
time periods. The induced significant increase in population of cells at both G0/G1 and G2/M 
phase in HT-29 cells could be related to the low IC50 values obtained in the cytotoxicity assays. 
The cell cycle results imply that the compounds arrest cells substantially at G0/G1 phase of the 
cell cycle. Cell cycle arrest at G0/G1 stage relates to the induction of cell cycle inhibitory 
proteins such as p16, p21, p27 related with reduced expression of cyclins required for the G1 to 
S transition. Liu et al. (2003) in their work on molecular mechanisms of G0/G1 cell-cycle arrest 
and apoptosis induced by terfenadine in human cancer cells showed that terfenadine treatment 
induced upregulation of p53, p21/Cip1 and p27/Kip1 while simultaneous downregulation was 
observed for CDK2 and CDK4. Many anticancer drugs from natural origin such as paclitaxel, 
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docetaxel, vinblastine and vincristine are known cell cycle inhibitors of the G2/M phase. 
Vinblastine and vincristine affect G2/M phase of cell cycle through inhibition of microtubule 
assembly while paclitaxel and docetaxel exert their actions through stabilization of microtubules 
which induces the inhibition of microtubule disassembly and eventual arrest at G2/M phase of 
cell cycle (Himes et al., 1976; Schiff et al., 1979; Rakovitch et al., 1999). G0/G1 and G2/M 
arrest might be important pathways by which the isolated compounds induce cytotoxicity in 
cancer cells. 
Agents that cause cell cycle arrest can be categorized into two classes: (1) those that directly 
inhibit DNA synthesis and (2) those that cause DNA damage leading to G1 or G2 arrest (Hung et 
al., 1996). The effects of the compounds on DNA synthesis were evaluated using the cell 
proliferation ELISA chemiluminescent BrdU kit. The results show that the two compounds 
significantly reduced cellular DNA synthesis within the duration of exposure to IC50 levels for 
the respective cells. This result implies that the compounds can be placed in the category of 
agents that directly inhibit cellular DNA synthesis, which is consistent with the observed results 
in the cell cycle analysis with reduction of S-phase. 
8.4 Two Steroidal Alkaloids from Holarrhena Floribunda Leaves Induced 
Apoptosis in Cancer Cells. 
Numerous anticancer activities of natural products are remarkably correlated with induction of 
changes in the regulation of target molecules in oncogenic signal transduction pathways 
implicated in cell growth, replication, angiogenesis, invasion, metastasis and apoptosis in 
transformed cells (Kuno et al., 2012; Mehta et al., 2010; Neergheen et al., 2010; Amin et al., 
2009). In the present study, the mechanistic effects of holamine and funtumine steroidal 
alkaloids isolated from the methanolic extract of Holarrhena floribunda leaves were evaluated. 
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The two compounds have been isolated before from Apocynaceae plant family, but their 
mechanistic cytotoxic effects remain undetermined.  
Cytotoxicity and antiproliferative activities of the compounds were evaluated using the 
multiplexed CytoTox-GloTM assay (Promega). The assay offers a convenient and cost-effective 
manner to address variation (by response normalization), flag non-conforming orthogonal data 
points and increase per well content (Niles et al., 2009). The cancer cells (HT-29, MCF-7 and 
HeLa) and non-cancerous cells (KMST-6) were treated with the two compounds with increasing 
concentrations (1.87, 3.75, 7.5, 15 and 30 µg/ml) for 24 hours. The results, as presented in 
Figures 6.1 and 6.2 reveal that the two compounds were significantly more toxic towards cancer 
cells compared to the normal cell line. There was no significant difference in the effectiveness of 
holamine among the cancer cells while funtumine showed significant cytotoxic towards MCF-7 
(P<0.5) and HT-29 (P<0.01) compared with HeLa cells. Previous work on the cytotoxic 
activities of steroidal alkaloids is consistent with the present result.  
Steroidal alkaloids, tomatidine and solasodine isolated from ground berries of Solanum 
aculeastrum (Srinivas et al., 2007), etioline from Solanum diphyllum (Magdi et al., 2009) and 
epipachysamines B and E, pachystermine A and E isolated from the methanolic extract of 
Pachysandra terminalis stem were reported to have significant cytotoxic effects against a panel 
of cancer cells (Funayama et al., 2000). Alkaloids are known to induce cytotoxicity as a result of 
the molecular interaction with one or several targets in a cell, including DNA, RNA and the 
associated enzymes and processes (Wink, 2007).  
Cytotoxicity of holamine and funtumine might be related to the effects on the cell processes 
associated with survival and resistance to cell demise. Some of these processes include induced 
external growth factors, intracellular matrix signalling via integrin and Ras protein mutation-
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derived constitutive mitogenic signals leading to growing neoplasms that cause destruction and 
atrophy of the surrounding tissue and adjacent organs (Srinivas et al., 2007; Lukashev and Werb, 
1998; Medema and Bos, 1993). The results imply that the compounds might influence on one or 
more of these processes and can therefore be good lead compounds for anticancer agents in view 
of their pronounced cytotoxic activities against cancer cells as compared with the normal control 
cells. Drugs with efficient and selective toxicity in tumour cells are attracting keen interest for 
the development of new classes of anticancer agents (Phonnok et al., 2010).  
Apoptosis is a programmed cell death characterized by morphological features and extensive 
DNA fragmentation (Collins et al., 1997). Apoptosis plays important role in cell normal survival 
and maintenance of cell development and homeostasis (Elmore, 2007; Reed and Tomaselli, 
2000). Thus, apoptosis induction in cancer cells is an important way to eradicate cancer (Dixon 
et al., 1997). Agents with apoptosis inducing ability have been used in cancer therapy as 
apoptotic pathways are frequently impaired in many cancers (Kang and Jang, 2012). In this 
study, induction of apoptosis by the isolated compounds was evaluated using APOPercentageTM 
dye and Annexin/PI double staining. The results shown in Figure 6.3 reveal that the two 
compounds induced significant apoptosis in cancer cell lines compared with the normal cell line. 
Significant late phase apoptosis compared with early phase was observed with the use of 
Annexin/PI dye (Figure 6.4) for the two compounds.  
A wide variety of apoptosis inducing natural plant products against tumour cells has been 
identified (Parsaee et al., 2013b). Most of the currently used anticancer drugs are known to 
induce apoptosis in cancer cells (Rosenkranz and Wink, 2007). The executioners of apoptosis are 
proteolytic enzymes known as cysteinyl aspartate specific proteases also referred to as caspases. 
These groups of enzyme function in the two main pathways of apoptosis, which are extrinsic 
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(caspase-2, -8,or -10) and intrinsic (caspase-9) (Parsaee et al., 2013b). Both initiator caspases 
activate caspase-3/-7 which eventually commits cells to apoptosis by inactivating PARP protein, 
which is involved in DNA repair (Looi et al., 2013). The convergence of proteolytic enzymes of 
both the extrinsic and intrinsic pathways on caspase-3 makes it an important biomarker for the 
evaluation of apoptosis. Caspase-3 activity was evaluated in this study using the Caspase-3/7 
GloTM assay kit. The results showed that the two compounds induced several fold increased in 
caspase-3 activity in HeLa cells compared with HT-29 and MCF-7 cells, with holamine the 
superior inducer. The activation of caspase-3 thus confirms that the induced cell death occurs 
through the apoptosis. Further to this result, a Western blot assay was carried out to assess the 
level of PARP-1 protein by treating HeLa cells with 15 µg/ml concentrations of the compounds 
for 6, 12 and 24 hours. The results, as presented in Figure 6.18 show that the compounds induced 
deactivation of PARP-1 by 12 hours treatment by cleaving PARP-1.  
ROS induction is one of the mechanisms of some forms of conventional treatments such as 
radiation, etoposide, bleomycin and anthracyclines relied on for the inhibition of cell 
proliferation (Looi et al., 2013). ROS modulate the delicate cellular redox balance, leading to 
oxidative stress due to their chemical reactivity. They destabilize mitochondria and attack 
various components of DNA, leading to generation of oxidized and modified cellular 
components and eventual induction of apoptosis (Looi et al., 2013; Engel and Evens, 2006). 
Induction of ROS is attributed to some alkaloids with oxidizing properties (Wink, 2007).  
The induction of ROS in this study was evaluated using cell permeant dye (CM-H2DCFDA) and 
evaluated using a flow cytometer. The results show that the two compounds induced a significant 
fold increase in mean fluorescence intensity (MFI) at 12- and 24-hour treatments of HeLa and 
HT-29 cell lines with 15 µg/ml, while a significant increase between the 12 and 24-hour periods 
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was not observed in the MCF-7 cell line. This result raises the possibility that induction of 
apoptosis in both HeLa and HT-29 cells might be due to the increase ROS occasioned by the 
treatment with both compounds.  
The continued rapid proliferation and survival of cancer cells depend, among other factors, on 
the glycolytic pathways of ATP generation (Gogvadze et al., 2009). The mitochondrion is the 
site of ATP production which maintains the balance between cell viability and programmed cell 
death (Koonin and Aravind, 2002). Nuclear functions such as ROS production, modulation of 
calcium levels and transport of small molecule metabolites are under mitochondrial control 
(Rizzuto et al., 2012). Mitochondria are attractive target organelles for anticancer agents to 
restore normalcy and repeal the progression to malignancy (Indran et al., 2011). Drugs with 
potential to perturb the mitochondrial functions might be an important therapeutic approach to 
cancer treatment (Gogvadze et al., 2009). Such drugs function by depleting ATP levels, causing 
the dephosphorylation of pro-apoptotic proteins, mobilization of Bax to the mitochondria, 
permeabilization of the outer mitochondrial membrane and eventual cell death (Xu et al., 2005).  
In this study, the effects of the compounds on the function of the cell mitochondria were 
evaluated using Mitochondrial ToxGlo™ assay. This assay was carried out to establish if the 
cytotoxic effects of the compounds occur through mitochondrial perturbation. The results as 
presented in Figure 6.8 show different cell types responded to the effects of these compounds 
differently. According to the result interpretation in the assay protocol (Promega, 2011), four 
different types of mechanistic profiles were given to interpret the results: (1) no change in ATP 
or membrane integrity equivalent to no mitotoxicity, (2) reduction in ATP with no necrosis 
implies mitochondrial toxicity, (3) ablation of ATP leads to dose-dependent membrane integrity 
changes shows mitochondrial toxicity while (4) reduction in ATP with commensurate membrane 
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integrity gives primary necrosis. In addition, however, a compound can be considered a potential 
mitochondrial toxin if it decreases the ATP measure with greater than 20% of the average control 
wells with less than 20% increase in cytotoxicity (Promega, 2011).  
According to the profile of results from this study presented in Figure 6.8, holamine induced 
mitotoxicity without necrosis in HeLa and HT-29 cells, but none in MCF-7 cells. Funtumine 
induced mitotoxicity without necrosis in HeLa and MCF-7 cells while primary necrosis was 
found in HT-29 cells. The sensitivity of the different cells to the mitochondrial induced toxicity 
of the compounds might be related to the differences in ROS generation and mitochondrial 
dysfunction in each particular cell which make them more vulnerable to oxidative stress induced 
by the compounds (Wen et al., 2013). Consistent with the results of ROS production in the 
treated cells, as presented in Figure 6.6, it was observed that both HeLa and HT-29 cells had a 
significant increase in the ROS induced by the treatment with the alkaloids. 
Light and fluorescence microscopy were used to evaluate morphology of the cells while 
undergoing holamine and funtumine treatments. For fluorescence microscopy, the cells were 
stained with TRITC-conjugated phalloidin to evaluate the short-term effects of the treatment on 
the actin filament of cells as presented in the Figures 6.9 and 6.10. CM-H2DCFDA was used to 
check the intracellular ROS production and the Mitotracker™ dye was used to evaluate 
mitochondrial function. F-actin is important for the establishment of cell architecture and 
integration towards apoptosis (Wink, 2007). It is also plays essential role in cell mobility and 
contraction during cell division, implicated in the initiation phase of apoptosis in certain 
conditions also forms important constituents of cell cytoskeleton (Wooley et al., 1998).  
In the present study treatment of cells with both holamine and funtumine for 3 and 6 hours 
caused disruptions of F-actin filaments compared with well-organized stress fibres of actin 
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filaments (Figures 6.9 and 6.10). It is known that during bleb formation, actin and myosin 
filaments slide over each other, leading to contraction of the cell border toward the centre as 
observed in the treated cells (Figures 6.9 and 6.10) (Niero and Machado-Santelli, 2013). This 
result implies that the compounds can disrupt actin filament organization which can lead to 
apoptosis. Drugs that induce apoptosis and DNA breakage are known to cause nuclear alteration 
by disruption of cytoskeletal organization (Niero and Machado-Santelli, 2013; Manelli-Oliveira 
and Machado-Santelli, 2001).  
Intracellular ROS production was evaluated flow cytometrically by staining cells after treatment 
with compounds for 6 and 12 hours. Figure 6.9 shows that after 12 hours treatment, the 
compounds induced significant ROS as shown by a bright green colour compared with untreated 
control. Furthermore, measurement of the effects of the compounds on mitochondrial function 
showed that the compounds lowered mitochondrial function (Figure 6.10) with low imparted 
intensity of the mitochondrial stained with Mitotracker red in the treated cells compared with the 
untreated control. This shows that the effects of the compounds can probably be related to the 
mitochondrial impairment influenced by the treatment of cells with the compounds for 6 and 12 
hours. Morphological analysis of cells treated with the two compounds by observation and 
capturing of images with a ZEISS Primo Vert (Germany) light microscope shows that the cells 
demonstrated cellular shrinkage which suggests induction of apoptosis. It further reveals a 
reduction in cell numbers which was due to cell cycle arrest as previously observed.  
In addition to the evaluation of antiproliferative mechanism of the compounds, inhibition of 
DNA topoisomearse-1 was evaluated. Inhibition of DNA topoisomerase-I is known to induce 
cell cycle arrest and cell death by apoptosis (Wink, 2007). This is because of the essential roles 
DNA topoisomerase-I plays by relaxing DNA supercoiling during processes like cell replication, 
 
 
 
 
CHAPTER 8 | 8.5 ISOLATION, CHARACTERIZATION AND ANTIOXIDANT ACTIVITY OF FLAVONOIDS FROM 
HOLARRHENA FLORIBUNDA LEAVES. 
160 
recombination transcription, chromatin assembly and chromosome partitioning at cell division 
(Wink, 2007; Ganguly et al., 2007; Wang, 1996). Inhibition of topoisomerase-I can either be 
through catalytic inhibition or stabilization of transient cleavable ternary complexes by 
preventing religation (Hofmann and Mattern, 1993). The present work, however, shows that 
holamine and funtumine inhibited the DNA topoisomerase-I as presented in Figure 6.16. This 
shows that cytotoxicity and apoptosis activities of these compounds might not be unrelated to the 
topoisomerase-I inhibition. DNA topoisomerase-I and -II are excellent targets of clinically 
significant classes of anticancer drugs and an effective strategy for cancer therapy (Salerno et al., 
2010). Camptothecin (CPT) and its derivatives topotecan and irinotecan are known 
topoisomerase inhibitors through which they induced their anticancer activities. Some alkaloids 
isolated from plants such as pallidine and scoulerine from Corydalis saxicola and epibeberine 
and gloenlandcine from Coptis rhizomes have also been found to inhibit DNA topoisomerase-I 
(Cheng et al., 2008; Kobayashi et al., 1995). 
8.5 Isolation, Characterization and Antioxidant Activity of Flavonoids from 
Holarrhena floribunda Leaves. 
Dietary antioxidants with potential for therapeutics and prevention have been a major focus of 
research in recent years. Isolation and characterization of bioactive compounds from plants with 
health and disease preventing properties have led to the isolation and identification of various 
arrays of compounds, including flavonoids (Suganya et al., 2007a). The present work isolated 
flavonoids by subjecting the methanolic leaf fractions of Holarrhena floribunda to different 
chromatography techniques. The flavonoids were isolated, purified using HPLC, identified with 
NMR spectroscopy and data compared with that reported in the literature. Three pure compounds 
and an inseparable mixture of two compounds were isolated and identified. The compounds 
showed a dull spot under UV light, which indicate the nature of flavonoids.  
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Compound 1 in NMR (1 hour and 13C) showed typical signal of kaempferol (Table 7.1), 
substituted at C-3 (δc 133.6). It showed two signals at δH/δc 6.21/99.2 and 6.44/94.2 of H-6 and -
8 respectively; two signals (2H each/d) at 7.99/131.3 and 6.88/115.5 of H-2’,6’ and H-3’,5’ of 
ring B, additionally, two signals at 5.31/101.8 and 4.42/101.2 of two anomeric protons belong to 
glucose and Rhamnose, the methyl signal of the rhamnose unit appears at 0.99/18.2. The 
compound was identified as kaemperol-3-O-rutinoside and the structure was confirmed further 
by comparing the NMR data with the literature. 
Compound 3 was purified by HPLC as a yellowish white amorphous powder and its NMR 
showed signals at 6.20/99.2 and 6.40/94.0, corresponding to ring A H-6 and H-8; ring B showed 
1,3,4-trisubtituted pattern and showed signals at 754/115.6; 754/122.0 and 6.85/116.8. The above 
data, including others in Table 7.1, confirmed the presence of an aquercetin nucleus. The C-2 
signal at 156.5 and C-3 at 133.7 indicated the presence of a glucose unit at C-3. The glucose unit 
showed anomeric proton at 5.47/101.3 in addition to cluster of proton signals at 3.1-3.7 ppm. The 
above data are identical with quercetin-3-O-glucoside. 
Compound 4 was purified using HPLC and showed similar NMR data with the previous 
compound except for ring B which showed a 1-4 substituted pattern and demonstrated signals at 
(2H each) 8.05/131.3 and 6.89/115.5. The compound was identified as kaempferol-3-O-
glucoside from NMR spectroscopic data and confirmed by comparison with the literature. 
Compound 2 was isolated as singlet peak from HPLC and it showed typical data like compound 
3 with an additional sugar unit. The anomeric protons at 5.45/101.4 and 5.36/102.4 are counted 
for as glucose and galactose units. The integration of the two protons is equal to ½ of other 
protons in the spectra (i.e., H-6). These data indicate two inseparable compounds (viz compound 
3 and quercetin-O-galactoside) with the same polarity and found relatively in a ratio of 1:1. 
 
 
 
 
CHAPTER 8 | 8.5 ISOLATION, CHARACTERIZATION AND ANTIOXIDANT ACTIVITY OF FLAVONOIDS FROM 
HOLARRHENA FLORIBUNDA LEAVES. 
162 
However, further to the isolation of flavonoids from the leaves, isolated flavonoids were 
subjected to antioxidant evaluation using ORAC , FRAP, TEAC and inhibition of lipid 
peroxidation. The ORAC assay evaluates the ability of antioxidants to scavenge peroxyl radicals 
generated by 2’, 2’-azobis (2-amidinopropane) dihydrochloride (ABAP) and delay the decay in 
fluorescence of the fluorescein probe. The ORAC assay takes into account both inhibition time 
and the degree of inhibition into a single assay by considering the area under the curve (Cao et 
al., 1995).  
In this study, in addition to the commonly used AAPH as an oxidant, Cu2+-H2O2 and Cu2+ alone 
were used as a source of oxidants. Cu2+-H2O2 is used to mimic the in vivo generation of oxidant 
as H2O2 and transition metals are available in vivo and are frequently used in vitro to induce 
oxidative damage to proteins and nucleic acids (Cao et al., 1997; Parthasarathy et al., 1989; Sato 
et al., 1992). In the presence of transition metals like Cu2+ alone, it is believed that flavonoids act 
as a pro-oxidant (Cao et al., 1997). The Cu2+ was used in this study to evaluate potential pro-
oxidant capacity of the isolated flavonoids. Evaluation of the antioxidant of the isolated 
compound using ORAC peroxy radical (ORACROO·) assay presented in Figures 7.14 and 7.15 
above shows that all the isolated compounds have a high degree of in ORACROO· activity. 
However, compounds 2 and 3 show significantly higher activities compared with the compounds 
1 and 4. The ORACOH· activity of these compounds also followed a similar pattern to what is 
obtained in ORACROO· activities (Figure 7.15).  
The ORACOH· activities of the flavonoids were several fold higher than what is obtained for 
ORAC ROO·. This probably shows that the flavonoids are more specific to OH· radical protection. 
Previous structural-activity relationships studies concluded that phenolic hydroxyls in 
flavonoids, hydroxyl groups in A and B rings, ortho-dihydroxyl groups in A and B rings are 
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important to the hydroxyl radical scavenging activity of flavonoids (Chen et al., 2002). Inversely, 
however, the pro-oxidant activities using Cu2+ in ORAC assay show that compounds 1 and 4 
were more prone to induce prooxidant in the presence of the metal than the compounds 2 and 3 
(Figure 7.16). This was not unexpected because the previous reports have correlated the number 
of flavonoids’ OH group substitutions to their ORAC activity (Rice-Evans et al., 1996). The 
observed results can be related to the basic structure of the flavonoids as compounds 2 and 3 
have quercetin as their basic structures while 1 and 4 have kaempferol. Studies have 
demonstrated that ORACROO· activity of quercetin is higher than that of kaempferol (Cao et al., 
1997). The pro-oxidant activity can also be related to the number of substituted OH in the 
flavonoids—it was shown in this study that the lower the OH, the higher the pro-oxidation in the 
presence of Cu2+. 
FRAP measures reducing capacity based upon reduction of ferric ion in an acidic medium at 593 
nm. The present investigation shows that compounds 1 and 4 have significantly lower FRAP 
activity as compared with compounds 2 and 3, and the methanolic extract with high activity 
(1527.63, 15661.37 and 850.06 µmol TE/g, respectively) (Figure 7.17). The TEAC assay 
involves the evaluation of quenching potential of antioxidant in the presence of long-lived 
radical cation chromophore 2, 2’-azinobis-(3-ethylbenzothiazoline-6-sulphonate) ABTS·+. The 
results of the TEAC assay follows the same manner as observed in the FRAP assay above. 
Compound 3 shows (1649.4 µmol TE/g) > compound 2 (1589.9 µmol TE/g) > compound 1 
(394.8 µmol TE/g) > compound 4 (337.5 µmol TE/g) (Figure 7.18). The importance of the OH-
group, methoxy group and O-dihydroxy substitution in the B-ring have been related to the high 
activity of the flavonoid using a FRAP assay (Firuzi et al., 2005). 
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Furthermore, inhibition of iron-induced microsomal lipid peroxidation by the compounds was 
evaluated. Iron-induced lipid peroxidation is a reliable biological marker of cellular oxidative 
stress (Dargel, 1992). The results, as presented Table7.2 show that compounds 1 and 4 do not 
have significant inhibition of lipid peroxidation as the inhibition did not reach 50% inhibition in 
the concentration used while compound 2 , 3 and the total extract gave IC50 values of 15.5, 16.8 
and 17.1 µg/ml, respectively. The lipid peroxidation inhibitory activities of flavonoids are shown 
to be related to the number of hydroxyl group, substitution of the hydroxyl group, cathecol 
moiety on the B-ring and double bonds between carbon 2 and 3 of the C-ring (Cholbi et al., 
1991; Mora et al., 1990). The presence of a sugar moiety, however, affects the activity of the 
lipid peroxidation inhibition due to steric hindrance between the sugar and adjacent hydroxyl 
group and likewise the methoxy group (Cholbi et al., 1991).  
This can be related to the result obtained in the present study when the inhibition of lipid 
peroxidation of the isolated glycosylated flavonoids was compared with the quercetin standard. 
The results showed that IC50 inhibition of peroxidation by the standard is about 3-fold lower than 
the isolated flavonoids. On the other hand, glycosylation of flavonoids increases the 
hydrophilicity and hence enhances bioavailability better than aglycone flavonoids (Kumar and 
Pandey, 2013). Despite the lower activity of glycosylated flavonoids compares to their 
aglycones, bioavailability is a determining factor of their bioactivity in vivo (Thilakarathna and 
Rupasinghe, 2013). Enhancement of bioavailability will thus be an important dynamic in order to 
exert eventual beneficial effect in vivo (Thilakarathna and Rupasinghe, 2013). In addition, the 
results obtained in this study are in agreement with the number of hydroxyl group substitutions 
on the B-ring as compounds 2 and 3 with hydroxyl groups in B-ring showed effective dose-
dependent lipid peroxidation compared with compounds 1 and 4.  
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In summary, the antioxidant activity of flavonoids, which involve neutralization of free radicals 
initiating oxidative-cascade of reaction or termination of the free radical chain reaction due to 
hydrogen donating property can be related to their structures (Cao et al., 1997; Suganya et al., 
2007b). Compounds 2 and 3 have an ortho-dihydroxyl in the B-ring of the flavonoid skeleton 
(catechol) which plays essential roles in the antioxidant activity of flavonoids (Bors et al., 1990), 
and is responsible for the observed effects in those compounds. The antioxidant activity of 
flavonoids is known to depend largely on the functional groups attached to the nuclear structure 
(Heim et al., 2002). It is noteworthy that the entire antioxidant assay carried out in this study 
revealed no significant difference between compounds 2 and 3 that are active in the entire assay 
on one hand and between these compounds (compound 1 and 4) which are selective in their 
activities on the other. This implies that the only common factor that is solely responsible for the 
observed differences in the antioxidant activities of the flavonoids in this study is the ortho-
dihydroxyl in the B-ring. 
8.6 Conclusion 
The increasing rates of world cancer incidence and morbidity require every effort to stem the 
tide. Most of the currently used anticancer drugs derive from natural products because of the 
inherent phytochemical diversity that is beyond human comprehension. In this view, the current 
study evaluates the potential anticancer bioactive compounds from the leaf of H. floribunda. The 
study led to the isolation of two steroidal alkaloids—holamine and funtumine—from the 
methanolic leaf extract of the plant. The cytotoxic activities of the compounds were found to be 
mediated through induction of apoptosis by activation of caspase-3, reactive oxygen species, 
mitochondrial toxicity, cell cycle arrest, F-actin filament disassembly and topoisomerase-I 
inhibition. In addition, from the leaves of this plant, four flavonoids were successfully isolated 
which might be responsible for the protection of the body’s systems against ROS-induced 
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cancer. However, based on the findings of the present study, the two steroidal alkaloids can be 
good leads as anticancer drugs and they also hold potential as a template for the synthesis of 
desirable anticancer agents.  
8.7 Future Perspective  
This study has shown that the MLE of H. Floribunda contains compounds with potential for 
anticancer drug development and discovery. However, further studies are still needed to decipher 
the mechanisms of action of the compounds and their safety both in in vitro and in vivo models. 
In addition, combinations of the two alkaloids can be rationalized to evaluate their synergistic 
ability against cancer hallmarks. It also reasonable to combine them with other currently used 
anticancer drugs to study if they will ameliorate any known side effects. 
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